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Abstract 
Biomolecules such as bone growth factors, extracellular matrix proteins, bioactive 
factor-derived peptides, and other mineralisation-promoting proteins are gaining 
increasing attention in bone tissue engineering due to the fact that they can play an 
important role in cell attachment, growth, differentiation, and migration, and 
therefore be used to enhance bone formation and develop bone substitutes. 
 
This study is focused on the development of engineered biomolecules with improved 
functionality, and their combination with supporting matrix materials for bone tissue 
engineering applications. Two types of biomolecules are studied: The first are short 
peptides derived from the growth factor bone morphogenetic protein 7 (BMP-7), 
which induces bone regeneration, and regulates bone formation. The second is an 
engineered recombinant metalloenzyme E. coli alkaline phosphatase (E. coli ALP), 
which hydrolyses organic phosphate and generates the inorganic phosphate required 
for the mineralisation of hard tissue. Titanium (Ti) implants and polycaprolactone (PCL) 
scaffolds were used to incorporate these engineered biomolecules to verify the 
improvement of their functionality and biological efficiency. Results indicate that the 
BMP-7-derived peptides have a limited function and are not promising candidates for 
bone tissue engineering applications; while the mutant E. coli ALP shows superior 
activity compare to the wild-type ALP (nearly 25 times) and bovine ALP (more than 9 
times), and is shown to be a promising factor to enhance bone formation. The activity 
of E. coli ALP can be affected by many factors including NaCl, lyophilisation, histidine, 
and imidazole. When the ALP is combined with either a Ti implant or an ALP/PCL 
scaffold, it demonstrates outstanding mineral-promoting ability, making it a potential 
candidate for bone tissue engineering applications. In conclusion, this study 
demonstrates the potential of engineering biomolecules with improved functionalities 
for bone tissue engineering applications. 
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PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PEO Poly(ethylene oxide) 
PCL Poly(ε-caprolactone) 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
Pi Inorganic phosphate 
PGA Poly(glycolic acid) 
PLA Poly(lactic acid) 
PLAP Placental alkaline phosphatase 
PLGA Poly(lactic-co-glycolic acid) 
PLLA Poly(L-lactic acid) 
PPi Pyrophosphate 
PVDF Polyvinylidene fluoride 
ρNPP ρ-Nitrophenylphosphate 
rbs Ribosomal binding site 
RGD Arginine-glycine-aspartic acid 
ROP Organic phosphate monoesters 
rpm Rounds per minute 
SBF Simulated body fluid 
SDS Sodium dodecyl sulfate 
SEM Scanning electron microscope 
Taq Thermus aquaticus 
TBE Tris/borate/EDTA buffer 
TEMED N,N,N,N'-tetramethylenediamine 
TGF Transforming growth factors 
TFA Trifluoroacetic acid 
Ti Titanium 
TMA Tetramethylammonium 
TNAP Tissue nonspecific alkaline phosphatase 
VEGF Vascular endothelial growth factor 
Wt Wild-type 
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Amino acid residues 
 
A (Ala) Alanine M (Met) Methionine 
C (Cys) Cysteine N (Asn) Asparagine 
D (Asp) Aspartic acid P (Pro) Proline 
E (Glu) Glutamic acid Q (Gln) Glutamine 
F (Phe) Phenylalanine R (Arg) Arginine 
G (Gly) Glycine S (Ser) Serine 
H (His) Histidine T (Thr) Threonine 
I (Ile) Isoleucine V (Val) Valine 
K (Lys) Lysine W (Trp) Tryptophan 
L (Leu) leucine Y (Tyr) Tyrosine 
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CHAPTER 1  
Introduction 
1.1 Scope of the thesis  
This thesis is concerned with the development of biomolecules with improved 
functionalities to stimulate mineralisation and bone formation. Two types of 
biomolecules are studied. First are short peptides derived from the bone growth factor 
bone morphogenetic protein 7 (BMP-7) which induces bone regeneration, and 
regulates bone formation. Second is an engineered recombinant metalloenzyme E. coli 
alkaline phosphatase (E. coli ALP) that hydrolyses organic phosphate and generates 
inorganic phosphate required for mineralisation of hard tissue. Titanium (Ti) implants 
and polycaprolactone (PCL) scaffolds have been used to incorporate these engineered 
biomolecules to verify the improvement of the functionality and biological efficiency. 
 
The Introduction chapter provides a general review of bone tissue engineering and 
covers different approaches of developing advanced tissue through cells, scaffolds and 
biologically active molecules. Focusing on biomolecules, some widely used 
biomolecules such as bone growth factors, extracellular matrix proteins, and other 
mineralisation-promoting proteins are reviewed in Section 1.4. The background 
knowledge of engineered recombinant proteins and immobilisation methods of 
biomolecules are presented in Section 1.5 and 1.6.  
 
In Chapter 2, some short BMP-7-derived peptides which are reported to possess 
similar bone inducing properties to whole BMP-7 are studied. In order to immobilise 
the peptides onto titanium implants, a His-tag is added into the short BMP-7-derived 
peptides. After the synthesis and characterisation of the BMP-derived peptides, in 
vitro cell culture studies are performed to determine the effect of peptides on C2C12 
and MC3T3-E1 cells. 
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The following chapters focus on the second type of biomolecule: E. coli ALP. Chapter 3 
provides a description of producing and purifying the wild-type and mutated 
recombinant E. coli ALP with improved biological activity. After genetic modification, 
the mutant E. coli ALP shows higher biological activity than the normal wild-type E. coli 
ALP. Therefore the mutant E. coli ALP is promising for the construction of biomaterials 
for bone regeneration. 
 
In Chapter 4, modification of the mutant recombinant E. coli ALP is performed to 
achieve a controlled biomolecule immobilisation. In order to maximally expose the 
active sites of ALP upon immobilisation, recombinant E. coli His-ALP is engineered. The 
production and purification of the engineered recombinant His-ALP are described in 
Section 4.2. 
 
Chapter 5 describes and discusses two applications of bone tissue engineering with E. 
coli ALP, one being a Ti implant with recombinant ALP coating, and the other being an 
ALP/PCL scaffold. Preparation methods of both biomaterials are introduced in Section 
5.2. Soaking experiments are performed to determine the mineral formation efficiency. 
 
Finally, some concluding remarks and following research strategies of this study are 
presented in Chapter 6. 
 
1.2 Tissue engineering  
Due to the increase of human life expectancy, there is an increasing need for materials 
to substitute for tissues. Millions of patients suffer tissue loss or failure in the United 
States every year [1]. Examples of tissues needing replacement include liver, skin [2], 
bone [3], cartilage [4], lung, heart, kidney, and blood vessels[5]. Traditionally, the 
treatment for tissue damage is a transplantation that uses autologous or allogeneic 
materials and surgical reconstruction. However, both materials are limited by the 
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scope of their use and available resources. For example, although transplants are 
considered an effective treatment for liver failure [6], many patients die while waiting 
for a suitable replacement due to the severe shortage of donors [7]. Therefore, it is 
necessary to develop new approaches for tissue repair so that the need for 
transplantation is reduced or even eliminated. 
 
Tissue engineering is a thriving field of medical science that addresses tissue loss or 
failure [8, 9]. As defined by Langer and Vacanti, tissue engineering is "an 
interdisciplinary field that applies the principles of engineering and life sciences 
toward the development of biological substitutes that restore, maintain, or improve 
tissue function or a whole organ" by manipulating cells via their extracellular 
microenvironments [1]. The aim of tissue engineering is to create substitute tissues or 
organs that can replace or enhance tissue which has been damaged by disease, injury, 
or ageing [10]. Although tissue engineering covers a broad range of applications, it can 
be mainly divided into two applications: 1) therapeutic application, for which a 
substitute tissue is either grown inside or outside a patient and then transplanted; 2) 
diagnostic applications, where a substitute tissue is made in vitro and used for testing 
drug metabolism, toxicity, and pathogenicity [11].  
 
1.2.1 General principle  
The general principle of tissue engineering is illustrated in Figure 1. The approach 
combines cells, scaffolds, and bioactive factors. Patient-derived cells, following 
expansion in vitro, are mixed with bioactive factors and then seeded in a scaffold to 
induce functionality. The engineered scaffold usually needs to undergo a pre-
implantation in vitro culture before implantation in vivo for tissue regeneration. 
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Figure 1. General principle of tissue engineering. Cells are isolated from the patient, 
expanded in cell culture, and then seeded on a scaffold material with bioactive factors 
to induce functionality. The scaffold is cultured in vitro before implantation in the 
defect area in the patient [12].  
 
According to the definition, tissue engineering includes the following research areas: 
(1) Cells: Living cells play important roles in tissue engineering. Cell studies include 
determining the ideal cell source, and researching the mechanism of cell biology such 
as proliferation and differentiation [13, 14]. Cell based strategies to enhance bone 
regeneration have a rapid development since the understanding of musculoskeletal 
cell behaviour improves [15]. 
(2) Scaffolds: Scaffolds are artificial structures made by biocompatible materials to 
enhance tissue formation. The surface of the scaffolds should permit cell attachment 
and reorganisation, and should finally form a substitute tissue following proliferation, 
extracellular matrix synthesis, and migration [16]. Three-dimensional scaffolds with 
high porosity suitable for cell attachment and migration in bone tissue engineering 
have increasingly gained attention [17, 18]. 
(3) Bioactive factors: In addition to choosing cells and fabricating scaffolds, other 
aspects such as biomechanical properties [19], or bioactive molecules such as growth 
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factors that show positive effects on tissue formation [20] are critical for developing 
substitute functional tissues [12].  
 
These research areas are not isolated from each other. Combined approaches of 
mixing cells, scaffolds, and bioactive factors together are also highly interesting in bone 
tissue engineering [21]. For example, by optimising the initial cell density of bone 
marrow-derived cells seeded on three-dimensional scaffolds, an early differentiation 
and mineralisation was achieved within 3 weeks, and the new bone tissue was formed 
after 6 weeks [22]. The cell-scaffold system can be further combined with bioactive 
factors, such as an RGD-containing peptide that promotes osteoblast adhesion and 
spreading [23] to benefit bone tissue regeneration. 
 
1.2.2 Bone biology 
Bone is a living tissue with an outstanding ability to continuously remodel throughout 
the lifetime of an individual [24, 25]. Mature bone contains two morphologically 
distinct types of tissue: a hard outer layer called cortical or compact bone, which is 
strong, dense and tough, and a spongy inner layer called trabecular or cancellous bone, 
which is lighter, less dense and less elastic than compact bone [26]. Trabecular bone 
can bear more strain than cortical bone. Bones are responsible for providing structural 
support for the body. In addition, it supports muscular contraction, protects internal 
organs, and serves as a mineral store of Ca2+ and P3- ions in the body [26]. Bone is 
composed of inorganic mineral, organic matrix, and water. The absolute amounts of 
these components may change with certain factors, such as species, age, and sex. The 
inorganic mineral, which is mainly composed of calcium hydroxyapatite 
(Ca10(PO4)6(OH)2), is responsible for rigidity and hardness of bone as well as being a 
mineral store [26]. The organic part of the bone (see more information in Section 1.4.2), 
which is mainly collagen fibres, provides nucleation sites of hydroxyapatite crystals and 
makes the bone resilient [27].  
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Cells are also important components of bone and are responsible for bone formation, 
maintenance and (re)modelling. Typically, there are several types of cells in the bone 
originating from two lineages: the mesenchymal stem cell lineage and the 
hematopoietic stem cell lineage. The mesenchymal stem cell lineage produces 
undifferentiated cells or preosteoblasts, osteoblasts, bone lining cells, and osteocytes. 
The hematopoietic stem cell lineage provides circulating or marrow monocytes, 
preosteoclasts, and osteoclasts. These cells are widely used in bone tissue engineering. 
For example, human mesenchymal stem cells were grown on a highly porous and 
degradable poly(ε-caprolactone) scaffold to develop bone grafts for bone tissue 
engineering [28]. Figure 2 shows the function and location of cells in the bone matrix 
[29, 30]. 
 
 
Figure 2. Schematic representation of cells in calcified bone matrix. Osteoblasts are 
responsible for bone matrix synthesis and mineralisation. When surrounded by bone 
matrix and incorporated within the newly formed osteoid, osteoblasts eventually 
transform into osteocytes. Osteoclasts are responsible for bone resorption. Only 
osteocytes are situated deep in bone matrix, other cells such as osteoblasts, bone-
lining cells, and osteoclasts are situated on the bone surface [29].  
 
Cells play important roles in the bone modelling and remodelling process. Bone 
modelling is an essential process associated with the growth and re-shaping of bones 
in childhood and adolescence [31]. Meanwhile, bone remodelling is a life-long process 
consisting of resorption and ossification. Its purpose is to support skeletal integrity, 
shape, and mass [31]. 25% of trabecular bone volume is renewed every year by 
osteoclasts and osteoblasts during remodelling [32]. The remodelling process consists 
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of four phases: first, preosteoclasts are stimulated and differentiated into osteoclasts 
under the influence of bone growth factors. Then osteoclasts digest old mineral matrix 
(resorption). When the resorption is finished, osteoblasts start to synthesise new bone 
matrix (ossification). Finally, osteoblasts transform into bone lining cells situated on 
the newly formed bone surface. 
 
1.2.3 Approaches toward bone tissue engineering 
Compared to other tissues, the requirement of bone substitutes is of particularly high 
importance. Although bone has a high regenerative ability to heal the most minor 
fractures by itself, large bone defects still require a template for regeneration, which 
often involves operations [24, 33]. Bone substitutes, which act as templates, are often 
necessary in a widely range including trauma, congenital and degenerative diseases, 
cancer and cosmetics [34, 35]. Approximately 500,000 operations requiring bone 
substitutes are carried out every year in the United States [34]. Currently available 
bone substitutes, including autologous grafts (from the patient), allogeneic grafts 
(from a donor), demineralised bone matrices, as well as a wide range of synthetic 
biomaterials such as metals, ceramics, polymers, and composites are far from ideal 
and have many associated problems [36]. For example, autologous grafts have limited 
sources and may lead to significant donor site morbidity, while synthetic materials do 
not behave like native bone [37]. Therefore, bone tissue engineering has emerged as 
the alternative strategy to the current therapies for bone regeneration or substitution.  
 
As described in Section 1.2.2, bone has a complex structure and function. In order to 
operate, close interactions between bone and cells, matrix, bioactive factors are of 
vital importance. Therefore engineering bone requires a comprehensive approach 
with broad expertise [38]. Bone tissue engineering is based on the understanding of 
principles of bone formation and regeneration, and aims to combine living bone cells 
with biocompatible scaffolds as well as appropriate bioactive factors to induce new 
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functional bone tissue. Cells, scaffolds, and bioactive factors, especially biomolecules 
which induce bone functionality, are the main research areas in bone tissue 
engineering. Different approaches for developing biological bone substitutes are 
shown in Figure 3. 
 
(1) Cells: Various types of cells have been considered as promising candidates in bone 
tissue engineering including autologous cells, allogeneic cells, xenogeneic cells, stem 
cells, and genetically engineered cells. Autologous cells, such as periosteal cells, 
cortical cells, marrow cells, and cells derived from the surrounding soft tissues are 
preferred because of their non-immunologic effect [39]. However, patients are 
frequently unable to provide enough cells, especially those who have end-stage organ 
diseases.  
 
Stem cells are considered an alternative cell source because their outstanding ability 
to undergo osteogenic differentiation. The types of stem cells used in bone tissue 
engineering include embryonic stem cells, bone marrow-derived mesenchymal stem 
cells, umbilical cord blood-derived mesenchymal stem cells, adipose tissue-derived 
stem cells, muscle-derived stem cells, and dental pulp stem cells [40]. For example, 
embryonic stem cells can differentiate into the osteoblast lineage by supplementing 
the serum-containing media with ascorbic acid, β-glycerophosphate, and/or 
dexamethasone/retinoic acid, or by co-culture with fetal murine osteoblasts [41]. 
Moreover, pre-osteoblasts and osteoblasts, which are important for the development 
and maintenance of bone, have been widely used in bone tissue engineering. For 
example, pre-osteoblast MC3T3-E1 cells were seeded on polymer scaffolds to enhance 
bone regeneration [42].  
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Figure 3. Schematic representation of three main research areas in bone tissue 
engineering: cells, scaffolds, and bioactive factors. In each area, there are several 
different approaches that can be used individually or in combination to achieve bone 
regeneration. 
 
(2) Scaffold: A good scaffold must facilitate cells to attach, proliferate, and develop in 
a predictable and controlled way. At the same time, the scaffold needs to mimic the 
mechanical properties of the natural bone tissue, allow the diffusion of nutrients and 
waste products, and avoid an immune response [43]. Additionally, the scaffold should 
allow an efficient release and delivery of bioactive factors to induce bone formation 
[44]. In order to meet these requirements and to develop novel biocompatible and 
bio-functional scaffolds for bone tissue engineering applications, various natural and 
synthetic biocompatible materials have been developed and investigated. A brief 
review of porous material scaffolds used in bone tissue engineering is in Section 1.3. 
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(3) Bioactive factors: Cells need certain signals to survive and develop in their new 
environment after being seeded on scaffold. In order to stimulate the correct biological 
signals and induce the desired functionality, a number of bioactive factors including 
growth factors, hormones, specific metabolites, and chemical and physical stimuli are 
required for bone regeneration [45]. In the area of bone tissue engineering, 
biomolecules such as bone growth factors, extracellular matrix proteins, bioactive 
factor-derived peptides and other mineralisation-promoting proteins are of high 
interest. For example, bone morphogenetic proteins have been widely used in bone 
tissue regeneration because of their ability to promote differentiation and regulate 
cellular processes [46]. Examples of the biomolecules related to bone tissue 
engineering is reviewed in Section 1.4.  
 
1.3 Scaffolds for bone tissue engineering 
In vivo, the extracellular matrix provides an environment for cells to attach, proliferate, 
and differentiate. In tissue engineering, scaffolds are required to undertake this 
responsibility [47]. Three important steps are necessary for fabricating a suitable 
scaffold for bone tissue engineering applications [25]. The first step is to fully 
understand and consider the essential properties (listed in Table 1) of the scaffold for 
bone tissue engineering. Such properties affect not only cell survival, signalling, growth, 
propagation, and reorganisation, but also gene expression and phenotype [48].  
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Property Requirements 
Biocompatibility  Well integrated in the surrounding tissue 
 No immune response 
Porosity  With large surface area to volume ratios 
 Fully interconnected geometry 
 Well balanced with the mechanical needs 
Pore size  Within the 200-900 μm range for bone tissue engineering 
[49, 50] 
Surface properties  Well controlled chemical and topographical properties 
such as the surface roughness for easy adhesion of cells 
and proteins [51]  
Osteoinductivity  Controlled release of bioactive factors 
 Induction of osteogenic differentiation pathway 
Mechanical 
properties  
 Comparable to the living bone 
Biodegradability  Well matched degradation rate with the growth rate of 
the new bone 
Table 1. Essential properties of scaffolds for bone tissue engineering. 
 
The next step is to select the most appropriate materials to produce a scaffold. This is 
a very important step since the properties of the material will largely determine the 
properties of the scaffold [52]. Numerous materials have been considered including 
metals, polymers from natural and synthetic origins, and ceramics. Despite their lack 
of biodegradation, metal implants, particularly titanium implants, have been widely 
used in reconstructive surgery, orthopaedic surgery, and oral implantology as scaffolds 
for load-bearing, bone replacing, and contacting applications [53]. The purpose of 
using titanium implants is to obtain a life-long secure anchoring of the implants in the 
surrounding bone tissue [54]. A brief summary of titanium implants and surface 
modification methods of titanium implants is shown in Section 1.3.1 and 1.3.2, 
29 
 
respectively. In addition to metal, natural polymers such as fibrin, collagen, chitosan, 
and hyaluronic acid, and synthetic polymers such as poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-
caprolactone)(PCL), and poly(l-lactic acid) (PLLA) are well-studied scaffold candidate 
materials [55-57]. Table 2 reviews some polymers commonly used in bone tissue 
engineering [55, 58-60]. Among them, poly(ε-caprolactone) (PCL), which has been 
widely used as a model polymer, is reviewed in Section 1.3.3. 
 
The final step of fabricating a suitable scaffold is to develop or choose an appropriate 
processing technique. The chosen technique should not only be accurate and 
consistent, but also have no negative side effects on the materials properties [48]. 
Some common techniques are summarised in Table 3 including nano-fibrous 
electrospinning, solvent casting, gas foaming, and freeze drying [36].  
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Origin Material Positive features Negative features 
Natural Fibrin  Promotes cell migration 
and vascularisation 
 Promotes osteoconduction 
 Poor mechanical 
properties 
Collagen  Low immune response 
 Promotes osteoconduction 
 Poor mechanical 
properties 
Chitosan  Promotes osteoconduction 
and wound healing 
 Not soluble in 
water and organic 
solvents 
Hyaluronic 
acid 
 Minimal immunogenicity  
 Promotes osteoconduction 
 Poor mechanical 
properties 
Synthetic 
 
PLA  Easily metabolised in the 
body 
 Good mechanical 
properties 
 Strongly 
hydrophobic 
PGA  Good mechanical 
properties 
 Quick degradation 
 Not soluble in 
most organic 
solvents 
PLGA  Good mechanical 
properties 
 Adjustable degradation 
rate 
 Unstable 
compared to 
homopolymers 
PCL  Easily metabolised in the 
body 
 Low chemical versatility 
 Promotes osteoconduction 
 Slow degradation, 
unsuitable for 
short term 
applications 
Table 2. Natural and synthetic polymers used for bone tissue engineering. 
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Technique Advantage Disadvantage 
Nano-fibrous 
electrospinning 
 Simple operation 
 Adequate control of pore 
size and porosity  
 Fibre diameters ranging 
from several microns 
down to several hundred 
nanometers 
 Usually sheets or 
cylinders, not 3D scaffold 
shapes 
Solvent casting  Simple operation 
 Adequate control of pore 
size and porosity  
 Limited pore shape and 
thickness 
 Limited thickness ranging 
from 0.5 to 2 mm [61]  
 Limited inter-pore 
connectivity 
Gas foaming  Highly porous foams 
without the use of 
organic solvents 
 Closed-pore structure, 
with only 10–30% of 
interconnected pores 
[62]  
Freeze drying  Highly porous foams 
(over 90%) 
 Pore size ranging from 20 
to 200μm  
 Low mechanical stability 
 Pore sizes in the range of 
100 μm 
 Closed-pore structure 
[63]  
Table 3. The processing techniques for fabricating a suitable scaffold for bone tissue 
engineering. 
 
1.3.1 Bone substitute implants  
An implant is an artificial medical device made from a biocompatible material that is 
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designed and fabricated for substitution of a missing or damaged tissue [64]. Common 
applications include bone implants [65], dental implants [66], and cardiac implants 
[67].  
 
Titanium (Ti) is one of most widely used bone substitute implant materials, especially 
in load-bearing applications because of its superior properties, such as high 
mechanical strength, low weight, outstanding corrosion resistance, and very 
importantly, its biocompatibility. The biocompatibility of Ti implants is attributed to 
the 3-10 nm thick stable oxide layer on the implant surface which is formed by 
reactions with oxygen [68]. The oxide layer not only prevents the formation of fibrous 
tissue around the implant, but also creates direct contact with osseous tissue [53]. Ti 
used for medical implants began as early as the 1940s [69]. Since then, the usage of Ti 
implants has continually increased worldwide, with more than 1,000 tonnes of Ti 
implanted into patients every year [70]. Ti implants are also widely used in bone tissue 
engineering. For example, titanium foams, which have a pore distribution architecture, 
show excellent biomechanical properties and bioactivity to form a bone-like apatite 
layer [71]. However, although Ti shows good biocompatibility, implant fixation delay 
may be caused by the non-physiological surface that is directly exposed to a 
physiological environment of the native surrounding bone tissue without any 
physiological transition after implantation [72]. This can seriously diminish the quality 
of life for the patient. To enhance the interface between Ti and the surrounding tissue, 
and to reduce the time needed for bone implant fixation, surface modification of the 
Ti implants is believed to be an effective approach. Surface modification improves 
implant properties by modifying the implant surface characteristics such as 
composition, structure, and morphology, but leaving the mechanical properties intact 
[73]. Through surface modification, the tissue compatibility of the surface layer can be 
improved. 
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1.3.2 Surface modification of titanium implants 
Implant surface topography, surface biochemistry, and mechanical loading are 
believed to affect new bone formation [53]. For example, the surface roughness of Ti 
implants affects osteoblast growth and adhesion [74]. Surface modification is now a 
key consideration in developing functional bone implant materials. 
 
Several reviews summarise a variety of surface modification approaches for Ti or Ti 
alloys in the biomedical field (Figure 4) [54, 66, 75-78]. The approaches can be divided 
into two parts. First, surface topography approaches, which are achieved mainly 
through mechanical methods such as grinding, machining [79], and polishing [80], and 
chemical methods such as acid etching [81] and alkali etching [82]. Surface topography 
approaches have been widely used in industry because they are easy to perform. 
Second, surface biochemistry approaches which use coating techniques to create 
biologically active implant surfaces to promote bone formation [83, 84]. Research has 
been focused on biochemical methods to produce bioactive coatings that induce a 
specific cellular response and promote osseointegration. For example, chitosan was 
used as a biocompatible bioactive coating on Ti implant to enhance osteoblast 
attachment and growth [85]. There are mainly two bioactive coating types on titanium 
implants: inorganic coatings, such as calcium phosphate (CaP) coatings which mimic 
the mineral phase in nature bone [86], and organic biomolecule coatings which are 
fabricated from bone-related biomolecules such as growth factors, extracellular matrix 
proteins, and other mineralisation-promoting proteins. Growth factors such as 
platelet-derived growth factor and insulin-like growth factor on the Ti implant 
stimulated bone regeneration [87] and alkaline phosphatase, an important enzyme in 
bone formation, accelerated mineralisation when coated on Ti implants [72], improved 
the osteogenic response [88], and enhanced periprosthetic bone formation [89]. Some 
peptides derived from these biomolecules can also be immobilised onto Ti implant 
surfaces to enhance bone regeneration. For example, the well-known peptide 
sequence Arg-Gly-Asp (RGD), which plays an important role in osteoblast adhesion, 
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was coated on Ti implant to enhance tissue integration [90] and stimulate bone 
formation [91]. 
 
 
Figure 4. Surface modification techniques of titanium implants used in bone tissue 
engineering to improve biocompatibility [54, 66, 75-78].  
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1.3.3 PCL scaffolds for bone tissue engineering 
Poly(ε-caprolactone) (PCL) is one of the most widely studied polymers and has been 
successfully used as a scaffold in bone tissue engineering applications [92, 93]. PCL is 
a fully biodegradable, semi-crystalline polymer with a low glass transition temperature 
(-60°C), a low melting temperature (59 to 64°C) and a high decomposition temperature 
(350°C) [94]. PCL degrades at a lower rate than PLA and PLGA due to its high 
hydrophobicity and crystallinity [95], making PCL suitable for long term, load-bearing 
applications. Additionally, PCL is cheaper, more stable, and available in larger 
quantities than other polymers.  
 
In addition to using it alone, PCL can also be combined with various other polymers 
and biomolecules. Numerous studies have been carried out using PCL biocomposites 
and copolymers with polymers and proteins [96, 97]. For example, the enzyme alkaline 
phosphatase was directly encapsulated in PCL microtubes fabricated by co-
electrospinning [98]. And an encapsulated lipase in PCL preserved 50% of its original 
activity after the 10th run in the transesterification reaction in hexane medium [99].  
 
1.4 Biomolecules for bone tissue engineering 
In many bone tissue engineering applications, simply culturing cells on scaffolds is 
insufficient for bone regeneration. This is because cells require appropriate bioactive 
factors to induce functionality and to thereafter develop tissue. As described in Section 
1.2.3, biomolecules such as bone growth factors, cellular matrix proteins, bioactive 
factor-derived peptides, and other mineralisation-promoting proteins can be used as 
bioactive factors to enhance bone formation and develop bone substitutes [38]. These 
biomolecules may play a role in the steps towards bone formation including 
modulating cell attachment, growth, differentiation, and migration. 
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Bone formation is an extremely complex process involving a large number of 
biomolecules that therefore have the potential to be used in bone tissue engineering. 
Here, the highly studied ones are reviewed, including bone growth factors, in 
particular bone morphogenetic proteins and derived peptides, cellular bone matrix 
proteins, and other mineralisation-promoting proteins such as alkaline phosphatase. 
 
1.4.1 Bone growth factors 
Growth factors, which play a key role between cells and the microenvironments, have 
the ability to stimulate proliferation and differentiation, and to regulate various cellular 
processes including cellular development, matrix production, and tissue regeneration 
[20]. With regard to bone growth factors, various bone-derived growth factors have 
been investigated, including insulin-like growth factor I and II (IGF-I, IGF-II), 
transforming growth factors (TGF-beta 1, TGF-beta 2), platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF), and bone morphogenetic proteins (BMPs). The 
origin, functions, signalling pathways, and cellular target of these bone growth factors 
are listed in Table 4. They are mainly isolated from bone matrix extracts and bone cells, 
or bone organ culture media [100]. All of these bone growth factors play important 
roles in the local regulation of bone formation, but they may target different cells of 
the osteogenic lineage, and have a specific role in different stages of regulating cell 
proliferation and differentiation [101]. For example, IGF-I stimulates bone matrix 
synthesis in calvariae through its stimulatory effect on DNA synthesis [102]. Basic FGF 
stimulates calvarial DNA synthesis, which causes an increased number of collagen-
synthesizing cells, and eventually enhances bone formation [103].  
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Bone growth factor Origin Main functions Cellular target 
Insulin-like growth factor 
(IGF) 
Bone extracellular matrix, 
osteoblasts, chondrocytes 
 Stimulates type I collagen production 
 Stimulates cellular proliferation  
Tyrosine kinase 
receptors 
Transforming growth factor 
beta(TGF-beta) 
Bone extracellular matrix, platelets  Stimulates type II collagen production 
 Stimulates cell replication and the 
formation of extracellular matrix 
Serine/threonine kinase 
receptors 
Platelet-derived growth 
factor (PDGF) 
Osteoblasts, platelets  Signals inflammatory cells to migrate 
to fracture site 
 Promotes angiogenesis 
 Stimulates cell replication 
Tyrosine kinase 
receptors 
Fibroblast growth factor 
(FGF) 
Osteoblasts, chondrocytes, 
macrophages, mesenchymal cells 
 Promotes angiogenesis 
 Stimulates cell replication 
Tyrosine kinase 
receptors 
Bone morphogenetic 
protein (BMP) 
Bone extracellular matrix, 
osteoprogenitor cells 
 Activates mesenchymal cells to 
transform into osteoblasts 
 Regulates chondrocytes and bone-
marrow stromal cells 
Serine/threonine kinase 
receptor 
Table 4. Growth factors used in bone tissue engineering and their main functions [100, 101].
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In addition to the five main bone growth factors mentioned in Table 4, there are other 
regulators of bone listed below. Although they may have other main functions, they 
are all directly or indirectly related to bone formation. Some of them may have a 
biphasic effect on bone formation depending on timing, dosage and the duration of 
administration. 
 
(1) Vascular endothelial growth factor (VEGF): Although VEGF is an essential regulator 
in the development and modulation of angiogenesis, it is also functional in bone repair. 
It has been shown that blocking VEGF activity in mice results in an enlarged area of 
hypertrophic cartilage and impaired trabecular bone formation [104]. VEGF is also 
believed to regulate growth plate morphogenesis, cartilage remodelling and 
ossification [105].  
 
(2) Epidermal growth factor (EGF): EGF has biphasic effects on cell growth, 
proliferation, differentiation, and bone formation. Osteoblast growth and bone 
formation can be either increased or decreased by controlling the treatment time and 
dosage of EGF [106-108]. The results indicate that EGF may be functional in the early 
phase of bone formation process to promote osteoblast growth rather than the late 
phase involving mineralisation [109].  
 
(3) Nerve growth factor (NGF): NGF is an important regulator for the growth, 
maintenance, and survival of certain neurons. It is also has the ability to enhance bone 
regeneration in a fracture model and to stimulate osteoblast differentiation [110].  
 
(4) Erythropoietin (EPO): EPO is an essential factor controlling erythropoiesis. In 
addition, studies show that EPO induces bone formation either by activating the 
production of BMPs or by directly activating mesenchymal cells to form osteoblasts in 
vitro [111]. 
 
(5) Wnt proteins (Wnts): Wnts are a group of glycoproteins which regulate cell 
behaviours including cell growth, differentiation, and function. They also regulate the 
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bone remodelling process [112]. For example, Wnt7b, which is expressed by 
osteogenic cells, induces osteoblast differentiation in vitro and promote bone 
formation [113].  
 
1.4.1.1 Bone morphogenetic proteins 
Among all bone growth factors used to induce bone formation, bone morphogenetic 
proteins (BMPs) are the most potent inducers of ectopic bone formation described to 
date. They show clear functions in the regulation of bone formation, which have been 
examined extensively in vivo [114-116]. BMPs are members of the transforming 
growth factor superfamily, and are inducers of bone regeneration and ectopic bone 
formation [117], as well as regulators of the key steps of cartilage and bone 
morphogenesis [118]. BMP was first identified to be responsible for the induction of 
new bone in the 1960s, when demineralised bone matrix implants in ectopic sites in 
rats were found to induce bone formation [119]. The role of BMP became clear when 
the purification and sequence of bovine BMP-3 and cloning of human BMP-2 and -4 
were investigated in the late 1980s [120-122].  
 
Similar to other members of the TGF superfamily, BMPs are first synthesised as large 
precursor proteins containing a hydrophobic leader sequence, followed by the pro-
peptide and the mature part of the protein. The precursor protein will cleave to yield 
carboxyl terminal mature dimers upon dimerisation [121]. The crystal structure reveals 
that BMPs contain a cysteine knot containing six cysteine amino acid residues in their 
carboxyl terminal [123]. The cysteine knot is responsible for the formation of dimer 
through disulphide bonds. In addition, BMPs contain N-linked glycosylation sites [123]. 
After secretion to the extracellular space, BMPs bind to serine/threonine kinase 
receptors which contain type I and II subtypes on the cell surface to achieve their 
signalling function [124]. Type I and II BMP receptors and their downstream molecules 
Smad-1, 5 and 8 are essential for signal transduction [125].  
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Approximately 20 BMPs have been identified and characterised to date [126]. The 
functions of some BMP family members are summarised in Table 5. Based on the 
amino acid sequence similarities of the mature regions of BMPs, the BMP family 
members can be broadly classified into several subfamilies [127]. Both BMP-2 and 
BMP-4 have 80% amino acid sequence homology of molecules; BMP-5, -6, -7 and -8 
have 78% amino acid sequence homology; BMP-12, -13 and -14 also have high 
homology. However, BMP-3 and BMP-11 are significantly different from the any other 
members and stand as two separate subfamilies [122, 126, 127].  
 
Although various BMPs are naturally existing in the body, researchers have focused on 
BMP-2 and BMP-7 because of their specialist functions. For example, BMP-2 is one of 
the most thoroughly investigated BMPs that has been approved for clinical studies to 
successfully simulate spinal fusion equal to or better than the patient’s own bone [128]. 
This means spinal fusion can be achieved without painful surgery and patients 
experience fewer side effects and complications. BMP-7, also called osteogenic protein 
(OP-1), has the ability to stimulate osteoblast differentiation [129], and convert C2C12 
cells from myoblasts into osteoblast lineage cells [130]. However, large amounts of 
BMP-2 are required during the treatment [131-133]. Although BMPs are natural 
components in the body, high concentrations of BMPs may lead to immunological and 
carcinogenic effects. In addition, difficulties in the mass production of BMP-2 make it 
expensive and thus it does not have extensive applications in clinical practice [134, 
135]. Furthermore, BMPs have several hundred amino acids, which are too large and 
complex to chemically functionalise on nanostructured materials (such as particles and 
fibres) [135, 136]. 
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BMP Main functions 
BMP-2  Induces osteoblast differentiation 
 Mediates retinoid 
BMP-3  Inhibits osteogenesis 
BMP-4  Induces osteoblast differentiation 
 Regulates the formation of teeth, limbs, and bone 
 Repairs fractures 
BMP-5  Induces chondrogenesis 
BMP-6  Plays a key role in osteoblast differentiation  
 Induces chondrogenesis  
 Controls iron homeostasis via regulation of hepcidin 
BMP-7 (OP-1)  Induces osteoblast differentiation 
 Regulates renal development and repair 
BMP-8a  Induces osteoblast differentiation 
 Induces chondrogenesis 
BMP-8b  Induces osteoblast differentiation 
BMP-9  Induces hepatogenesis  
 Plays a role in the nervous system 
BMP-10  Plays a role in the trabeculation of the embryonic heart 
BMP-11 (GDF-8)  Plays a role in mesodermal and neuronal tissues 
BMP-12(GDF-7)  Induces tendon-iliac tissue formation 
BMP-13(GDF-6)  Induces tendon and ligament-like tissue formation 
BMP-14(GDF-5)  Induces chondrogenesis 
 Enhances tendon healing 
BMP-15  Modifies follicular development 
Table 5. BMP family members and their main functions [126, 127]. 
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1.4.1.2 Peptides derived from BMPs 
To overcome the problems triggered by the use of full-length BMP proteins, peptides 
derived from BMPs were designed and used for bone tissue engineering applications 
as listed in Table 6 [118, 129, 136-140]. 
 
Peptide Source Main functions 
P24 peptide BMP-2 Enhances the osteoblastic 
differentiation of bone 
marrow stem cells 
KIPKASSVPTELSAISTLYL ‘knuckle 
epitope’ of 
BMP-2 
Increases alkaline phosphatise 
activity in osteoblasts 
KPCCAPTQLNAISVLYFDDS, 
AISVLYFDDSSNVILKKYRN 
BMP-7 Encourages the mineralisation 
process in osteoblasts 
SNVILKKYRN, KPSSAPTQLN BMP-7 Promotes osteoblast 
proliferation 
KAISVLYFDDS BMP-7 Increases osteoblast calcium 
deposition 
Table 6. Peptides derived from BMPs used for bone tissue engineering applications. 
 
By using peptide sequences, a specific cellular interaction related to a certain fragment 
of the entire protein can be targeted without any unwanted responses. In addition, 
peptide sequences can be easily produced by chemical synthesis, which allows a 
precise control of the chemical components and avoids the species differences from 
biological synthesis [141]. Furthermore, small peptide sequences tend to be a more 
efficient approach especially in surface coating applications because more peptides 
with active sites can be immobilised on the same surface area than large proteins, 
therefore exposing more active sites. Even more important, these peptide sequences 
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possess similar functionalities compared to the proteins. It was reported that specific 
peptides support bone mineralisation [129] and induce bone formation [142]. For 
example, the BMP-7-derived peptide KAISVLYFDDS has the ability to increase 
osteoblast calcium deposition, which is an essential step in bone formation [136]. 
Therefore, the use of BMP-derived peptides is a promising approach for the 
construction of biomaterials for bone repair. 
 
1.4.2 Extracellular matrix proteins 
Bone matrix is a composite material located between the cells that contains inorganic 
and organic components. The inorganic component, which is composed of carbonate 
rich hydroxyapatite (with a carbonate content between 4% and 8%, w/w) [143], 
provides compressive strength and serves as a mineral store of calcium and phosphate 
[26]. The organic part of bone matrix contains 90% collagen (primarily type I collagen) 
and a number of non-collagenous proteins to make up the remaining 10%. 
 
Collagen, which is the most abundant protein in the body, plays critical roles in the 
structure and function of bone tissue. Cell and molecular evidence indicates that 
collagen also has direct effect on bone cell function including apoptosis, proliferation, 
and differentiation [144-146]. For example, type I collagen plays a key role in mediating 
the signalling cascade for expression of a mature osteoblast phenotype and 
mineralisation of the extracellular matrix [146]. Non-collagenous proteins, such as 
osteocalcin, osteonectin, bone sialo-protein, fibronectin, thrombospondin, and 
certain proteoglycans, are expressed by osteoblasts during osteogenesis. Similar to 
collagen, many non-collagenous proteins have been shown to have multiple functions 
on bone cells including regulation of collagen fibril mineralisation, cell division, 
migration, differentiation and maturation, growth factor activity, and tissue integrity 
and function [147, 148]. For example, osteocalcin, the most abundant non-collagenous 
protein in bone (10-20% of total, w/w), is important in bone metabolic regulation and 
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is thought to play a role in bone mineralisation and calcium ion homeostasis [149]. It 
has also been used as a clinical marker for bone turnover by measuring its presence in 
urine. Table 7 gives information about some of the most highly studied bone matrix 
proteins to date [150].  
 
Bone matrix protein Main functions 
Type I collagen  Provides tensile strength 
 Plays a key role in the structure and function of bone 
tissue 
 Affects bone cell function 
Osteocalcin  Promote mineralisation and bone formation  
 Regulates bone metabolism 
 Binds calcium 
Osteonectin  Induces osteoblast differentiation 
 Regulates mineralisation  
Osteopontin  Increases angiogenesis  
 Enhances bone resorption 
Bone sialo-protein  Binds to integrins, may assist cancer cells 
Fibronectin  Regulates osteoblast differentiation 
Thrombospondin  Inhibits bone cell precursors 
Proteoglycan  Responsible for compressive strength  
 Inhibits mineralisation 
Table 7. Bone matrix proteins and their main functions [150]. 
 
Because of the importance of bone matrix proteins in the bone formation process, 
extensive studies have been carried out to functionalise scaffolds with elements of 
bone matrix proteins in bone tissue engineering. The bone matrix proteins involved in 
the cell adhesion process including type I collagen, osteopontin, bone sialo-protein, 
fibronectin, thrombospondin and vitronectin are of particular interest [151, 152]. Cells 
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need specific adhesion molecules to bind to a surface, the extracellular matrix or 
another cell. Cell adhesion is essential because it directly influences the following steps 
of cell behaviour, including growth, differentiation, and migration. One family of well-
known cell adhesion molecules are the integrins, which bind to specific amino acid 
sequences such as arginine-glycine-aspartic acid (RGD) within bone matrix proteins 
[153]. Thus, bone matrix proteins containing the RGD sequence have been widely 
considered as bioactive factors for mimicking the nature interface, promoting cell 
adhesion, and influencing the response of osteoblasts. 
 
Similar to BMPs, it is not only the entire bone matrix proteins that are effective in 
enhancing cell adhesion, and short peptides derived from them have also been 
considered as potential bioactive factors. The most widely used peptide sequence in 
bone tissue engineering is the cell adhesion peptide RGD [154]. Covalent attachment 
of RGD peptides on different polymers stimulates adhesion and spreading of cells 
[155]. Combination of RGD peptides with other bioactive factors such as bone growth 
factors has been considered another promising approach [151, 156].  
 
1.4.3 Other mineralisation-promoting proteins 
Bone is formed in two stages: first a protein matrix that can become calcified is 
synthesised, and then mineral is deposited. The process of depositing apatites and 
other salts onto extracellular matrix fibres is referred to as bone mineralisation [157]. 
Although the mechanism of bone mineralisation has not been fully understood, two 
possibilities for the control of mineralisation are known [30]. First, the process may 
controlled by growth factors and other regulators which mediate cell activity of 
producing the components of mineral. Second, bone mineralisation may also 
controlled by the organic component of the bone matrix such as collagen, non-
collagenous proteins, alkaline phosphatase, as well as citrates and lipids [30]. Among 
them, the metalloenzyme alkaline phosphatase (ALP) is the most studied 
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mineralisation-promoting factor in bone tissue engineering applications [72].  
 
1.4.3.1 Alkaline phosphatases 
Alkaline phosphatase (ALP) is a metalloenzyme that can be widely found in most 
species, from bacteria to humans [158]. They naturally exist as homodimers and each 
monomeric subunit contains a catalytic site with two Zn2+ and one Mg2+. These three 
metal ions are necessary for enzymatic activity, and also play a role in the conformation 
of the ALP monomer and indirectly regulate subunit-subunit interactions [159, 160]. A 
single subunit fails to display any catalytic activity on its own. 
 
There are a total of four kinds of ALPs in mammals, all of which reside on the surface 
of the plasma membrane by a covalently attached glycosylphosphatidylinositol anchor 
[161]. Three of them are tissue-specific: placental alkaline phosphatase (PLAP), germ 
cell alkaline phosphatase (GCAP), and intestine alkaline phosphatase (IAP). The 
functions are not been clearly understood, but PLAP may play a role in the regulation 
of cell division and proliferation as well as the mediation of IgG transport through the 
placenta; GCAP may be related to early embryonic development and germ cell 
development; IAP is likely to be involved in the intestinal absorption of lipids [161]. 
The fourth ALP in mammals is tissue nonspecific alkaline phosphatase (TNAP). As its 
name implies, it can be found in more than one tissue, mainly in bone, liver and kidney.  
 
ALPs were first noted by Robison in 1924, who found that a higher than normal level 
of ALPs were detected at the sites of mineralisation in bone and calcifying cartilage 
[162]. The hypothesis derived from the observation was that ALPs have the ability to 
hydrolyse organic phosphates phosphoric esters and generate inorganic phosphates, 
thus resulting a local increasing of phosphate ions which were finally precipitated as 
calcium phosphates at the site of calcification [162]. Over decades, many researchers 
have gained a deeper understanding of the bone mineralisation process and the 
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function of ALPs. There are two stages of mineralisation in woven bone and calcifying 
cartilage: biologic mineralisation and crystal growth [163, 164]. Biologic mineralisation 
is initiated from specific regions of the outer plasma membrane of osteoblasts, 
chondrocytes and odontoblasts, which contain high levels of ALPs. ALPs hydrolyse 
organic phosphatases and provide inorganic phosphate. Then the inorganic phosphate 
ions are transported into vesicles, which contain calcium binding proteins through 
Na+/Pi co-transporters. Calcium binding proteins have the ability to concentrate 
calcium ions. With the gradual accumulation of both phosphate ions and calcium ions 
in these particles, the first hydroxyl apatite crystal appears. Once the apatite crystal 
forms, the vesicle breaks down, which marks the end of the first biologic mineralisation 
stage. In the next stage of mineralisation, crystal growth continues and spreads 
throughout the bone matrix with a constant supply of phosphate ions and calcium ions 
from the body fluid [165].  
 
The process of bone mineralisation indicates that ALPs are essential components that 
catalyse the hydrolysis of organic phosphate monoesters present in the surrounding 
body fluids and generate inorganic phosphate ions during the first stage of bone 
mineralisation. Additionally, ALPs have an equally important function of reducing the 
level of pyrophosphate, which is an inhibitor of mineralisation that not only poisons 
the crystals, but also prevents interactions between crystals and the interstitial fluids 
by covering the crystal surface [166]. Figure 5 shows how ALPs increase the local 
concentration of inorganic phosphate, a mineralisation promoter, and at the same 
time, decrease the concentration of extracellular pyrophosphate, an inhibitor of 
mineral formation [167].  
 
 
Figure 5. The role of ALPs in the bone mineralisation process. The catalytic action of 
Pyrophosphate 
Inhibitor of minerlisation 
Hydroxyapatite 
HA 
Organic phosphate 
monoesters 
ROP 
 
Inorganic phosphate 
Pi 
PPi 
ALP 
ALP 
48 
 
TNAP increases the inorganic phosphate (Pi) concentration of hydroxyapatite (HA) by 
hydrolysis of organic phosphate monoesters (ROP) as well as pyrophosphate (PPi), an 
inhibitor of mineralisation [167]. 
 
ALPs are considered well-conserved enzymes. According to a sequence analysis of 
mammalian ALPs, PLAP, GCAP and IAP are highly homologous (90-98%) with each other, 
and TNAP is 50% identical to the others [168]. The same is true for Escherichia coli (E. 
coli), and although E. coli ALP has a relatively low sequence identity with the 
mammalian enzymes (25-30%), the residues involved in the active site and the ligands 
coordinating three metal ions are largely conserved [169]. In addition, the X-ray 
analysis of the E. coli ALP and the mammalian ALPs suggests that all ALPs have a similar 
fundamental three-dimensional structure [170]. Therefore, based on the sequence 
and structural homology, E. coli and mammalian ALPs are believed to have a similar 
catalytic mechanism [159]. The general reaction scheme of ALPs is summarised in 
Figure 6. The whole process occurs in four steps: 1) reaction of the enzyme ALPs and 
organic substrate to form an enzyme-substrate complex (EROP), 2) phosphorylation 
of the enzyme serine residue to form the covalent enzyme-phosphate complex (E-P), 
3) hydrolysis of E-P to form the non-covalent enzyme-phosphate complex (EP), and 4) 
dissociation of enzyme-bound phosphate and release of inorganic phosphate [159].  
 
E + ROP ⇋ E ROP ⇋ E-P ⇋ EP ⇋ E + P 
Figure 6. The general scheme for the ALPs-catalysed hydrolysis of phosphate 
monoesters. E represents the enzyme ALPs, ROP represents an organic phosphate 
monoester, and P represents the phosphate product. The non-covalent bond is 
represented by a dot and the covalent chemical bond is represented by a dash. A 
substrate is first reacted with the enzyme to form an enzyme-substrate complex. Then 
a temporary covalent enzyme-phosphate complex is formed by attacking a serine 
residue of the substrate, followed by the hydrolysis of the complex. Finally inorganic 
phosphate is released.  
 
Although ALPs have commonality in their catalytic mechanism, sequence, and 
conformation, E. coli ALP is smaller, has a lower optimum pH and displays higher heat 
stability compare to mammalian ALPs [158, 161]. In addition, E. coli ALP is located in 
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the periplasmic space between the cell membrane and cell wall, which makes it more 
durable and easier to isolate [171, 172].  
 
Similar to other members in the ALP family, E. coli ALP (EC 3.1.3.1) is a dimeric 
metalloenzyme. Each monomer contains 449 amino acid residues and two atoms of 
zinc and one atom of magnesium at each active site [159]. The enzyme is encoded by 
the phoA gene, and synthesised as a precursor monomer with a signal peptide at the 
N-terminus. The active enzyme is formed by removing the signal peptide and 
dimerising two of the resulting mature monomers before transportation to the 
periplasmic space of E. coli [173, 174]. The molecular weight of the dimer has been 
reported as ranging from 80-100 kDa [173].  
 
Based on the X-ray crystal structure analysis of E. coli ALP, the active site can bind the 
inorganic phosphate by the two zinc atoms and the guanidinium group of arginine 166 
[168, 175]. In order to better understand the function of certain conserved amino acid 
residues around the active site and to investigate the reaction mechanism of E. coli 
ALP, a number of studies have been performed using a site-directed mutagenesis 
strategy [175-179]. Results suggest the catalytic activity of E. coli ALP can either be 
increased or reduced by different mutations. For example, when arginine 166 is 
substituted by alanine or serine, the catalytic activity is reduced; but when aspartic 
acid 101 is replaced by alanine, enzyme activity is increased at alkaline pH which may 
due to an increasing accessibility of the substrate and a reducing affinity for phosphate 
[175]. High catalytic activity is always a desired property for ALPs because it means a 
stronger ability to generate inorganic phosphatase from organic phosphatase. Based 
on the former research, Xu et al. have developed a series of E. coli ALP mutations with 
significantly higher catalytic activity and decreased affinity for the phosphate 
competitive inhibitor compared to the wild-type (wt) E. coli ALP [180]. By applying a 
directed evolution strategy, mutant E. coli ALP 4-186, which contains three amino acid 
residue replacements (aspartic acid 101 was replaced by serine (D101S), lysine 167 
was replaced by arginine (K167R), and serine 374 was replaced by cysteine (S374C)) 
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was engineered with an improved catalytic activity of nearly 35 times than that of wt 
E. coli ALP (Table 8, Figure 7) [180]. These mutated E. coli ALPs are promising 
candidates for bone tissue engineering applications. 
 
E. coli ALP Amino acid residuals 
replacement 
Specific activity  
(unit/mg protein) 
 pH 10.05 1M 
Activity increased times  
(compared to wild-
type) 
Wild-type None 37.5 1 
D101S D101S 415.8 11.1 
2-834 D101S, K167R 539.4  14.4 
4-186 D101S, K167R and S374C 1302.1 34.7 
Table 8. Biological activity of the wild-type and some mutant E. coli ALPs according to 
Xu et al. Among them, mutation 4-186 shows almost 35 times higher activity compare 
to the wild-type [180]. 
 
Figure 7. The three-dimensional protein structure of the mutant E. coli ALP 4-186 dimer, 
which contains D101S (green), K167R (blue) and S374C (red) replacements. This figure 
was drawn using PyMOL (www.pymol.org). 
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1.4.3.2 Lipids 
In addition to the biomolecules mentioned above, lipids are also important 
components of the bone matrix and may have the potential to be functional in bone 
tissue engineering. It has been found that a calcium-phospholipid-phosphate complex 
has the ability to induce crystallisation [181]. Phospholipids are also associated with 
matrix vesicles in calcifying cartilages [182].  
 
1.5  Engineered recombinant proteins for bone tissue 
engineering 
As introduced in Section 1.4, bioactive molecules such as bone growth factors, cellular 
matrix proteins, and other mineralisation-promoting proteins play a crucial role in 
bone formation and regeneration. However, there is the question of how to produce 
these biomolecules in a large scale to meet the demands for medical treatments and 
research, while maintaining their native function and activity. 
 
There are two main strategies for obtaining biomolecules for bone tissue engineering 
[45, 183]. The first is to isolate biomolecules from bone tissue. Since these 
biomolecules are produced by cells and naturally exist in bone tissue, the 
straightforward way of using them is to isolate and purify them from bone tissue. It is 
a classical way of obtaining biomolecules and the functions of these molecules can be 
preserved. However, many of these biomolecules are naturally expressed at very low 
concentrations in bone tissue so that the amount of production is limited and the 
purification process is difficult and time-consuming. The second strategy is 
recombinant protein synthesis [184, 185]. In order to produce abundant amounts of 
biomolecules and to overcome the purification problem, recombinant protein 
synthesis system was developed [183]. A recombinant protein is a manipulated form 
of a protein that is derived from recombinant DNA [186]. In the following section, the 
52 
 
general principles and production strategies of recombinant proteins are summarised. 
 
1.5.1 General principles 
Recombinant proteins are generated in various ways from the expression of 
recombinant DNA. Recombinant DNA, as the name implies, is a type of DNA that is 
artificially created by combining one or more strands of DNA into a different set of 
DNA using cloning methods [187, 188]. The recombinant DNA technique was first 
developed in the early 1970s after the discovery of restriction enzymes, which have 
the ability to open a strand of DNA at certain “restricted” points and combine foreign 
DNA with the carrier DNA at this point [189].  
 
Generally, the cloning and expression recombinant protein can be divided into six steps 
(Figure 8) [186, 190-192]:  
(1) Choose a target gene and a vector. In bone tissue engineering, the target gene 
usually codes for a bioactive molecule such as a bone growth factor. A vector is a carrier 
of the target DNA. The most widely used vectors are plasmids. They are small and 
replicable circular DNA molecules which do not act as a part of the main cellular 
genome but can carry foreign genes that may entitle host cells with useful properties 
such as drug resistance, mating ability, and toxin production [173]. Section 1.5.2.2 
reviews the most commonly used cloning vectors and expression vectors in genetic 
engineering to produce recombinant proteins. 
 
(2) Cleave the target gene and the vector with a restriction enzyme. Restriction 
enzymes recognise and cut the DNA at specific target sequences. After cutting, either 
sticky ends or blunt ends are produced. Sticky ends, the single-stranded overhang DNA 
ends at the site of cleavage, are of particular interest because they have identical 
nucleotide sequences and can pair with other overhangs with the same ends [193]. 
Therefore, by cutting with the same enzyme, the target DNA and the vector have a 
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strong possibility of ligation because of the complementary sticky ends. 
 
(3) Construct recombinant DNA. In order to construct a stable recombinant DNA, both 
hydrogen bonds and covalent bonds need to be sealed. While the hydrogen bonds can 
be formed between the complementary sticky ends of the target DNA and the vector 
because of the restriction enzymes, the covalent bonds that hold the sugar-phosphate 
backbone have to be sealed by an enzyme DNA ligase which catalyses the formation 
of phosphodiester linkages between nucleotides [194]. This process is called ligation. 
 
(4) Transform into a host cell. A ligation solution containing a population of 
recombinant DNA is mixed with competent living cells, which are specially treated cells 
with high acceptability to foreign DNA. This process is called transformation. There are 
two popular transformation methods: by heat shock and by electroporation [195]. The 
preparation of competent cells and transformation are described in Section 3.2.7. 
After transformation, the recombinant DNA molecule will replicate along with the 
dividing and reproducing of the host cells. Expression systems and host cells are 
introduced in Section 1.5.2.1. 
 
(5) Screen transformants. The mixture solution of transformed cells is spread out on 
a Petri dish with selectable medium so that the cells are separated from one another. 
The vector usually contains a selectable marker such as an antibiotic marker to identify 
successful recombinant. Only the hosts with the vector will live because they have 
resistance to the antibiotics. In addition to antibiotics, the substrate of target 
recombinant protein can be used to select successful recombinant. 5-bromo-4-chloro-
3-indolyl phosphate (BICP) can react with ALPs and generate a blue product. Blue 
colonies developed on the BCIP-plate indicating the expression of ALPs [175]. Each 
colony growing on the dish is a cell clone, which is genetically identical and therefore 
contains the same recombinant vector [196]. 
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Figure 8. The cloning process to produce recombinant plasmids. The target DNA and 
the vector are cut with the same restriction enzymes to generate complementary 
sticky ends. By adding the enzyme DNA ligase, the target DNA and the vector are 
ligated to form a new recombinant DNA molecule. After transforming into suitable 
host cells, the recombinant DNA is reproduced along with the host cell DNA. 
 
(6) Recombinant protein production and purification. Recombinant protein 
production involves inserting the target recombinant DNA into an expression vector 
following a promoter so that the recombinant protein can be expressed by triggering 
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the promoter with an inducer. Take one of the most widely used expression vectors 
pTrc which contains a tac (trp/lac) promoter for example. If a recombinant DNA is 
inserted into a pTrc vector and is located after the tac promoter, the expression of 
desired recombinant proteins will be stimulated by the inducer lactose or its analog 
isopropyl-β-D-thiogalactopyranoside IPTG [197]. 
 
1.5.2 Strategies of producing recombinant proteins 
The requirement of high quality recombinant proteins used for either laboratory 
studies or industrial applications has increased dramatically in recent years [198]. 
According to www.phrma.org, more than 75 types of recombinant proteins have been 
used as pharmaceuticals, and more than 360 new medicines based on recombinant 
proteins are being developed [199]. Higher production efficiencies as well as lower 
costs of the final product are important factors for recombinant protein production 
[200]. In order to achieve the mass production, different strategies have been applied 
by using different expression systems and different vectors. 
 
1.5.2.1 Choice of expression system 
There are two main systems for the expression of recombinant proteins: prokaryotic 
(phage, bacteria) expression systems and eukaryotic (mammalian cell, yeast) 
expression systems [198, 201]. The choice of expression system is very important 
because it determines the choice of vector and affects the expression and purification 
method of the recombinant protein. In order to find the most suitable host, the 
specific requirements and applications for the recombinant protein should be 
considered, such as cell growth characteristics, expression levels, biological activity of 
the target protein, and potential toxicity [202, 203]. Table 9 summarises the 
advantages and disadvantages of some commonly used host systems. 
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Host Advantage Disadvantage 
Bacteria E. coli  Rapid cell growth 
 Easy induced 
expression by IPTG 
 Easy to grow with high 
yields (up to 50% of 
total cell protein) 
 Simple purification 
 Easy to form inclusion 
bodies 
 No post-translational 
modification 
 Biological activity and 
immunogenicity may differ 
from natural protein 
Bacteria 
Staphylococcus 
aureus 
 Secretes fusion proteins 
into the growth media 
 Lower expression levels 
than E. coli 
Mammalian cell  Same biological activity 
as native proteins 
 High levels of 
expression 
 Slower cell growth 
 Manipulated cells can be 
genetically unstable 
Yeast  Easy to form disulphide 
bonds and glycosylation  
 Well established large 
scale production and 
downstream processing 
 Difficult to control gene 
expression  
 Glycosylation not identical 
to mammalian systems 
Baculovirus cells 
(insect) 
 High level of expression   Product not always fully 
functional 
Fungi  Secrete large quantities 
of product into growth 
media 
 Cheap  
 Low level of expression 
 No cloning vectors 
available 
Table 9. Advantages and disadvantages of the commonly used host systems for 
recombinant protein production. 
 
Bacteria expression systems, especially E. coli host cells, are believed to be the simplest 
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and most inexpensive way to produce large amounts of recombinant proteins [186]. 
That is mainly attributed to the easily achieved high cell density culture of E. coli [204]. 
In addition, because E. coli is such a well-characterised system, various approaches for 
the efficient production have been established. Recent studies have made it possible 
that recombinant proteins can be secreted into a specific cellular compartment of E. 
coli as shown in Figure 9 [203]. These features will further improve E. coli as a host for 
production of recombinant protein.  
 
 
Figure 9. Advantages and disadvantages of the recombinant protein production into 
each compartment (the cytoplasmic space, the periplasmic space or the extracellular 
culture medium) of E. coli [203]. 
 
1.5.2.2 Choice of vectors 
In order to transport the target gene into host cells for protein expression, molecular 
vehicles called vectors are used. Essentially, a vector is a genetic frame which carries 
the target gene to be cloned, together with a number of necessary parts that will 
ensure the protein expression in the host [186, 190, 205]. As mentioned above, the 
choice of vector is determined by the host. Once the host has been selected, matched 
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vectors are available for consideration. Same as the choice of host system, the final 
choice of vector should consider the specific requirements of the application and the 
behaviour of the target protein [206].  
 
Generally, there are two types of vectors: cloning vectors and expression vectors [190, 
207]. A cloning vector is designed mainly for cloning purposes. There are many types 
of cloning vectors, but plasmids are the most commonly used ones. The cloning vectors 
usually have high copy numbers so that target DNA fragments within the vector will 
be amplified in the host cells. Once enough copies of the target DNA is achieved, the 
target DNA fragment may be further subcloned into another vector such as expression 
vector which is designed for protein expression in cells [207]. To achieve this goal, an 
expression vector must include a strong promoter, the correct translation initiation 
sequence such as a ribosomal binding site and start codon, a strong termination codon, 
and a transcription termination sequence [208]. The pET vector (Figure 10) is one of 
the most popular expression vectors for recombinant protein expression 
(invivogen.com) [209].  
 
One important point is that the division of cloning vectors and expression vectors is 
not absolute. Some cloning vectors have the ability to express recombinant proteins; 
at the same time, expression vectors can finish cloning as cloning vectors because they 
contain necessary features for cloning including an origin of replication, a selectable 
marker, and a suitable site for the insertion of a gene such as the multiple cloning site 
[205]. Still, it is typical to first clone into a cloning vector and the cloning gene is then 
transferred to an expression vector [210]. This additional step can ensure the accuracy 
of the cloned gene.  
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Figure 10. The map of pET expression vector. An antibiotic resistance marker is shown 
in pink, a lacI gene is shown in orange, and a pBR322 origin is shown in grey. The blue 
arrow shows the cloning/expression region. It contains a T7 promoter, a lac operator, 
a ribosomal binding site (rbs), the multiple cloning sites, and some functional tags such 
as His-tag. 
 
In expression vectors, the promoter is of vital importance because it controls the 
expression of the cloned gene. A strong and tightly controlled promoter is always 
desired. The promoters are normally inducible so that protein expression is only 
initiated when required by the introduction of an inducer [211]. Figure 11 illustrates 
the induction principle of T7 promoter in pET expression vector by IPTG [212-215].  
 
IPTG induction of recombinant 
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Figure 11. The general principle of IPTG induction of T7 promoter-driven expression of 
a recombinant protein from E. coli BL21(DE3) host cell contains pET plasmid [215]. lac 
repressor prevents expression of T7 RNA polymerase gene by cellular RNA polymerase. 
By addition of IPTG, lac repressor is dissociated from the operator allowing expression 
of T7 RNA polymerase gene from lacUV5 promoter. Then the T7 RNA polymerase binds 
to the T7 promoter and initiates expression of the target protein. Therefore, IPTG 
induces lacUV5 promoter to transcribe the T7 RNA polymerase, which in turn 
transcribes the target DNA in the plasmid.  
 
In addition to the choice of the promoter, one other key factor to be considered when 
choosing a vector is a fusion tag, which is a small sequence with certain biological 
functions [216, 217]. It has been widely used because it can greatly simplify 
subsequent isolation, purification and detection [208, 218]. Table 10 and 11 
summarises a list of expression vectors containing fusion tags and reviews the main 
features of both fusion protein and non-fusion proteins that may influence the final 
choice of vector [219-222]. 
 
IPTG
lacUV5
promoter
T7 
polymerase
T7 promoter Target gene
Induce Produce Induce Produce 
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Expression vector Tag 
pGEX Glutathione S-transferase (GST-tag) 
pQE His-tag 
pET His-tag 
pEZZ18 IgG binding domain of protein A 
pRIT2T IgG binding domain of protein A 
Table 10. Common expression vectors containing fusion tags. 
 
 Advantages Disadvantages 
Fusion 
protein 
 Cell compartments can be 
targeted 
 Provides a marker for 
expression 
 Simple purification using 
affinity chromatography 
 Easy detection 
 Refolding achievable on a 
chromatography column 
 Ideal for secreted proteins as 
the product is easily isolated 
from the growth media 
 Tag may interfere with 
protein structure and 
affect folding and 
biological activity 
 Cleavage site is not always 
100% specific if the tag 
needs to be removed 
Non-fusion 
protein 
 No cleavage steps necessary  Difficult to purify and 
detect 
 Problems with solubility, 
reducing potential yield 
Table 11. Advantages and disadvantages of fusion protein and non-fusion proteins 
expressed by expression vectors. 
 
His-tag is one of the most commonly used tags. In the following section, more 
information about the His-tag and His-tag fusion protein will be reviewed. 
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1.5.3 His-tag fusion proteins  
The DNA sequence of five to nine histidine (His) residues is frequently used in 
expression vectors for recombinant protein production. The expressed recombinant 
protein with poly His-tag at its N- or C-terminus is called the His-tag fusion protein [208, 
216]. The choice of either N-terminal His-tag or C-terminal is dependent mainly on the 
characteristics of the protein [223]. An end cannot be chosen if it is folded inside the 
structure or is important for the function or structure of the protein.  
 
There are several advantages of using a His-tag [219, 224, 225]. First, it can be used in 
any expression system and has a low metabolic burden to host cells. Although it is 
more common to use in E. coli and other prokaryotic expression systems, it also can 
be used in a mammalian host. Second, a His-tag can greatly simplify the purification of 
the fusion protein through an affinity purification procedure because it has a high 
affinity for metals ions such as nickel, cobalt, and copper [226]. Thus a His-tag fusion 
protein can be easily and quickly purified by using affinity chromatography at any scale 
(Figure 12) [227]. Third, the His-tag has a low likelihood of affecting the structure and 
the function of the fusion protein because it only contains several amino acids. If 
required, it can be easily cleaved by site-specific proteases. In addition, the His-tag can 
be easily detected using an immunoassay. 
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Figure 12. Interaction between a His-tag fusion protein and nickel-nitrilotriacetic acid 
(Ni-NTA) metal-affinity chromatography matrix. The blue part represents the His-tag 
and the red colour represents NTA. Ni has six chelating sites, four of them bind to NTA 
beads, and the other two metal coordination sites are free to interact with the 
functional groups of His-tag fusion proteins[227].  
 
His-tag has a wide range of applications. First of all, it has been widely used to purify 
fusion proteins [225]. Take the E. coli expression system for example as shown in Figure 
13 [228]. After expression of the His-tag fusion protein in E. coli, the cell pellets are 
collected and lysed. By adding the bacterial lysate, which contains various cell proteins 
as well as the fusion protein to a nickel affinity column, and washing out unbound 
proteins, the His-tag fusion protein should bind the column and can be eluted by 
imidazole. 
Histidine 
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Figure 13. Purification process of the His-tag fusion protein from an E. coli expression 
system under both native and denaturing conditions. The blue colour represents the 
fusion protein and the red represents His-tag. E. coli proteins are shown in green. His-
tag fusion proteins are first absorbed on the Ni-NTA metal-affinity column, then eluted 
by imidazole [228]. 
 
This is a one-step purification procedure with high purification efficiency because very 
few natural proteins contain histidine regions, so the target fusion protein is the only 
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one that binds to the column in most situations [229]. The His-tag can also be used to 
detect the fusion protein through anti-His-tag antibodies or by in-gel staining with 
fluorescent probes bearing metal ions in ELISA, western blotting or other analytical 
methods [230]. In addition, the His-tag can be used for the immobilisation of proteins 
on implant surfaces such as nickel-coated implants [231]. More information about 
immobilisation will be discussed in Section 1.6. 
 
There are two main methods to construct a His-tag fusion protein (Figure 14). The first 
is through a His-tag vector such as pET24 (Figure 14A) [216]. Proteins expressed 
through these vectors will automatically contain a His-tag. The other method is by 
using polymerase chain reaction (PCR) (Figure 14B) [232, 233]. The PCR is a rapid way 
of amplifying (duplicating) specific DNA sequences (Figure 15) [234, 235]. A brief 
introduction of PCR is described in Section 4.2.3. If a primer used in PCR contains 
histidine codons (CAT or CAC) next to the START or STOP codon, the encoding protein 
will contain a His-tag.  
 
 
Figure 14. Two methods to construct a His-tag recombinant DNA: by inserting the 
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target DNA sequence encoding a protein of interest in a His-tag vector (A), by using 
either forward primer or reverse primer containing the His-tag to obtain either N-
terminal or C-terminal His-tag fusion protein after a PCR reaction (B and C). 
 
 
Figure 15. General principle of the PCR cycle. The first three cycles of PCR are shown. 
In the first cycle, double-strand DNA is denatured at 94-96°C to generate two single 
chains. Each single strand DNA then binds to the primers at 54-65°C. The temperature 
is raised again to 72°C to start the synthesis of new complementary strands by DNA 
polymerase. After the first cycle, two gene copies are generated. When the cycle 
repeats, more identical gene copies will be amplified. At the end of 32 cycles 1 billion 
gene copies will be amplified [236]. 
 
1.6  Immobilisation of biomolecules on bone substituting 
materials 
As described in Section 1.2.3, bone tissue engineering combines living cells, 
biocompatible scaffolds, and appropriate bioactive factors especially biomolecules to 
induce new functional bone tissues. Although free bioactive factors can be used 
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directly in bone tissue engineering and have been proven as effective, they display 
some disadvantages compared to the use of immobilised bioactive factors on solid 
substrates [237]. First, the initial burst of the free bioactive factors may cause 
uncontrolled bone formation and undesired inflammation [238]. Second, a large 
amount of bioactive factors are wasted by diffusion. In addition, the activity of free 
bioactive factors is not as stable as the immobilised ones. The combination of 
biomolecules and scaffolds not only offers better control of biomolecules and 
increases their stability and efficiency, but also provides an extracellular environment 
for cells to modulate bone regeneration [239]. Therefore, extensive research has 
focused on bioactive scaffolds with immobilised biomolecules. A brief review of 
immobilisation methods is summarised in the following sections. 
 
1.6.1 General principles 
Immobilised biomolecules refer to biomolecules physically attached to a solid support 
or enclosed in a network to allow exchange but maintain separation from the bulk 
phase of substrate, inhibitor, and other molecules [240, 241]. They can be used 
repeatedly and continuously while their biological activity remains. Based on their 
superior properties, immobilised biomolecules have been widely used not only in 
bone tissue engineering, but also in the development of biosensors, bioprocessing for 
the chemical industry and the pharmaceutical industry, and bioremediation [242, 243]. 
Table 12 lists the advantages and disadvantages of immobilised biomolecules. In order 
to eliminate or at least reduce the disadvantages of immobilised biomolecules, 
choosing a suitable immobilisation method is of vital importance.  
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Advantages Disadvantages 
 Multiple or repetitive use and 
continuous use  
 More stability, longer half-lives and 
less degradation 
 Better process control and less labour 
intensive 
 Reduced reaction time 
 Less chance of contamination in 
products and easy separation 
 High loading rate 
 Loss or reduction of biological 
activity 
 Diffusional limitation 
 Additional cost 
Table 12. Advantages and disadvantages of immobilised biomolecules in bone tissue 
engineering. 
 
1.6.2 Strategies of immobilising biomolecules on bone 
substituting materials  
Various immobilisation methods have been developed for different biomolecules and 
supporting scaffolds. Below the most commonly used methods are listed (Figure 16) 
[242-245]. 
(1) Adsorption: Adsorption is the simplest and cheapest immobilisation method. It is 
a reversible process that depends on the conditions such as pH, ionic strength, 
temperature, and polarity of the solvent. Based on the binding mode of the 
biomolecules, adsorption can be divided into physical adsorption and ionic binding. In 
physical adsorption, biomolecules are bound to the scaffold surface by hydrogen 
bonds, van der Waals forces, or hydrophobic interactions; while in ionic binding, 
biomolecules are bound to scaffold surface through salt linkages. Both methods cause 
little or even no structure change of the biomolecules so that the biological activity of 
biomolecules is well-preserved. However, due to a weak binding force of adsorption, 
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the immobilised biomolecules may leak from the support scaffolds. BMP-2 immobilsed 
on a nanofibrous chitosan membrane by physical adsorption was found insufficient 
after 4 weeks of long term incubation [237]. Although ionic binding force is stronger 
than physical adsorption, leakage of biomolecules still occurs when the ionic strength 
is too high or the pH is varied [246].  
 
(2) Covalent binding: This method is based on the formation of covalent bonds 
between the chemical groups of biomolecules and chemical groups on the surface of 
support materials. It is one of the most widely used methods because it suits a broad 
range of pH and ionic strength conditions. ALPs were covalently immobilised on 
microporous nanofibrous fibrin scaffolds to promote mineralisation and osteoblast 
differentiation in vitro and in vivo [247] and cell adhesive peptides were immobilised 
on Ti implants to mediate surface-cell interactions by covalent chemical attachment 
[248]. Various reactions between the chemical groups have been developed 
depending on the functional groups available on the matrix including amino-groups, 
carboxyls, sulhydryls, hydroxyls, imidazoles, phenolics, thiols, threonines and indoles 
[249]. However, the chemical groups of biomolecules that are essential for their 
biological functions must be avoided in the covalent linkage. Covalent binding leads to 
a non-reversible and strong bond between biomolecules and support materials so that 
no leakage of biomolecules occurs. On the other hand, because the bond is strong, the 
support materials have to be changed together with the biomolecules once they lose 
their biological activity, thus increasing their cost. 
 
(3) Cross linking: The covalent binding method is based on the formation of covalent 
bonds between biomolecules and supporting materials, while the cross linking 
method is based on the formation of covalent bonds between biomolecules to develop 
three-dimensional cross-linked aggregates through multifunctional reagents such as 
glutaraldehyde, diazonium salt, hexamethylene disocyanate, and N-N' ethylene 
bismaleimide [250]. More than one biomolecule can be cross linked together to 
achieve multiple functions [251]. Although it provides strong binding and prevents 
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leakage, cross linking may cause significant changes in the biological activity of 
biomolecules, and severely limit diffusion. 
 
(4) Entrapment: The entrapment method is based on enclosing biomolecules within a 
matrix network in gels [252], fibres [253], or microcapsules [254]. The most commonly 
employed entrapment matrixes are polymeric gels and natural gels such as agar, 
gelatin and alginate. By adjusting the pore size of matrix, biomolecules can be trapped 
while still allowing the penetration of substrates and products [255, 256]. This method 
is distinguished from the crosslinking and coupling methods described above in that 
the biomolecule is not chemically bound to the matrix.  
 
(5) Encapsulation: This method involves encapsulating biomolecules in the membrane 
rather than in the lattice of a polymer matrix like entrapment [257]. It is an affordable 
and simple method, and a larger quantity of biomolecules per unit volume can be 
immobilised than any other methods. Encapsulation immobilisation of enzymes in 
nanofibres by co-electrospinning has been studied [258, 259], and has shown great 
potential to be used in bone tissue engineering. By using this method, not only a high 
enzyme loading (up to 50%, w/w) in the fibres can be easily reached, enzymatic 
activities of the fibres were well-preserved during and following electrospinning [260]. 
In addition, co-electrospinning nanofibres with a small substrate molecule alkaline 
phosphatase (80 kDa) acts as an enzyme release device which is a desirable feature in 
bone tissue engineering [98].  
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Figure 16. Schematic representation of the main biomolecule immobilisation methods. 
(A) Physical adsorption. Biomolecules (shown in green) are randomly attached on the 
supporting surface (shown in pink). Biomolecules may overlap each other, and the 
active site of biomolecules (shown in red) may hide inside. (B) Ionic binding. Positively 
charged supporting materials non-covalently interact with negatively charged 
biomolecules and vice versa. (C) Covalent binding. Covalent bonds are formed 
between the chemical groups of biomolecules and chemical groups of supporting 
materials. (D) Cross linking. A three-dimensional cross-linked aggregate is generated 
by the formation of covalent bonds between biomolecules. Either one type of 
biomolecule or more than one type (other biomolecules show in purple) can be cross-
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linked. (E) Entrapment. Biomolecules are trapped within the lattice of a polymer matrix 
in gel (E1) or in fibres (E2). (F) Encapsulation. A larger quantity of biomolecules is 
enclosed within membrane. Method E and F have little effect on the conformation and 
the activity of biomolecules, but may have severely limited diffusion. (G) Chelation. 
Biomolecules are immobilised by the formation of coordinate bonds with metal ions 
on the supporting materials. It is an orientation-controlled immobilisation so that the 
active site of biomolecules may be maximally exposed. 
 
(6) Chelation: Chelation or metal binding is based on the formation of two or more 
separate coordinate bonds between a polydentate ligand and a single central atom 
[261]. A well-known example is the Ni-NTA complex and the His-tag interaction shown 
in Figure 12. Four chelating sites of Ni bind to NTA beads, the other two metal 
coordination sites can interact with functional groups of His-tag to immobilise fusion 
proteins on various supporting scaffolds such as titanium implants [231], nanoparticles 
[262, 263] and gold surfaces [264]. It is a simple and reversible method. The binding is 
highly specific and strong. High purity fusion proteins can be easily eluted by imidazole. 
In addition, an orientation-controlled immobilisation can be achieved through this 
method. Most methods mentioned above lead to a non-specific random 
immobilisation, which may decrease the biological activity of biomolecules. Chelation, 
on the other hand, can immobilise biomolecules in a controlled, orderly way so that 
the active site of biomolecules may be maximally exposed.  
 
The above immobilisation methods can be classified according to different standards. 
(1) Physical methods: adsorption, entrapment and encapsulation; chemical methods: 
covalent binding, cross linking and chelation. (2) Reversible methods: adsorption and 
chelation; irreversible methods: covalent binding, cross linking, entrapment and 
encapsulation. (3) Surface immobilisation: adsorption, covalent binding, cross linking 
and chelation; encapsulation immobilisation: cross linking, entrapment and 
encapsulation. To make it easy to compare, Table 13 summarised the main features of 
each immobilisation method. Each has different strengths and weakness. Choosing the 
immobilisation method is based on the characteristics of the biomolecules and 
supporting scaffolds, as well as the specific application. 
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 Advantages Disadvantages 
Physical 
adsorption 
 Little or no conformational 
change of the active sites 
 Simple and cheap 
 Desorption from changes in 
temperature, pH, ionic 
strength 
 Non-specific 
Ionic binding  Milder conditions than 
chemical method. 
 Little change in the 
conformation and the 
active site  
 High activities reserved in 
most cases 
 Leakage from the carrier 
may occur in substrate 
solution of high ionic 
strength or upon variation 
of pH 
Covalent 
binding 
 Stable method  
 Prevents elution of protein 
into the production stream 
 Suits a broad range of pH, 
ionic strength and other 
variable conditions 
 Site-specific binding 
 Relatively expensive 
 Low activity yields due to 
harsh environments or 
toxic reagents  
 Active site may be modified 
through the chemical 
reactions used to create 
covalent bonding. 
Cross linking  Very little desorption, 
strongly bound 
 Helps stabilising 
biomolecules  
 Relative high loading rate 
 May cause significant 
changes in the active site 
 Severe diffusion limitation  
 Affects biological activity 
Table 13. Main features of immobilisation methods used in bone tissue engineering. 
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 Advantages Disadvantages 
Entrapment  Relative high loading rate 
 Helps stabilising 
biomolecules 
 Little change in the 
conformation and the 
active site  
 Leakage of low molecular 
weight biomolecules 
 Diffusion limitation  
Encapsulation  Cheap and simple 
 Highest loading rate 
 Easy tailored system 
 Severe diffusion limitation  
 May cause significant 
changes in the active site 
Chelation  Site-specific binding 
 The binding is highly 
specific and strong 
 Orientation-controlled 
immobilisation 
 Restrict biomolecules 
contains selective tags 
 Fusion tags may affect 
biological activity 
Table 13. (Continued) Main features of immobilisation methods used in bone tissue 
engineering. 
 
1.7  Hypotheses 
The hypotheses tested was that two engineered biomolecules, short peptides derived 
from BMP-7, and recombinant metalloenzyme E. coli alkaline phosphatase, have the 
ability to enhance mineralisation, induce bone regeneration, and stimulate bone 
formation. In this respect these biomolecules may have potential applications in the 
field of bone tissue engineering. In order to test these hypotheses, the following 
questions have been addressed in the thesis: 
(1) What is the biological activity of these biomolecules? 
(2) What is the effect of these biomolecules on osteoblasts? 
(3) What is the improvement of the functionality and biological efficiency when these 
biomolecules are incorporated with supporting materials?  
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CHAPTER 2  
BMP-derived peptide for surface modification 
of bone substituting implants 
2.1  Introduction 
In this chapter, BMP-7-derived peptides for surface modification applications of bone 
substituting implants are described. The concept of developing peptide coated 
implants is to mimic the natural environment of bone formation, and to enhance 
implant fixation with the surrounding tissue (Figure 17). Since a non-physiological 
surface of the implant is exposed in a physiological aqueous environment, specific 
requirements are imposed on the implant coating to mediate these different structural 
entities [53]. The coating should facilitate the attachment of proteins and cells while 
maintaining their native conformation and biological activity. Ideally, a bioactive 
coating also has the ability to induce a specific cellular response, and to promote bone 
formation. This chapter demonstrates the main concepts and principles of engineered 
BMP-7-derived peptide coating for bone tissue engineering. 
 
 
Figure 17. Concept of the development of implants with bioactive coating. A non-
physiological surface of an implant (A) lacking interactions with proteins and cells, 
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which are necessary for bone regeneration. However, a bioactive coating (B) on an 
implant, which induces a specific cellular response, can reduce the time required for 
implant fixation and enhance the interaction between implant and the surrounding 
tissue, thus enhancing bone formation. 
 
2.1.1 Engineered BMP-derived peptides 
Among the relevant biomolecules involved in bone tissue engineering, bone 
morphogenetic proteins (BMPs) are one of the most studied bioactive factors because 
their outstanding contributions towards bone formation. As mentioned in Section 
1.4.1.1, BMPs play an important role in ectopic bone formation and regulate the key 
steps of bone and cartilage morphogenesis [116]. Exclusive studies have been carried 
out to immobilise BMPs on the implants to fabricate bioactive coatings [265, 266]. For 
example, BMP-2 coatings markedly increased the osteoinductive potential of Ti 
implants [267]. BMP-4 immobilised on Ti-6Al-4V alloy by plasma surface modification 
strategy induced alkaline phosphatase activity in pluripotent C3H10T1/2 cells [268]. 
However, the applications of full-length BMPs are limited due to their large structure, 
potential immunological and carcinogenic risks, low chemical stability, and high cost 
[134-136]. In addition, the active site of BMPs can be easily hidden during 
immobilisation due to its complex structure. 
 
One promising solution is to use peptides derived from BMPs for bone tissue 
engineering applications. As mentioned in Section 1.4.1.2, compared to full-length 
proteins, peptides offer easier production, more precise control of the chemical 
components and a higher utilisation efficiency while preserving the entire or a certain 
part of the protein function [118, 136, 137]. Immobilising a part of BMPs on an implant 
to produce a peptide coating has been investigated. For example, a synthetic receptor 
binding motif mimicking BMP-2 immobilised on Ti surfaces enhanced the bone healing 
rate when compared with untreated Ti surfaces [269]. Biological evaluations showed 
that the peptide coated implants enhanced cell growth rate, protein expression, and 
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alkaline phosphatase production in MC3T3-E1, and significantly improved bone 
growth in the canine mandibles [269].  
This chapter is focused on a short peptide KAISVLYFDDS derived from BMP-7 (Figure 
18) [129, 136]. Amino acids AISVLYFDDS are derived from the 111-120 amino acid 
residue sequence of BMP-7, and the K terminal amino acid is designed for an easier 
functionalisation on nano-materials [270, 271]. There are several reasons to choose 
this specific peptide. First, this peptide is derived from the Finger 2 domain of BMP-7, 
which contributes to the ligand-receptor binding interactions [272]. Second, this 
peptide has been shown to increase osteoblast calcium deposition, which is an 
essential step in bone formation [129, 136]. In addition, this peptide only has 11 amino 
acids, which is easy to synthesise and engineer.  
 
Figure 18. The three-dimensional protein structure of BMP-7. It contains two bioactive 
areas, Finger 1 and 2 domains, which contribute the ligand-receptor binding 
interactions. The amino acids shown in colourful dots in Finger 2 domain represent the 
peptide sequence AISVLYFDDS (111-120 amino acid residue sequence of BMP-7). This 
figure was drawn using PyMOL (www.pymol.org). 
 
In order to immobilise KAISVLYFDDS on Ti implants in a highly efficient way without 
affecting its biological activity, two immobilisation methods are chosen: adsorption 
and chelation (see Section 1.6.2). Chelation immobilisation requires an engineered 
BMP-7-derived peptide with a sequence of six histidine residues (His-tag) that bind to 
Finger 1  
Finger 2  
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nickel chelates. The concept is inspired by the His-tag fusion protein in which a protein 
containing a His-tag can be easily immobilised on nickel matrix [231] (Figure 12). 
Similarly, a His-tag peptide can bind to nickel pre-treated Ti implants. By using 
chelation, a higher loading rate and efficiency is expected compare to adsorption. 
Figure 19 is a schematic representation of the immobilisation of the BMP-7-derived 
peptides on Ti implants. Figure 19A shows the peptides KAISVLYFDDS are randomly 
immobilised on the un-treated Ti implant by physical adsorption. After treatment with 
a nickel solution, nickel ions on the Ti implant showed a specific affinity for His-tag 
peptides so that peptides can be orderly immobilised (Figure 19B). 
 
 
Figure 19. The immobilisation of BMP-7-derived peptides KAISVLYFDDS on Ti implants 
by (A) adsorption and (B) chelation. The BMP-7-derived peptides are shown in green, 
His-tags are shown in blue, red dots represent the nickel (Ni) ions on the Ti implant. 
 
2.1.2 C2C12 cells 
Previous studies indicates that the C2C12 myoblast cells are useful models to 
investigate the biological activity of BMPs [273, 274]. BMPs inhibit myotube formation 
and induce osteoblastic differentiation of C2C12 [130, 275, 276]. In addition, C2C12 
cells express an extremely high level of alkaline phosphatase activity when treated 
with BMPs. In this study, C2C12 cells were used to verify the biological activity of the 
BMP-7-derived peptides. 
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2.1.3 Scope of chapter 
The objective of this chapter is to re-engineer the short BMP-7-derived peptides for 
bone tissue engineering with improved functionality. In this chapter, some short BMP-
7-derived peptides which are reported to possess similar bone inducing properties to 
whole BMP-7 are studied. In order to immobilise the peptides onto Ti implants, a His-
tag is added into the short BMP-7-derived peptides. After the synthesis and 
characterisation of BMP-derived peptides, an in vitro cell culture study is performed 
to determine the effect of peptides on C2C12 and MC3T3-E1 cells. 
 
2.1.4 Hypotheses 
The hypotheses tested was that BMP-7 derived peptides have the ability to increase 
osteoblast calcium deposition, and may have potential applications in the field of bone 
tissue engineering. In order to test these hypotheses, the following questions have 
been addressed in this Chapter: 
(1) What is the molecular weight and purity of BMP-7 derived peptides after 
synthesis? 
(2) What is the biological activity of these BMP-7 derived peptides? What is the effect 
of these biomolecules on C2C12 myoblast cells? 
(3) What is the effect of these peptides on MC3T3-E1 pre-osteoblasts? 
 
2.2  Materials and methods 
2.2.1 BMP-derived peptides synthesis and characterisation 
2.2.1.1 Materials 
DMSO (99.9%), tetramethylammonium hydroxide pentahydrate (TMA) (97%), 3-
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mercaptopropionic acid, EDTA, amino acids, lyophilised bovine serum albumin (BSA) 
(96%), nickel sulphate (99.99%), Bradford reagent were purchased from Sigma-Aldrich 
(Gillingham, UK). Chloroform (99%), Tris buffer and glycerol were purchased from 
VWR (Poole, UK). 
 
2.2.1.2 BMP-derived peptides design 
Peptide KAISVLYFDDS consists of two parts: the amino acids AISVLYFDDS are derived 
from the 111-120 amino acid residue sequence of BMP-7, and the K terminal amino 
acid is added to make the peptide easier to eventually functionalise on nanomaterials 
[136].  
 
In order to immobilise the peptide on Ti implants by chelation, a His-tag (HHHHHH) 
that strongly interacts with the nickel-Ti implant surface via metal-affinity coordination 
was added. His-tag was added on both C-terminal (KAISVLYFDDSHHHHHH) and N-
terminal (HHHHHHKAISVLYFDDS) to compare the immobilisation effects. 
 
2.2.1.3 BMP-derived peptides synthesis 
In peptide synthesis, multiple amino acids are linked via peptide bonds, which are 
covalent bonds that form between amino acids when the carboxyl group (C-terminus) 
of one amino acid reacts with the amino group (N-terminus) of the other [277]. 
Chemical peptide synthesis starts from the C-terminal and ends at the N-terminus of 
the peptide.  
 
There are two types of peptide synthesis methods: liquid-phase peptide synthesis and 
solid-phase peptide synthesis. The first is the classical approach, and mainly used in 
large-scale industrial peptide production. The second one, solid-phase peptide 
synthesis (Figure 20 [278]), is now widely used in laboratory-scale manufacturing. The 
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core principle of solid-phase peptide synthesis is a repeating deprotection-wash-
coupling-wash cycle [279]. First, an N-protected peptide is covalently attached to a 
small solid bead (resin). Then the peptide is deprotected by removing the Fmoc, an α-
amino protecting group, and by revealing a new N-terminal amine to which the next 
amino acid can be attached. Next, the free N-terminal amine of this peptide is coupled 
to a single N-protected but C-activated amino acid. The peptide chain is building up by 
repeating this cycle. Once the synthesis is completed, peptide chain can be cleaved 
from the resin by trifluoroacetic acid (TFA). 
 
 
Figure 20. The process of solid-phase peptide synthesis. A resin bead acts as the solid-
phase. 1-hydroxybenzotriazole/o-(benzotriazole-1-yl)-1,1,3,3- tetramethyluronium 
hexafluorophosphate (HOBt/HBTU) is used to activate the carboxyl group before 
coupling the amino acids. Fluorenylmethyloxycarbonyl (Fmoc) functions as an α-amino 
protecting group[278]. 
 
In this chapter, three peptides (KAISVLYFDDS, KAISVLYFDDSHHHHHH, and 
HHHHHHKAISVLYFDDS) were synthesised by solid phase peptide synthesis method 
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[279] using Fmoc-protected amino acid monomers and HOBt/HBTU activation on a 
QUARTET multiple synthesiser (Protein Technologies. Inc., USA). In each coupling step, 
a 10-fold excess of amino acids was used. Cleavage from the resin and side-group 
deprotection was performed by using TFA and triisopropylsilane. The peptides were 
lyophilised and analysed by matrix-assisted laser desorption/ionisation (MALDI) mass 
spectrometry (MALDI micro MX (Micromass, UK)) from the Chemistry Department, 
Imperial College London. The lyophilised peptides were stored at -20°C. 
 
2.2.1.4 HPLC 
High performance liquid chromatography (or high pressure liquid chromatography, 
HPLC) is a chromatographic technique that can separate compounds from a mixed 
solution. It is widely used in biochemistry and analytical chemistry applications to 
identify, quantify and purify the individual components from the solution [280].  
 
The HPLC instrument consists of a reservoir of mobile phase, a pump that provides 
higher pressures, an injector, a separation column, and a detector that provides a 
characteristic retention time for the sample (Figure 21) [281]. Compounds are 
separated by the column because different components in the mixture have different 
passing rate.  
 
HPLC (GX-271; Gilson, Sweden), was used to purify the peptides synthesised in this 
study. A c18 reverse-phase HPLC column was used with a gradient of acetonitrile and 
water. A flow rate of 9.98 ml/min was used and fractions were collected in Eppendorf 
tubes.  
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Figure 21. Schematic of an HPLC instrument [281]. (Image adapted from Chemistry 
Hypermedia Project website). 
 
2.2.1.5 MALDI Mass Spectrometry 
Matrix-assisted laser desorption/ionisation (MALDI) is a soft ionisation technique used 
in mass spectrometry. It is a popular analytical tool for peptides, proteins and other 
biomolecules which tend to be fragile when ionized by more conventional ionisation 
methods [282]. MALDI can be used for the identification of biomolecules, and the 
determination of their molar mass distribution. It is also a very simple and rapid 
analytical method to determine the molecular weight of biomolecules. 
 
Upon MALDI analysis, the sample is first co-crystallised with a matrix compound, which 
protects the biomolecules from being destroyed by the direct laser beam and 
facilitates the later vaporisation and ionisation. Laser radiation results in the 
vaporisation of the sample-matrix mixture. The energy transfer during a matrix-
assisted laser induced desorption provides high ion yields of the intact sample and 
allows high accuracy and sensitivity measurement of peptide compounds [283].  
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2.2.2 In vitro cell culture study of BMP-derived peptides  
2.2.2.1 Materials 
Unless stated otherwise, all cell culture reagents and media were purchased from 
Gibco/Life Technologies, UK. BMP-2 was kindly provided by Professor W. Sebald 
(Universität Würzburg). Routine cell culture was carried out under aseptic conditions 
in a class II microbiological safety cabinet (Medical Air Technology LTD, UK). Cells were 
maintained in a GA 3000 LEEK incubator (LEEK LTD, UK). Cells were routinely viewed 
on an IX-70 phase contrast inverted microscope (Olympus, UK) and photographed 
using an Olympus OM-4 mounted automatic camera. 
 
2.2.2.2 C2C12 cell culture 
The mouse myoblast cell line, C2C12 was purchased from American Type Culture 
Collection (ATCC, USA). For each experiment, a vial of frozen cells was thawed and 
seeded on 75 cm2 plastic culture flasks in the growth medium (Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) FBS, 100 units/ml penicillin, 
and 100 mg/ml streptomycin), in humidity 5% CO2 at 37°C until they reached 80% 
confluence.  
 
The number of cells was quantified using a haemocytometer. The cells were collected 
by centrifugation at 1600 rpm for 5 min at ambient temperature. The pellet was 
resuspended in 5 ml growth medium. 20 μl of cell suspension was mixed with 20 μl of 
0.4% trypan blue. The mixture was added on a haemocytometer. Cells were counted 
manually from four different fields and averaged, giving the number of cells/ml.  
 
To examine the effects of BMP-7-derived peptides on C2C12 cells, the cells were 
seeded at a density of 2.5×106 cells/cm2 in 24-well plates (4 wells per group). After 
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confluence had been reached, the growth medium was replaced by treatment media 
containing different concentrations of peptides and cultured for an additional 3, 6, 9 
and 14 days, respectively. The treatment media (with and without the peptides of 
interest to this study) were changed every 2-3 days. The growth medium containing 
300 ng/ml BMP-2 was used as positive control group. The cells were washed twice 
with phosphate buffered saline (PBS) after removal from the treatment media, and 
kept in -80°C until their total protein content, total DNA content and ALP activity was 
analysed. After 3, 14 and 21 days, the cells were fixed in 2.5% (v/v) glutaraldehyde and 
dehydrated in a graded ethanol series followed by incubation in hexamethyldisilazane. 
The cells were sputter coated with chromium then visualized by SEM. 
 
2.2.2.3 MC3T3-E1 cell culture 
Pre-osteoblasts are widely used to determine the biology activity of BMPs [284, 285]. 
MC3T3-E1, a mouse pre-osteoblast cell line, was used to determine the biological 
activity of the BMP-7-derived peptides. MC3T3-E1 cells were seeded on 75 cm2 plastic 
culture flasks in the growth medium (α-minimum essential medium (α-MEM) 
supplemented with 10% (v/v) FBS, 100 units/ml penicillin, and 100 mg/ml 
streptomycin), in humidity 5% CO2 at 37°C.  
 
In order to determining the effect of the BMP-derived peptides on MC3T3-E1 cells,   
the same treatments were performed as above. The growth medium containing 50 
ng/ml BMP-2 was used as positive control group. The cells were washed twice with 
PBS after removal from the treatment medium, and kept in -80°C until their total 
protein content, total DNA content and ALP activity were analysed. MC3T3-E1 cells 
were fixed in the same method as above and then visualised by SEM. 
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2.2.2.4 Scanning electron microscopy 
The scanning electron microscope (SEM) images the sample by scanning a focused 
beam of high-energy electrons to generate signals at the sample surface. The signals 
derived from electron-sample interactions reveal information of the sample such as 
the external morphology, the chemical composition, the crystalline structure, and 
other properties such as electrical conductivity [286]. In this study, SEM is used to 
observe surface morphologies and cell behaviour after treatment with BMP-7-derived 
peptides. 
 
2.2.2.5 Energy dispersive spectroscopy 
Energy dispersive spectroscopy (EDS) is an analytical technique usually linked to SEM 
[287]. It uses an emitted X-ray spectrum to identify particular elements (qualitative 
analysis) and determine their relative proportions (quantitative analysis) in a sample 
[288]. In this study, EDS was used to analyse the extracellular matrix deposition in cell 
culture experiments. 
 
2.2.2.6 Biochemical assays 
A) Total protein assay 
The total protein content of cells was determined by a commercial micro BCA 
(bicinchoninic acid) protein assay kit (Thermo Scientific Pierce Protein Research 
Products). The assay combines the well-known reduction of Cu2+ to Cu1+ by proteins in 
alkaline conditions with the highly sensitive and selective coluorimetric detection of 
the Cu1+ using a unique reagent containing BCA [289]. The purple-coloured reaction 
product shows a strong absorbance at 562 nm that is nearly linear with increasing 
protein concentrations from 20 µg/ml to 2000 µg/ml [289]. After three thaw-freeze 
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cycles, 100 μl of cell lysate was mixed with the assay reagent in a 96-well plate and 
incubated for 2 hours at 37°C. Light absorbance of these samples was measured at 562 
nm on a 96-well plate reader (Labsystems, Life Sciences International Ltd, Hampshire, 
UK). Experiments were performed independently in triplicate. 
 
B) Total DNA assay 
The total DNA content of cells was determined using a commercial Quant-iT™ 
PicoGreen dsDNA reagent Kit (Invitrogen, UK). Quant-iT™ PicoGreen dsDNA reagent is 
an ultra-sensitive fluorescent nucleic acid stain for quantitating double-stranded DNA 
(dsDNA) in solution [290]. The amount of dsDNA can be used as a marker for cell 
proliferation. After three thaw-freeze cycles, 10 μl of cell lysate was mixed with 
PicoGreen in a 96-well plate. The samples were excited at 480 nm and the fluorescence 
emission intensity was measured at 520 nm using a 96-well plate reader. Experiments 
were performed independently in triplicate. 
 
C) ALP activity assay for cells  
The ALP activity assay depends on the hydrolysis of ρ-nitrophenylphosphate (ρNPP) by 
the enzyme ALP and generates ρ-nitrophenol and inorganic phosphate. ρ-nitrophenol 
is converted to a yellow product under alkaline conditions and shows a strong 
absorbance at 400-420 nm. After specified days of culture, the cells were washed with 
PBS before stored at -80°C. After three thaw-freeze cycles, 80 μl of cell lysate was 
mixed with ρNPP (Sigma, UK) in a 96-well plate and incubated for 60 min at 37°C, and 
the reaction was stopped by adding 100 μl 1 M NaOH. Light absorbance of these 
samples was measured at 405 nm on a 96-well plate reader. A standard curve was 
constructed using ρ-nitrophenol (Sigma, UK) as a standard. Experiments were 
performed independently in triplicate, and the ALP activity of each sample was 
normalised to protein content and expressed as mean standard deviation. 
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2.2.2.7 Statistical analysis 
Statistical analyses on the data of the in vitro experiments of BMP-derived peptides 
were performed by a one-way variance (AVOVA) with Tukey-Kramer Multiple 
Comparisons post-test. A p < 0.05 was considered as statistically significant. 
Calculations were performed in Graphpad InStat 3 (Graphpad software Inc., San Diego, 
USA). 
 
2.3 Results and discussion 
2.3.1 BMP-derived peptide synthesis 
The BMP-7-derived peptide KAISVLYFDDS, and the other two peptides with His-tag, 
KAISVLYFDDSHHHHHH and HHHHHHKAISVLYFDDS, were synthesised on a QUARTET 
multiple peptide synthesiser (Figure 22). The molecular weight and purity of the BMP-
7-derived peptides were determined by MALDI (Figure 23) and HPLC, respectively. The 
theoretical molecular weight of peptide KAISVLYFDDS (11 amino acids) is 1256.60 Da, 
and those with His-tag (17 amino acids) is 2079.30 Da. The difference between the real 
molecular weight and the theoretical molecular weight is insignificant. The results 
indicate that the peptide synthesis technique is accurate and reliable. In addition, all 
peptides synthesised on the QUARTET multiple peptide synthesiser have a more than 
90% purity according to the results of HPLC. 
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Figure 22. Chemical structure of BMP-7-derived peptides KAISVLYFDDS (A), and KAISVLYFDDSHHHHHH (B) and HHHHHHKAISVLYFDDS (C).  
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Figure 23. MALDI mass spectral analysis of BMP-7-derived peptides KAISVLYFDDS (A), 
KAISVLYFDDSHHHHHH (B) and HHHHHHKAISVLYFDDS (C). The P+H+ peak corresponds 
to monoprotonated mass (H+) on MALDI mass spectrum indicating a peptide molecular 
weight. The P+Na+ peak corresponds to Na+ salt.  
 
2.3.2 Assessment of biological activity of BMP-derived 
peptides on C2C12 cells 
2.3.2.1 Cell proliferation 
Three independent runs of C2C12 cell culture experiments were carried out. Figure 24 
shows the proliferation of C2C12 cells cultured in treatment media containing different 
concentrations (0, 0.1, 10, and 1000 μg/ml) of BMP-7-derived peptide KAISVLYFDDS 
by measuring the total protein content and total DNA content. In Figure 24A, all groups 
cultured in the presence of the peptide showed a continuous increase in total protein 
content along with the time for 14 days, although the increase in the group cultured 
in the presence of 0.1 μg/ml peptide between day 9 and day 14 was insignificant. Only 
the control group with no addition of peptide showed an early protein content peak 
P+H+ 
P+Na+ 
C 
1645.1443 
873.6926 
2102.5588 
2080.7437 
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around day 9. On day 14, significantly decreased protein content values were observed 
for the control group compared to the groups of C2C12 cells treated with 0.1 μg/ml (p 
< 0.05), 10 μg/ml (p < 0.001) and 1000 μg/ml (p < 0.001) BMP-7-derived peptide. In 
addition, C2C12 cells treated with higher BMP-7-derived peptide concentrations (10 
μg/ml and 1000 μg/ml) showed significantly increased protein content compared to 
the low peptide concentration group (0.1 μg/ml) (p < 0.001). Most importantly, total 
protein content in 10 μg/ml and 1000 μg/ml peptide groups was significantly increased 
(p < 0.001 and p < 0.01, respectively) compared to the peak value in the control group. 
However, there was no significant difference of protein content between two higher 
BMP-7-derived peptide concentration groups on day 14. 
 
Total DNA content of C2C12 cells showed similar increasing trends when cells were 
treated with 10 μg/ml and 1000 μg/ml BMP-7-derived peptide within 14 days. 
However in addition to the control group, the cells treated with 0.1 μg/ml BMP-7-
derived peptide also showed an early DNA content peak around day 9. A significant 
decrease occurred from day 9 to day 14 in the same group (p < 0.001). On day 14, total 
DNA content values of C2C12 cells were increased along with the concentration of 
BMP-7-derived peptide presented in the treatment media. There was a significant 
increase between the groups containing BMP-7-derived peptide (p < 0.001). In 
addition, total DNA content in 10 μg/ml and 1000 μg/ml peptide groups on day 14, as 
well as the peak value of total DNA content in 0.1 μg/ml peptide groups on day 9 was 
significantly increased (p < 0.001) compared to the peak value in the control group. 
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Figure 24. Effect of BMP-7-derived peptide KAISVLYFDDS on the proliferation of C2C12 
cells by measuring the (A) total protein content and (B) total DNA content. 0 μg/ml 
peptide is the negative control group which contains no BMP-7-derived peptide in the 
treatment medium. 0.1 μg/ml peptide, 10 μg/ml peptide and 1000 μg/ml peptide 
represents the concentration of BMP-7-derived peptide in the treatment medium was 
0.1 μg/ml, 10 μg/ml and 1000 μg/ml, respectively. * p < 0.05 and *** p < 0.001 
*** 
* 
*** 
*** 
A 
B 
*** 
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indicating significant differences between the respective group with the control group 
on day 14. 
 
The cell culture experiments revealed a normal cell growth in all experimental groups. 
It demonstrated that the BMP-7-derived peptide KAISVLYFDDS did not affect C2C12 
cell growth. Both total protein content and total DNA content results indicated that 
the BMP-7-derived peptide in treatment media supported the proliferation of C2C12 
cells. 
 
In particular, higher concentration of peptide (10 μg/ml and 1000 μg/ml) in the media 
may increase the total protein content and total DNA content more than the low 
concentration groups. At the same time, a delayed proliferation was observed for the 
higher concentration of peptide groups (from day 9 to day 14). In order to improve the 
proliferation of C2C12 cells while minimising the side effects on cellular behaviours by 
the BMP-7-derived peptide, a concentration of 10 μg/ml of BMP-7-derived peptide 
was chosen for the next studies. 
 
The same cell culture experiments were performed with the other two BMP-7-derived 
peptides contain His-tag, KAISVLYFDDSHHHHHH and HHHHHHKAISVLYFDDS, and 
statistically similar results to the peptide KAISVLYFDDS were obtained.  
 
2.3.2.2 Cell morphology  
The cell morphology of C2C12 cells cultured in treatment media containing different 
BMP-7-derived peptides (KAISVLYFDDS, KAISVLYFDDSHHHHHH and 
HHHHHHKAISVLYFDDS) was evaluated by light phase contrast inverted microscopy at 
day 3, day 6, day 9 and day 14 (Figure 25). On day 3, no significant differences were 
observed, with cells attaching and proliferating normally. On day 6, however, the 
phenotype of C2C12 cells in the presence of BMP-7-derived peptides as well as the 
negative control group displayed obvious changes. Some spindly fibre-like thin 
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myotubes formed by cells fusing with each other were beginning to emerge in these 
groups. Only the cells treated with BMP-2 remained unfused, with mononuclear 
polygonal cell morphology. Striking morphological changes of cells treated with the 
peptides of interest as well as the negative control group occurred over the course of 
day 6 to day 9. On day 9, all cells in the four groups eventually fused into mature 
multinucleated myotubes.  
 
The cells treated with BMP-2, however, revealed osteoblast-like morphology as 
expected. On day 14, more osteoblast-like morphology was observed in the BMP-2 
treated group while numerous myotubes were formed in the other groups. Some cell 
clusters were also found in these groups due to their high confluency. No significant 
differences of cell morphology among the three BMP-7-derived peptide groups was 
found. In addition, cells cultured in the presence of BMP-7-derived peptides exhibited 
similar morphology features as the negative control group.  
 
The purpose of the cell morphology study was to determine whether or not the BMP-
7-derived peptides have the same ability to influence the differentiation of C2C12 
myoblasts into osteoblasts as BMPs. The results of cell morphology proved that 300 
ng/ml BMP-2 in the growth medium has the ability to inhibit myotube formation and 
induce osteoblast trans-differentiation. However, 10 μg/ml of BMP-7-derived peptides 
failed to converts the differentiation, even though these peptides were derived from 
the active site of BMP-7 and shown the ability to increase osteoblast calcium 
deposition. The phenotype of cells in the presence of BMP-7-derived peptides was 
similar as the negative control, which had no additives in the culture medium. More 
studies were carried out to further investigate the effect of BMP-7-derived peptides 
on C2C12 differentiation. 
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Figure 25. Gross changes in cell morphology of C2C12 cells cultured in treatment media with 10 μg/ml BMP-7-derived peptides KAISVLYFDDS 
(first column), KAISVLYFDDSHHHHHH (second column) and HHHHHHKAISVLYFDDS (third column) after 14 days in culture. Cells treated with 300 
ng/ml BMP-2 was the positive control (fourth column). The control (negative) group represents cells were cultured in growth medium with no 
additives (fifth column). Each row represents a time point from day 3 to day 14. Scale bars represent 200 μm. 
KAISVLYFDDS KAISVLYFDDS+6H 6H+KAISVLYFDDS 300 ng/ml BMP-2 Control 
Day 3 
Day 6 
Day 9 
Day 14 
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2.3.2.3 Cell differentiation 
Figure 26A shows the number of myotubes generated after 6 days of culture in 
treatment media containing BMP-7-derived peptides. C2C12 cells cultured for 6 days 
in the presence of 10 μg/ml BMP-7-derived peptides differentiated into myoblasts and 
formed myotubes similar to the control group. The number of myotubes formed from 
the three peptides and the control were statistically insignificant. However, BMP-2 in 
the culture media changed the differentiation pathway of C2C12s so that no myotubes 
were found in the BMP-2 groups. 
 
The results of the ALP activity measurements are showed in Figure 26B. ALP indicates 
the early differentiation of C2C12 cells. Cells treated with 300 ng/ml BMP-2 expressed 
significantly higher ALP activity compared with other groups at each time point (p < 
0.001). Cell treated with 10 μg/ml BMP-7-derived peptides as well as the control group 
expressed consistently low ALP activity from day 3 to day 9. On day 14, a slight increase 
of ALP activity was observed in the BMP-7-derived peptide groups. Among them, 
peptide HHHHHHKAISVLYFDDS showed the highest value. In addition, all of the values 
exceeded the control group, but the difference between the groups was statistically 
insignificant. 
 
These results support the conclusion drawn from the cell morphology results, which is 
that 10 μg/ml of BMP-7-derived peptides fails to convert the differentiation pathway 
of C2C12 myoblasts to osteoblasts. Unlike BMP-2, BMP-7-derived peptides generated 
no burst of ALP activity when applied to C2C12 cells. 
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Figure 26. The effect of BMP-7-derived peptides on myotube formation and ALP 
activity in C2C12 cells. Control group has no additives in the culture media. (A) The 
number of myotubes were counted after culturing in the presence of 10 μg/ml P 
(represents BMP-7-derived peptide KAISVLYFDDS), P+6H (represents peptide 
KAISVLYFDDSHHHHHH) and 6H+P (represent HHHHHHKAISVLYFDDS), and 300 ng/ml 
BMP-2 as positive control for 6 days. (B) The ALP activity of C2C12 cell lysate treated 
A 
B 
*** 
*** 
*** 
*** 
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with 10 μg/ml BMP-7-derived peptides and 300 ng/ml BMP-2 for 14 days was 
measured using ρNPP as a substrate. *** p < 0.001 indicates statistically significant 
differences between the BMP-2 group with the other groups on the respective day. 
 
The purpose of assessing the biological activities of BMP-derived peptides on C2C12 
cells was to compare the biological activity of peptides with that of BMP proteins. 
Although BMP-derived peptides were shown to have similar activity as the full-length 
proteins, no literature has reported the effect of BMP-7-derived peptides on C2C12 
cells. This study indicates BMP-7-derived peptides support the proliferation of C2C12 
cells, but 10 μg/ml of BMP-7-derived peptides failed to converts the differentiation 
pathway of C2C12 myoblasts to osteoblasts, in contrast to the activity of BMP-2. The 
possible reason is the peptide KAISVLYFDDS is not derived from the responsible active 
site of BMPs. Although the mechanism of regulation of C2C12 differentiation by BMPs 
is not fully understood, it may be related to the DNA binding and/or transcriptional 
activities of MyoD, which is an important regulator of myogenic differentiation in 
C2C12 cells [275]. Peptide KAISVLYFDDS, however, is derived from the Finger 2 domain 
of BMP-7 that is responsible for ligand-receptor binding interaction. 
 
2.3.3 Determining the effect of the BMP-derived peptides on 
MC3T3-E1 cells 
2.3.3.1 Cell proliferation 
Figure 27 shows the proliferation of MC3T3-E1 cells cultured in treatment media 
containing 100 μg/ml of different BMP-7-derived peptides (KAISVLYFDDS, 
KAISVLYFDDSHHHHHH, and HHHHHHKAISVLYFDDS) by measuring the total protein 
content and total DNA content within 21 days. In Figure 27A, all groups cultured in the 
presence of peptides showed a continuous increase in total protein content between 
days 1 and 14 after cell seeding. Around day 14, a maximum was reached for those 
groups, after which the total protein content decreased until day 21. The control group 
containing no peptide showed an early protein content peak around day 10. Before 
day 14, there was no significant difference in total protein between the control group 
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and the groups treated with BMP-7-derived peptides. On day 14 and day 21, 
significantly decreased protein content was observed for the control group compared 
to the peptide treated groups (p < 0.001). On day 14, cells treated with 100 μg/ml 
KAISVLYFDDS showed the highest protein content value among all conditions, though 
there was no statistically significant difference between the three BMP-7-derived 
peptides at day 14 and day 21. It is worth noting that large experimental variability was 
measured in the late time points of culture, which may have been due to the high 
degree of cell confluence.  
 
Total DNA content of MC3T3-E1 cells (Figure 27B) showed similar patterns for three 
BMP-7-derived peptides treated groups within 21 days. The total DNA content values 
were generally increased in the first 14 days and reached their peak values, then 
rapidly decreased on day 21. The control groups, however, showed an early DNA 
content peak around day 7, and maintained the peak value for 7 days, after which the 
value decreased until day 21. Different from the total protein content, only on day 14 
a significant decrease of total DNA content values was observed for the control group 
compared to the peptide treated groups (p < 0.001). Although no significant difference 
of DNA content between the three BMP-7-derived peptides was found, cells cultured 
in the presence of KAISVLYFDDSHHHHHH and HHHHHHKAISVLYFDDS showed more 
similarity compared to the other BMP-7-derived peptide without a His-tag.  
 
The results demonstrated that the BMP-7-derived peptides KAISVLYFDDS, 
KAISVLYFDDSHHHHHH, and HHHHHHKAISVLYFDDS do not affect MC3T3-E1 cell growth. 
Both total protein content and total DNA content results indicated BMP-7-derived 
peptide in treatment media supported the proliferation of MC3T3-E1 cells. 
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Figure 27. Effect of 100 μg/ml BMP-7-derived peptide KAISVLYFDDS, 
KAISVLYFDDSHHHHHH (KAISVLYFDDS+6H) and HHHHHHKAISVLYFDDS (6H 
+KAISVLYFDDS) on the proliferation of MC3T3-E1 cells by measuring the (A) total 
protein content and (B) total DNA content. *** p < 0.001 indicates statistically 
significant differences between the experimental group and the control group on the 
respective day. 
 
B 
A 
*** 
*** 
*** 
102 
 
The cells cultured in the presence of KAISVLYFDDS showed the peak values of total 
protein content and total DNA content on day 14, although no significant difference 
between three BMP-7-derived peptides was found due to the large experimental 
variability. The cells cultured in the presence of two His-tag peptides 
(KAISVLYFDDSHHHHHH and HHHHHHKAISVLYFDDS) showed similar responses 
compared to the other BMP-7-derived peptide. The results indicated that a His-tag in 
the peptide in treatment media do not lead to a significant difference in cell 
proliferation. In addition, the N- or C-terminal His-tag had a minimal effect on MC3T3-
E1 cell proliferation.  
 
2.3.3.2 Cell morphology  
Cell morphology of MC3T3-E1 cells cultured in treatment media containing 100 μg/ml 
BMP-7-derived peptide KAISVLYFDDS, KAISVLYFDDSHHHHHH and 
HHHHHHKAISVLYFDDS was evaluated by light phase contrast inverted microscopy 
(Figure 28) and SEM (Figure 29) after 14 days. According to Figure 28, no differences 
were observed in cell morphology between all the experimental groups on day 14 
including the positive control which cells were treated with 50 ng/ml BMP-2, and the 
negative control group which cells were cultured in growth medium with no additives. 
Figure 29 shows cells interacted with each other and were surrounded by fibrous 
extracellular matrix in all groups after 14 days. EDS analysis revealed no mineral 
deposit was formed from cells cultured in treatment media containing 100 μg/ml BMP-
7-derived peptides, nor cells cultured in growth medium with no additives. Only the 
positive control, which cells were treated with BMP-2, showed a signal of mineral 
deposit (Ca/P ratio between 1.6 and 1.8) (Figure 30).  
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Figure 28. Light phase contrast inverted micrograph of MC3T3-E1 cells cultured in 
treatment media with 100 μg/ml BMP-7-derived peptides KAISVLYFDDS (A), 
KAISVLYFDDSHHHHHH (B) and HHHHHHKAISVLYFDDS (C) after 14 days in culture. Cells 
treated with 50 ng/ml BMP-2 was the positive control (D). The control (negative) group 
represents cells were cultured in growth medium with no additives (E). Scale bars 
represent 10 μm. 
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Figure 29. Scanning electron micrographs of MC3T3-E1 cells cultured in treatment 
media with 100 μg/ml BMP-7-derived peptides KAISVLYFDDS (A), 
KAISVLYFDDSHHHHHH (B) and HHHHHHKAISVLYFDDS (C) after 14 days in culture. Cells 
treated with 50 ng/ml BMP-2 was the positive control (D). The control (negative) group 
represents cells were cultured in growth medium with no additives (E). Scale bars 
represent 1 μm. 
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Figure 30. EDS analysis of mineral depositions from cells treated with 100 μg/ml BMP-
7-derived peptide KAISVLYFDDS (A), and cells treated with 50 ng/ml BMP-2 (B) after 
14 days in culture. 
  
Unlike C2C12 cells, MC3T3-E1 pre-osteoblasts can only differentiate into osteoblasts. 
Therefore whether MC3T3-E1 cells were treated with BMP-7-derived peptides or not 
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had no effect on the cell differentiation pathway. The results of cell morphology study 
indicated that 100 μg/ml BMP-7-derived peptides did not affect the morphology of 
MC3T3-E1 cells. The EDS results indicate 100 μg/ml BMP-7-derived peptides did not 
possess the same ability as BMP-2 to induce mineral deposit. 
 
2.3.3.3 Cell differentiation 
Figure 31 shows the differentiation of MC3T3-E1 cells cultured in treatment media 
containing 100 μg/ml of different BMP-7-derived peptides (KAISVLYFDDS, 
KAISVLYFDDSHHHHHH, and HHHHHHKAISVLYFDDS) within 21 days by measuring the 
ALP activity, which is considered an early marker of osteoblast differentiation. Cells 
treated with 50 ng/ml BMP-2 expressed significantly higher ALP activity compared 
with all other groups on day 7 and 10 (p < 0.001). On day 14, although BMP-2 groups 
still shown significantly higher values (p < 0.001 for peptide KAISVLYFDDS and 
HHHHHHKAISVLYFDDS groups, p < 0.001 for peptide KAISVLYFDDSHHHHHH and 
control group), the ALP activity of cells in the presence of BMP-7-derived peptides 
gradually increased. In particular, peptide KAISVLYFDDS and HHHHHHKAISVLYFDDS 
groups showed a rapid increase in the ALP activity. On day 21, the ALP activity of the 
BMP-2 groups only showed a significant increase compared to the control group (p < 
0.001). The differences between other groups, however, were not significant due to 
large experimental variance. All of the values of BMP-7-derived peptide groups 
exceeded the control group after day 14. Among the three BMP-7-derived peptides, 
HHHHHHKAISVLYFDDS resulted in the highest ALP activity on day 14 and 21. However, 
there was no statistically significant difference between these peptides.  
 
The cell differentiation experiment results showed that 100 μg/ml BMP-7-derived 
peptides in the culture media of MC3T3-E1 cells induced significantly lower amounts 
of ALP activity compared to BMP-2 within 14 days. On day 21, although the difference 
was not significant, a lower ALP activity in the presence of BMP-7-derived peptides 
was observed than BMP-2 groups. Therefore 100 μg/ml BMP-7-derived peptides did 
not possess the same ability as BMP-2 to induce osteoblast differentiation.  
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Figure 31. The ALP activity of MC3T3-E1 cell lysate treated with 100 μg/ml BMP-7-
derived peptides and 50 ng/ml BMP-2 for 21 days was measured using ρNPP as a 
substrate. ** p < 0.01 and *** p < 0.001 indicate statistically significant differences 
between the indicated group and BMP-2 group on the respective day. 
 
According to Chen and Webster, 100 μg/ml peptide KAISVLYFDDS in culture media 
increased alkaline phosphatase activity in human fetal osteoblasts after 14 days 
compared to negative controls and BMP-7 [136]. Although different cells (human fetal 
osteoblast progenitor cell line vs. mouse pre-osteoblast cell line) and positive control 
(BMP-7 vs. BMP-2) were used here, comparable results were expected in this study. 
However, negative results were obtained from the ALP activity assay and peptide 
KAISVLYFDDS induced significantly less alkaline phosphatase activity in MC3T3-E1 after 
14 days compared to BMP-2. One possible explanation is due to the different cell line. 
Although MC3T3-E1 is a popular pre-osteoblast cell line and has been widely used to 
determine the biological activity of BMPs [284, 285], it may fail to respond to the short 
peptides used in this study. Another possible reason is the concentration of peptides 
(100 μg/ml) was too low to induce cell differentiation in MC3T3-E1. Either of these 
reason indicates that BMP-7-derived peptides in this study have a restrictive 
application and do not warrant further study. While the ALP activity is believed to be 
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an early marker of osteoblast differentiation, the deposition of calcium is a late 
differentiation marker. Chen and Webster also reported peptide KAISVLYFDDS 
increased calcium deposited by osteoblasts after 7, 14, and 21 days compared to 
controls and BMP-7 [136]. However, no calcium assay to detect mineral deposition was 
performed in this study based on the negative EDS and ALP activity results. 
 
2.4 Conclusion 
In this study, BMP-7-derived peptide KAISVLYFDDS, and two His-tag peptides 
KAISVLYFDDSHHHHHH and HHHHHHKAISVLYFDDS were successful synthesised and 
characterised. Their biological activities were determined by the mouse myoblast cell 
line C2C12. The results indicate BMP-7-derived peptides support the proliferation of 
C2C12 cells, but fail to convert the differentiation pathway of C2C12 from myoblast to 
osteoblast and to induce high ALP activity when compared to BMP-2. A further cell 
culture study to determine the effect of the BMP-derived peptides on a mouse pre-
osteoblast cell line MC3T3-E1 was carried out. The results indicate BMP-7-derived 
peptides support the proliferation of MC3T3-E1 cells, but do not process the same 
ability as BMP-2 to induce osteoblast differentiation. In conclusion, these BMP-7-
derived peptides show limited function and are not promising candidates for bone 
tissue engineering applications.  
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CHAPTER 3  
Production and characterisation of 
engineered recombinant ALP with improved 
biological activity  
3.1 Introduction 
In this chapter, the production and purification of the wild-type and mutated 
recombinant E. coli ALP with improved biological activity are described. The motivation 
of this study was to develop a practical approach for the expression and purification of 
recombinant E. coli ALP for a future application in bone tissue engineering. As 
reviewed in Section 1.4.3.1, mammalian ALPs, especially TNAP, are essential 
components of the bone formation process that generate the inorganic phosphate 
ions needed for mineral deposition, and hydrolyse pyrophosphate, a mineralisation 
inhibitor [139, 143]. E. coli ALP, despite different features compared to mammalian 
ALPs such as protein size, optimal pH, and heat stability [135, 138], shares a similar 
catalytic mechanism of hydrolysing phosphate monoesters with mammalian ALPs 
[136]. In addition, E. coli ALP is durable and relatively easy to isolate [148, 149], which 
makes it a promising candidate for bone tissue engineering applications. This study 
demonstrates the production of mutated E. coli ALP with improved biological activity 
in the E. coli recombinant protein expression system. 
 
3.1.1 Engineering recombinant alkaline phosphatase  
After demonstrating the positive function of E. coli ALP in the bone formation process, 
numerous studies have focused on investigating its reaction mechanism [150-156, 159, 
291]. Results suggest the catalytic activity of E. coli ALP can be improved by substituting 
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certain amino acid residues and developing mutations through site-directed 
mutagenesis [152, 155-157, 292]. High catalytic activity of E. coli ALP is desirable 
because it increases the dephosphorylation efficiency and may cover the activity loss 
caused by immobilisation [157]. In this research, a mutant E. coli ALP 4-186 was studied 
[157], which shows an improved catalytic activity of nearly 35 times higher than the 
wide-type. This mutation, which contains three amino acid residue replacements 
(D101S, K167R, S374C) (Table 8, Figure 7), was developed by Xu et al. through a 
directed evolution strategy, and expressed by an E. coli strain SM547 containing an 
ampicillin resistant plasmid pEK48/4-186 [180]. The SM547 strain has deleted the 
phoA gene from the chromosome, and contains a mutation in the phoR regulatory 
gene [175]. Therefore, a phoA-containing plasmid, such as pEK48, in this strain will 
overexpress ALP from the phoA gene on the plasmid even in a rich phosphate medium.  
 
The plasmid pEK48 was originally developed by Chaidaroglou et al. and contains a 
complete wild-type phoA gene encoding the wide-type E. coli enzyme ALP [175]. The 
construction process of pEK48 has been divided into three steps, and is described 
below.  
 
(1) Construction of pHI-1 (Figure 32) [293]. A plaque-forming specialised transducing 
phage containing the phoA gene λp(phoA-proC) [294] was first digested with restriction 
enzyme PstI to produce a 6.4 kb fragment carrying the entire phoA gene. The fragment 
was then inserted into a cloning vector pBR322, which has a unique PstI site, to form 
a new plasmid named pHI-1 (10.7 kb). Vector pBR322 is a classical widely used E. coli 
vector for DNA cloning. It provides the new plasmid pHI-1 ampicillin and tetracycline 
resistance markers, and some restriction cleavage sites. When the pHI-1 was digested 
with restriction enzymes, for example, with HindIII, four fragments were produced: a 
2.35 kb fragment, a 0.05 kb fragment, and two 4.15 kb fragments. One of the 4.15 kb 
fragments contains the phoA gene. 
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Figure 32. Construction process of plasmid pHI-1. After digestion by PstI, a 6.4 kb DNA 
fragment that contains the entire phoA gene (shown in green) was isolated from phage 
λp(phoA-proC) DNA. When the phage DNA fragment was mixed with PstI treated 
pBR322, a new recombinant plasmid pHI-1 was ligated. An ampicillin resistance marker 
is shown in pink, and a tetracycline resistance marker is shown in grey. Blue arrows 
represent restriction cleavage sites. 
 
(2) Construction of pEK29 (Figure 33) [175]. When the plasmid pHI-1 was double 
digested with HindIII and XhoI, five fragments were produced. Among them, a 2.5 kb 
fragment that contains the entire phoA gene was isolated and combined with a 
plasmid pGC1 pretreated with HindIII and XhoI to form a new plasmid named pEK29 
(5.2 kb). pGC1 is a GC-clamp vector that is composed of 1900 bp from the pBR322 
plasmid including an ampicillin resistance marker and a colE1 origin, 671 bp from the 
bacteriophage M13 origin of replication, a GC-clamp, and a list of restriction cleavage 
sites [295]. The GC-clamp is a GC-rich DNA sequence usually next to target gene 
designed for an easy detection of single-base mutations in the melting domain. The 
bacteriophage M13 origin of replication, which is preserved in plasmid pEK29, allows 
the production and isolation of single-stranded DNA in a large quantity. 
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Figure 33. Construction process of plasmid pEK29. After double digestion by HindIII and 
XhoI, a 2.5 kb DNA fragment that contains the entire phoA gene (shown in green) was 
isolated from the plasmid pHI-1. The DNA fragment was mixed with the same 
restriction enzymes as pGC1, and a new recombinant plasmid pEK29 was ligated. An 
ampicillin resistance marker is shown in pink, a colE1 origin is shown in orange, a 
bacteriophage M13 origin is shown in grey, and a GC-clamp is shown in red. Blue 
arrows represent restriction cleavage sites. 
 
(3) Construction of pEK48 (Figure 34) [175]. The HindIII-BamHI fragment of pEK29 
which contains the entire phoA gene was recloned into a pUC119, which had been 
double digested with the same two enzymes to form a new plasmid pEK48 (5861 bp). 
pUC119 is a popular cloning vector. It provides the new plasmid pEK48 an ampicillin 
resistance marker, a colE1 origin, a M13 origin of replication, and a multiple cloning 
sites. The phoA gene inserted in one of the multiple cloning site can be expressed 
under control of the lac promoter.  
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Figure 34. Construction process of plasmid pEK48 and the complete coding sequence 
(cds.) of the E. coli alkaline phosphatase gene. (A) Plasmid pEK48 and pUC119 DNA 
were double digested with HindIII and BamHI, mixed, and ligated to form a new 
recombinant plasmid pEK48 containing the entire E. coli ALP phoA gene (2715 bp) 
between the HindIII and BamHI restriction sites shown in the green. An ampicillin 
resistance marker is shown in pink, a colE1 origin is shown in orange, and a 
bacteriophage M13 origin is shown in grey. Blue arrows represent restriction cleavage 
sites. (B) The phoA gene contains a signal sequence (nucleotide residues 283-345, 62 
bp, shown in red), a mature sequence (nucleotide residues 346-1695, 1.35 kb, shown 
in green) and linking sequences.  
 
In this study, plasmid pEK48/4-186, which contains a mutant phoA gene encoding the 
4-186 mutant ALP, as well as the wild-type ALP plasmid pEK48/phoA, were 
transformed into different host stains, such as DH5α and BL21 to produce and purify 
wild-type and mutant recombinant E. coli ALP with improved biological activity. 
 
3.1.2 Scope of the chapter 
This chapter focuses on the production and purification of wild-type and mutant 
A 
B 
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recombinant E. coli ALP with improved biological activity. Described herein are the 
steps taken to design and produce recombinant mutant E. coli ALP showing higher 
biological activity than the wild-type E. coli ALP. Some effects including sodium chloride 
(NaCl) and lyophilisation on recombinant ALPs are investigated. Different host cells 
such as BL21 and DH5α were considered to improve the production of E. coli ALP. 
 
3.1.3 Hypotheses 
The hypotheses tested was that recombinant mutant E. coli ALP have outstanding 
biological activity compared to wild-type ALP, and may be used in bone tissue 
engineering. In order to test these hypotheses, the following aims have been 
addressed in this Chapter: 
(1) Verify the recombinant mutant E. coli ALP gene, in particular the mutations. 
(2) Confirm the expression of recombinant mutant and wild-type E. coli ALP. 
(3) Purify the recombinant mutant and wild-type E. coli ALP from bacterial culture 
media. 
(4) Determine the specific activity of recombinant mutant and wild-type E. coli ALP.  
(5) Investigate the effect of sodium chloride (NaCl) and lyophilisation on recombinant 
ALPs. 
(6) Investigate the strategies to improve the expression of recombinant mutant and 
wild-type E. coli ALP. 
 
3.2  Materials and methods 
3.2.1 Materials 
Unless stated otherwise, all chemicals, restriction enzymes, and bacterial cell culture 
reagents were purchased from Sigma-Aldrich (Gillingham, UK). QIAprep plasmid 
purification kit was purchased from Qiagen. SYBR Safe DNA Gel Stain was purchased 
from Invitrogen. GeneRuler 1kb DNA Ladder was purchased from Fermentas. Page 
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Ruler Prestained Protein Ladder was purchased from Thermo Scientific. The 
NativeMark Unstained Protein Standard was purchased from Invitrogen. DC Protein 
Assay kit was purchased from Bio-Rad. Anti-alkaline phosphatase antibody (ab354) 
was purchased from Abcam, UK. ECL anti-rabbit IgG horseradish peroxidase-linked 
whole antibody (from donkey) was purchased from GC Healthcare. 
 
Bacterial strains SM547 (Δ(phoA-proC), phoR, tsx::Tn5, Δlac, gal K, leu, Strr), DH5α (F-, 
φ80dlacZΔM15, Δ(lacZYA-argF), U169, deoR, recA1, endA1, hsdR17(rk-, mk+), phoA, 
supE44, λ-, thi-1, gyrA96, relA1), and BL21 (F-, dcm, ompT, hsdS(rB- mB-), gal [malB+]K-
12(λS) were used as the host for gene expression. All strains and plasmids pEK48/phoA 
and pEK48/4-186 were kindly provided by Professor A. E. G. Cass (Imperial College 
London). 
 
3.2.2 E. coli bacterial culture 
A vial of frozen bacterial cells was thawed and plated on Luria-Bertani (LB) medium 
plates (see Appendices) containing 100 μg/ml ampicillin and 40 μg/ml 5-bromo-4-
chloro-3-indolyl phosphate (BICP), which can react with ALPs and generate a blue 
product. Blue colonies developed on the plate indicating the expression of ALP. Single 
blue colonies on the plates carrying the wild-type or mutant phoA gene were picked 
and suspended in 4 ml of LB media containing 100 μg/ml ampicillin. The cells were 
cultured in an incubator at 37°C, 200 rpm overnight. 1 ml of overnight culture medium 
was aseptically transferred into 100 ml of LB broth to incubate at 37°C with continuous 
shaking until the stationary phase of the culture was reached.  
 
The cells were harvested by centrifugation at 6500 rpm for 15 min. The cell pellet was 
washed twice with cold 0.01 M Tris-0.03 M NaCl washing buffer and the periplasmic 
protein E. coli ALP was released by a modified osmotic shock method according to 
Brockman and Heppel [296]. Briefly, the cell pellet was suspended in 2 ml 0.03 M Tris 
suspension buffer containing 20% (w/v) sucrose solution and 1mM EDTA. After 10 min 
incubation at ambient temperature, the mixture was centrifuged at 10000 rpm for 20 
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minutes at 0°C. Next, the supernatant was removed and the cells were resuspended 
in 10 ml ice cold water for 15 min allowing the E. coli ALP to be release into the 
supernatant. The supernatant was collected by centrifugation at 10000 rpm for 10 min. 
The precipitation of the proteins from the cold water was done by gradually adding 
ammonium sulphate to the supernatant to a final concentration of 608 mg/ml (85% 
saturation). The pellet was collected by centrifugation at 10000 rpm for 20 min at 0°C, 
and resuspended in 2 ml TMZP buffer [297]. Dialysis was carried out to remove the 
ammonium sulphate in the suspension. The dialysed solution containing E. coli ALP 
was filtered through a 0.45 μm filter before purification on a GC Healthcare ÄKTA 
explorer using Q-Sepharose Fast Flow anion exchange chromatography column 
(Pharmacia). Finally, proteins bound to the column were eluted with a linear gradient 
of 0-0.2 M NaCl in TMZP buffer. Pure E. coli ALP fractions were collected by detecting 
the absorbance at 280 nm, identified by electrophoresis, and characterised by 
biochemical assays. The proteins were lyophilised and stored at -80°C. 
 
3.2.3 Plasmid DNA Purification 
Plasmid DNA in bacterial cells was extracted using a QIAprep Spin Miniprep Kit [298] 
following the recommended protocol. The procedure is based on the lysis of bacterial 
cells followed by adsorption of DNA on a unique silica membrane in the presence of 
high salt [298]. Bacterial cells from a single colony were cultured in 4 ml LB medium in 
an incubator at 37°C, 200 rpm for 12 hours. The cell pellet was collected by 
centrifugation at 6500 rpm for 10 min at 4°C and resuspended in the resuspension 
buffer by vortexing. Then the lysis buffer was added to the cells and gently mixed to 
achieve a homogeneously blue suspension. Next, the neutralisation buffer was added 
into the mixture and immediately vortexed for 1 min until the suspension was became 
colourless, which indicates the SDS in the lysis buffer has been completely precipitated. 
The samples were centrifuged at 12000 rpm for 10 min at 4°C. The supernatant was 
transferred to a QIAprep spin column, and centrifuged at 12000 rpm for 1 min at 4°C 
allowing the binding of plasmid DNA to the silica membrane of the column. The 
column was washed twice with washing buffers to improve the purity of the plasmid 
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DNA. Finally, the plasmid DNA was eluted in to a clean Eppendorf in 25-50 μl of water 
depending on the quantity. The concentration of the plasmid DNA was determined by 
a NanoDrop 2000c (Thermo Scientific, USA). Plasmid DNA isolated from bacterial cells 
can be kept at -20°C up to six months. 
 
3.2.4 Gel electrophoresis 
Gel electrophoresis techniques are widely used to separate and purify charged 
molecules such as nucleic acids and proteins with different size, charge, and 
conformation [299]. The separation is based on the different molecular motilities 
under an electric field. DNA separation is usually performed in an agarose gel, while 
proteins are more often separated by polyacrylamide gel electrophoresis (PAGE) with 
or without sodium dodecyl sulphate (SDS).  
 
A) Agarose gel electrophoresis 
Agarose is a natural polymer extracted from seaweed. It can be dissolved in hot water, 
but when cooled down, the polymers crosslink with each other and form networks of 
pores. The pore size is dependent on the percentage of agarose. The DNA in the gel is 
forced to move from the negative electrode to the positive electrode during 
electrophoresis. Under the same strength of the electrical field, and the percentage of 
agarose gel, the only factor that can affect the moving speed of DNA is its size. Smaller 
DNA molecules move faster in the gel than larger DNA molecules because they more 
easily go through the pores. Although DNA is not directly visible in the gel, the position 
of DNA molecules can be visualised by the use of a dye under UV radiation. 
 
In this study, 1% (w/v) agarose gel was made with a TBE running buffer containing SYBR 
Safe DNA gel stain. Samples were mixed with 6X sample loading buffer before loading 
on the gel. The agarose gel electrophoresis was performed in a gel box (Bio-Rad, USA) 
at 100-150 V for 1.5 to 2 hours. The gels were visualised and imaged using a 
BioSpectrum 500 fluorescence reader from UVP (CA, USA). 
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B) Polyacrylamide gel electrophoresis 
A crosslinked polymer network can be formed by mixing the acrylamide with 
bisacrylamide as well as a polymerising agent, ammonium persulphate (APS), and a 
catalyst, TEMED (N,N,N,N'-tetramethylenediamine). The polymerisation process is 
inhibited by oxygen. The pore size in the polymer network can be controlled by the 
concentration of acrylamide and bisacrylamide. The original PAGE was developed by 
Ornstein and Davis in a discontinuous gel system [300]. The samples were first loaded 
on a short stacking gel which has a larger pore size to concentrate the samples into a 
tight band before entering the following running gel [301]. The separation of proteins 
in native PAGE is based on the size and charge of proteins. In order to simplify the 
separation process and increase the number of applications, a modified 
electrophoresis method SDS-PAGE containing a reducing agent, sodium dodecyl 
sulphate (SDS), was used. SDS covers the protein with a uniformly negative charge and 
denatures the proteins allowing the separation of proteins based on the size of 
proteins only. Once the PAGE is finished, protein bands can be visualised directly in the 
gel by staining, or by transferring to a membrane for analysis by Western blotting. 
 
In this study, proteins produced by bacterial cells were analysed using SDS-PAGE on an 
8% (w/v) polyacrylamide gel. Gel buffers used in electrophoresis are described in the 
Appendices. Samples were denatured by heating at 95°C for 10 min in the presence of 
a sample buffer containing a reducing agent dithiothreitol (DTT) before loading on the 
gel. The polyacrylamide gel electrophoresis was performed in a gel box (Bio-Rad, USA) 
at 100 V for 1 to 2 hours. The gels were stained by a ProteoSilver™ silver stain kit 
(Sigma-Aldrich, UK), and visualised and imaged on a BioSpectrum 500 fluorescence 
reader from UVP (CA, USA). 
 
3.2.5 Western blotting 
Western blotting, also named protein blotting or protein immunoblot, is a widely used 
technique to detect and analyse specific proteins. The methods was first described by 
Towbin et al in 1979 [302]. It contains four steps [303, 304]. First, gel electrophoresis. 
119 
 
Proteins are separated and immobilised by gel electrophoresis as described in Section 
3.2.4. Second, transfer. The gel-resolved proteins are electrophoretic transferred to a 
membrane, usually is made by nitrocellulose or polyvinylidene fluoride (PVDF), so that 
the proteins on the membrane keep the same pattern of separation as they had on 
the gel. Third, antibody probing. The membrane is first blocked by incubating with a 
generic protein, and then probed by adding a primary antibody. The primary antibody 
is specific but non-labelled. In order to detect and visualise the target proteins, a 
labelled secondary antibody is used. Finally, detection. The location of the antibody is 
revealed by using chemiluminescence, chemifluorescence, fluorescence, chromogenic 
or radioisotopic detections [305]. 
 
In this study, proteins produced by bacterial cells were first separated using SDS-PAGE 
gel electrophoresis on an 8% (w/v) polyacrylamide gel. The method is described in 
Section 3.2.4. Once the electrophoresis is finished, the gel is transferred to PVDF 
membranes at 100 V for another 1 hour. The membranes with protein bands are first 
incubated in 5% milky blocking solution with shaking at ambient temperature for 1 
hour, and then incubated in primary antibody solution (1/1000) with shaking at 4°C 
overnight. Next, the membranes are soaked in secondary antibody solution (1/20000), 
and incubated with shaking at ambient temperature for 1 hour. Finally, the membranes 
are washed, visualised and imaged on a BioSpectrum 500 fluorescence reader from 
UVP (CA, USA). 
 
3.2.6 DNA sequencing 
DNA sequencing is an essential molecular biology technique to determine the precise 
order of nucleotides in a DNA molecule. There are two different methods to sequence 
DNA, one is a chain termination method developed by Sanger and Coulson; the other 
is a chemical degradation method developed by Maxam and Gilbert. The chemical 
degradation method is not frequently used because it depends on the extensive use 
of toxic chemicals to cleave nucleotides. The chain termination method, also call 
Sanger sequencing method, is an easy and simple way for DNA sequencing. It depends 
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on the enzymatic synthesis of DNA chains in the presence of chain-terminating 
inhibitors [306]. 
 
DNA sequencing reactions in the chain termination method are similar to the PCR 
reactions for replicating DNA described in Section 1.5.3, Figure 15. The sample DNA is 
mixed with polymerase, free deoxynucleotides, and primers. The new DNA chains are 
generated according to the template sample DNA. However, differing from the PCR, 
some modified deoxynucleotides (Figure 35A), which lack hydroxyl group at their 3’ 
position to bond to the next deoxynucleotide, are used in addition to normal 
deoxynucleotides [307]. Once a modified deoxynucleotide is added on the chain, the 
chain is terminated. After enough time of reactions, all of the copies are terminated 
by a modified deoxynucleotide, and the copies are stopped at each possible 
deoxynucleotide to produce a series of DNA chains (Figure 35B). The separation of the 
products is carried out by gel electrophoresis to determine the length of each strand. 
The modified deoxynucleotides are either radioactively labelled or fluorescent labelled 
so the DNA sequence can be determined. 
 
 
 
A 
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Figure 35. General principle of DNA sequencing by the chain termination method [307]. 
(A), Modified deoxynucleotide lacks the hydroxyl group at their 3’ position so it cannot 
bind to the other deoxynucleotide to extend the DNA chain. (B) All of the copies 
produced by the chain termination method are terminated by a modified 
deoxynucleotide. These modified deoxynucleotides are labelled so the DNA sequence 
can be determined by a colour match. 
 
In this study, all DNA sequencing were performed by GATC Biotech Ltd. using the chain 
termination method. 
 
3.2.7 Preparation of competent cells and transformation 
Competent cells have the ability to accept foreign DNA or plasmids. One treatment to 
prepare competent cells is by electroporation, which provides high transformation 
efficiency [308]. However, special equipment is required in this process. Another 
method is a chemical method that replies on the treatment of calcium chloride (CaCl2) 
to change the permeability of the cell membranes. Although the transformation 
efficiency of the competent cells produced by the chemical method is relatively low, it 
is easy to perform so has been widely used in laboratory scale.  
 
Before the CaCl2 treatment, bacterial cells from a single colony were cultured in 4 ml 
B 
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LB medium in an incubator at 37°C, 200 rpm overnight. The overnight culture medium 
was diluted 100 fold into a fresh LB medium (see Appendices) and cultured at 37°C, 
200 rpm until the absorbance at 600 nm reached 0.5. The culture was centrifuged at 
6500 rpm for 10 min at 4°C, and the cell pellet was collected and incubated on ice for 
10 min. The cells were resuspended in 40 ml treatment buffer 1 which contains CaCl2 
at 4°C with gentle mixing for 1 hour. The cell pellet was collected and resuspended 
again with 20 ml treatment buffer 2 followed by incubation on ice for 15 min. The 
competent ability of these cells can be maintained for six months at -80°C. 
 
An aliquot of competent cells was gently mixed with the plasmid DNA, and incubated 
on ice for 25 min. Then the mixture was heat shocked by incubating at 42°C for 50 
seconds followed by incubation on ice for 2 min. The bacterial cells were cultured in 1 
ml SOC medium in an incubator at 37°C, 200 rpm for 1 hour. The cell pellet was 
collected and plated on LB plates containing selection antibiotic to screen for the 
successfully transfected cells. 
 
3.2.8 ÄKTA explorer purification system 
ÄKTA explorer purification system is a fully automated liquid chromatography system 
using a fast protein liquid chromatography (FPLC) technique designed for protein 
purification [309]. Compare to HPLC, the FPLC system has a lower pressure but a faster 
flow rate. 
 
The ÄKTA explorer purification system includes a pump, a UV detector, a pH and 
conductivity detector, an injector, a mixer, a fraction collector, set of valves, and a 
monitor. In this study, a Q-Sepharose Fast Flow anion exchange chromatography 
column was used on ÄKTA explorer to purify wild-type and mutant E. coli ALP. The 
column and system were equilibrated with 5 volumes of TMZP buffer. The proteins 
were eluted by a linear gradient method with 20 volumes of 0-0.2 M NaCl in TMZP 
buffer. A flow rate of 1 ml/min was used and fractions were collected in Eppendorf 
tubes. 
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3.2.9 Dialysis 
Dialysis is a simple separation technique to remove unwanted small molecules from 
larger molecules in solution by diffusion through a semi-permeable membrane. Figure 
36 illustrates the principle of dialysis. Dialysis has been widely used in medicine as an 
artificial replacement for lost kidney function to remove waste and excess water from 
the blood. It can also be used in protein purification process to adjust protein from one 
buffer to another, to change the metal and salt ion concentrations, and to remove 
unwanted small molecules in protein solution [310]. 
 
 
Figure 36. The general principle of dialysis [311]. By using a semi-permeable membrane, 
which allows small molecules pass through freely while larger molecules cannot, the 
concentration of those small molecules within the dialysis tube can be effectively 
reduced. Changing the dialysate buffer regularly allows more small molecules to 
diffuse into the dialysate buffer.  
 
In this study, dialysis through porous cellulose tubing against TMZP buffer (see 
Appendix) was used after the salt precipitation to remove the ammonium sulfate salts 
from the protein. Dialysis was performed at 4°C temperature for 12 h on a stirring plate. 
Three buffer changes of 10 volumes were preformed every 4 h. 
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3.2.10 Biochemical assays 
A) DC Protein assay 
The concentration of E. coli ALP produced by bacterial cells was determined by a 
commercial DC Protein Assay Kit (BIO-RAD). The assay is based on the well-known 
Lowry protein assay where proteins react with an alkaline copper tartrate solution and 
Folin reagent to produce a blue colour with a strong absorbance between 650 and 750 
nm [312]. The DC protein assay has two procedures, one is for standard samples having 
a protein concentration between 0.1 to 2 mg/ml, and the other is a microassay 
procedure that can measure protein concentrations from 5 to 250 μg/ml by using only 
20 μl of samples for a microplate assay. 20 μl protein samples after purification were 
mixed with the assay reagent in a 96-well plate and incubated for 15 min at ambient 
temperature. The light absorbance of these samples was measured at 750 nm on a 96-
well plate reader (Labsystems, Life Sciences International Ltd, Hampshire, UK). 
Experiments were performed independently in triplicate. 
 
B) ALP specific activity measurement of recombinant E. coli ALP  
Similar to the ALP activity assay for cells, ALP specific activity measurement of E. coli 
ALP depends on the hydrolysis of ρNPP by the E. coli ALP and generates inorganic 
phosphate and ρ-Nitrophenol, which is converted to a yellow product under alkaline 
conditions and shows a strong absorbance at 400-420 nm. 10 μl of the protein samples 
after purification was mixed with ρNPP (Sigma, UK) in a 96-well plate and incubated at 
37°C until a yellow colour was detected by eye, the reaction was then stopped by 
adding 100 μl 1 M NaOH. Light absorbance of these samples was measured at 405 nm 
on a 96-well plate reader. A standard curve was constructed using ρ-Nitrophenol 
(Sigma, UK) as a standard. Experiments were performed independently in triplicate, 
and the ALP specific activity of each sample was normalised to protein content and 
expressed as mean plus/minus standard deviation. 
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3.3 Results and discussion 
3.3.1 Confirmation of recombinant E. coli ALP gene 
The bacterial stain SM547 containing plasmids pEK48/phoA and pEK48/4-186, which 
encoding the wild-type and 4-186 mutant E. coli ALP, respectively, were cultured in LB 
media. Both plasmids DNAs were isolated for agarose gel electrophoresis and DNA 
sequencing to confirm the accuracy of the cloning. Figure 37 shows the agarose gel 
electrophoresis results of plasmids pEK48/phoA and pEK48/4-186. The difference 
between the plasmids is 3 amino acid substitutions, therefore they have the same 
theoretical size of 5861 bp. A clear single band of 5.8 kb was shown when the plasmid 
pEK48/phoA was digested with the restriction enzyme BamHI (Lane 5); two sharp 
bands (above 3.1 kb, below 2.7 kb, which contain the E. coli ALP gene) were shown 
when the plasmids were double digested with BamHI and HindIII (Lane 2 and 4); 
several bands were shown when the undigested plasmids were loaded on the gel (Lane 
3 and 6) due to their supercoiled structure. The results indicate the real sizes of the 
plasmids are consistent with the description, and demonstrate that the digestions of 
the plasmids by restrictive enzymes were correct and efficient. 
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Figure 37. Agarose (1% w/v) gel electrophoresis of restriction enzymes digested 
plasmids pEK48/4-186 and pEK48/phoA. Lane 1 is a 1 kb DNA ladder; lane 2, the 
plasmid pEK48/4-186 double digested with BamHI and HindIII; lane 3, undigested 
plasmid pEK48/4-186; lane 4, the plasmid pEK48/phoA double digested with BamHI 
and HindIII; lane 5, the plasmid pEK48/phoA single digested with BamHI; lane 6, 
undigested plasmid pEK48/phoA. 
 
In order to further confirm the accuracy of the cloning, especially the plasmid pEK48/4-
186 with the 3 amino acid mutations, several rounds of DNA sequencing were 
performed by GATC Biotech Ltd. (Figure 38). After comparing the DNA sequencing 
results of the 4-186 gene from the plasmid pEK48/4-186 with the current entries in 
GenBank/NCBI nucleotide data bases, a single data base entry of E. coli alkaline 
phosphatase (phoA) gene, complete coding sequence (GenBank: M13345.1), was 
identified with significant similarity. The aligned sequences show 99% identity over the 
region of the genes. Six DNA substitutions of the 4-186 were shown exactly as 
described by Xu et al [180]. One DNA sequencing reaction has an accurate reading 
limitation of 700 to 1000 bp. Totally, four DNA sequencing reactions were carried out 
for a complete reading of the entire E. coli ALP phoA gene of 2715 bp. 
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Figure 38. DNA sequence comparison of the wild-type E. coli ALP phoA (complete 
coding sequence, GenBank: M13345.1, lower line) and the mutation 4-186 gene from 
pEK48/4-184 plasmid (above line). Identical residue matches are indicated by 
connecting solid lines. DNA mutations are shown in red in blue boxes. The percent 
similarity value is based on the number of identical and two-point DNA comparisons. 
N appears at the end of the sequencing representing unidentified nucleotides. Some 
middle parts of the gene were omitted due to the space limitation. This sequence 
alignment in one reaction only shows five out of six DNA substitutions (g649a, a650g, 
c651t, a848g, and g1170t) described by Xu. This comparison was prepared by the 
BLAST sequence analysis program.  
 
3.3.2 Verifying the recombinant E. coli ALP expression 
After confirming the DNA sequence of wild-type and mutant alkaline phosphatase 
gene in the plasmids pEK48/phoA and pEK48/4-186, respectively, the proteins were 
produced from E. coli SM547. Figure 39 shows the LB Amp BCIP selective plate with 
blue colonies of SM547 pEK48/4-186 after culturing for 24 hours in an incubator at 
37°C. White colonies were found on the plate after 8 hours of culture, after which they 
gradually turned to blue. According to Chaidaroglou, bacterial cells after 
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transformation were first screened by using a selective LB plate containing not only 
ampicillin antibiotics, but also BICP, which is a substrate for ALPs [175]. BCIP reacts 
with E. coli ALP expressed from the bacterial cells and forms a blue products, thus 
turning the colony blue colour. Therefore the colonies grown on the LB Amp BCLP 
selective plate are cells containing the pEK48 plasmids, while blue colonies developed 
on the plate indicate the expression of active E. coli ALP. The difference between the 
plates cultured with SM547 pEK48/phoA and SM547 pEK48/4-186 was insignificant. 
 
 
Figure 39. Image of LB Amp BCIP selective plate grown with SM547 pEK48/4-186 after 
24 hours incubation at 37°C. All colonies grown on the selective plate contain the 
pEK48/4-186 plasmids. The blue colour indicates that they are expressing the active 
form of ALP.  
 
Cell lysates of SM547 pEK48/phoA and SM547 pEK48/4-186 after overnight culture 
were analysed by SDS-PAGE and western blotting (Figure 40). Several bands were 
shown on the SDS gel, most of which were under 35 kDa. The E. coli ALP showed a 
weak band at 53 kDa. The result indicates that E. coli ALP is not the main protein 
produced in SM547. Small molecular weight proteins (molecule weight under 35 kDa) 
were extensively produced by the bacterial cells. However, when the SDS gel 
transferred to a nitrocellulose membrane and reacted with anti-alkaline phosphatase 
antibody, one main band of E. coli ALP was evident. The western blotting result 
confirmed the expression of E. coli ALP from SM547. Although the same E. coli protein 
expression system was used to produce wild-type and mutant E. coli ALP, mutant ALP 
shown a darker and thicker band than wild-type ALP, which indicated a higher 
production rate of mutant ALP from SM547 pEK48/4-186. No related data of 
comparison of protein yield between SM547 pEK48/phoA and SM547 pEK48/4-186 
was provided from previous studies.  
129 
 
 
 
Figure 40. SDS-PAGE (8% w/v) gel electrophoresis (lane 2 and 3) and western blotting 
(lane 4 and 5) of cell lysates of SM547 pEK48/4-186 and SM547 pEK48/phoA after 
overnight cell culture at 37°C. Samples were electrophoresed in an SDS gel, then 
transferred to a nitrocellulose membrane and reacted with anti-alkaline phosphatase 
antibody. Lane 1, ladder; lane 2, cell lysates of SM547 pEK48/4-186 on gel; lane 3, cell 
lysates of SM547 pEK48/phoA on gel; lane 4, western blotting analysis of cell lysates 
of SM547 pEK48/4-186; lane 5, western blotting analysis of cell lysates of SM547 
pEK48/phoA. SDS-PAGE gel was stained with Coomassie blue. 
 
3.3.3 ÄKTA explorer purification of E. coli ALP  
After cells were grown for an appropriate time, they were collected by centrifugation. 
The periplasmic proteins were released by osmotic shock according to the method 
described in Section 3.2.2, and the E. coli ALP was purified by a Q-Sepharose Fast Flow 
anion exchange chromatography column on ÄKTA explorer purification system. Figure 
41 shows one example of ÄKTA explorer purification analysis of E. coli ALP expressed 
from SM547 pEK48/4-186.  
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Figure 41. ÄKTA explorer purification analysis of E. coli ALP expressed from SM547 
pEK48/4-186. The process contains four steps: sample injection, column washing with 
binding buffer, gradient elution with elution buffer, and column washing with elution 
buffer. Three main peaks were shown on the OD280 line (solid blue line), the unbound 
protein peak, the target protein peak (shown in the red box), and an unknown protein 
peak. 17 fractions were collected from the purification.  
 
Temperature, pH, conductivity, and OD280 were on-line monitored during the 
purification. Among them, OD280 indicated the protein concentration, so was of the 
most interest. The ÄKTA explorer purification process consisted of four steps. First, the 
protein mixture of E. coli proteins was injected into the system. Second, protein 
mixture passed through the column with the binding buffer. E. coli ALP was attached 
on the positively charged solid support so remained inside the anion exchange 
chromatography column. When the unbounded protein peak went down, which 
indicated the positive charged proteins were washed away with the binding buffer, the 
linear gradient started with elution buffer. The target E. coli ALP protein was eluted 
from the column in this step. OD280 result indicated that the main protein peak shown 
in the red box started to increase when the 0.02 M NaCl elution buffer was used in the 
system, and finished when 0.1 M NaCl elution buffer was used. This was in accordance 
with references [175, 313]. Other unknown protein peaks were revealed in the last 
step of column washing when 0.2 M NaCl elution buffer was used. 
 
Figure 42 shows the SDS-PAGE electrophoresis result of purified mutant and wild-type 
OD280 line 
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E. coli ALP after the ÄKTA explorer purification system. Only one band of E. coli ALP at 
53 kDa was observed on the gel for each sample. The result indicates the purification 
was successful. The western blotting result confirmed the expression of E. coli ALP 
from SM547. 
 
 
 
Figure 42. SDS-PAGE (8% w/v) gel electrophoresis analysis (lane 2 and 3) and western 
blotting (lane 4 and 5) of purified E. coli ALP after ÄKTA explorer purification system. 
Samples were electrophoresed in an SDS gel, then transferred to a nitrocellulose 
membrane and reacted with anti-alkaline phosphatase antibody. Lane 1, ladder; lane 
2, E. coli ALP expressed from SM547 pEK48/4-186; lane 3, E. coli ALP expressed from 
SM547 pEK48/phoA; lane 4, western blotting analysis of E. coli ALP expressed from 
SM547 pEK48/4-186; lane 5, western blotting analysis of E. coli ALP expressed from 
SM547 pEK48/phoA. SDS-PAGE gel was stained with Coomassie blue. 
 
3.3.4 Determining ALP specific activity of E. coli ALP 
In order to determine the activity of E. coli ALP, which was normalised to protein 
content, the protein concentration in the elution buffer was measured. Several protein 
measurements were considered to determine the ALP concentration including the 
Bradford protein assay, the BCA protein assay, the Dc protein assay and 
spectrophotometry on the Nanodrop. The Dc protein assay was chosen based on the 
reliable results, the wide measurement range (from 5 μg/ml up to 1.5 mg/ml), as well 
as the small amount of sample required (20 μl of sample for the microplate assay). 
Other than a normal protein standard of bovine serum albumin, bovine intestinal ALP 
(lyophilised powder) from Sigma-Aldrich was used as a standard in this study. Bovine 
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intestinal ALP shows a 26% sequence homology of the active site compare to E. coli 
ALP [314], and is widely studied with implants or scaffolds to develop bioactive 
materials for bone tissue engineering applications [53]. In order to obtain a 
comparable result, bovine ALP was used as a positive control in this study to compare 
with the biological activity of E. coli ALP.  
 
Figure 43A is a linear gradient line of E. coli ALP from the ÄKTA explorer purification 
analysis according to Figure 38. 17 fractions were collected and the target E. coli ALP 
should have been contained in the elution fractions from 5 to 14. The ALP specific 
activities of the E. coli ALP were measured by the method described in Section 3.2.10 
(Figure 43B).  
 
Initially, the ALP activity assay described in Section 2.2.2.5 was used to determine the 
E. coli ALP produced from bacterial cells. However, most of the fractions shown 
stronger absorbance signals than the standard after 60 min incubation at 37 °C. In 
order to suit the demands for the high ALP activity protein, a lower sample amount 
and shorter incubation time were modified in the new method described in Section 
3.2.9. According to Figure 43B, the highest values are from the elution fractions 9 to 
12. The results were in accordance with expectations, and indicated that pure E. coli 
ALP with high ALP specific activity was successfully separated. However, all 17 fractions 
shown ALP specific activities, which indicated the E. coli ALP existed in all fractions. 
This result demonstrates that the efficiency of this purification system was not very 
high due to a non-specific binding of E. coli ALP to the anion exchange column.  
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Figure 43. Quantification of ALP activity of 17 fractions after ÄKTA explorer purification 
analysis of E. coli ALP expressed from SM547 pEK48/4-186. (A) The linear gradient line 
of E. coli ALP from the ÄKTA explorer purification system; (B) ALP specific activity of 17 
fractions. ALP specific activity was normalised to total protein amount determined by 
the Dc protein assay. 
Figure 44 shows the comparison of ALP activity between the most active fractions of 
A 
B 
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mutant and wild-type E. coli ALP from SM547 pEK48/4-186 and SM547 pEK48/phoA, 
respectively. Bovine intestinal ALP was considered as a control. The mutant ALP 
showed a significantly higher activity compared to the wild-type ALP (24.60 ± 3.2675 
times) and bovine ALP (9.24 ± 2.3581 times) (p < 0.001). The wild-type ALP showed a 
significantly lower activity than bovine ALP (more than twice) (p < 0.01). The results 
were in line with the reference although lower increasing times were obtained. 
According to Xu, the mutant ALP showed a nearly 35 times higher activity than the 
wild-type in pH 10.05, 1 M Tris-HCl buffer. When the activity was measured in pH 10.05, 
0.5 M Tris-HCl buffer, the mutant ALP only showed activity 31 times higher than the 
wild-type [180]. Because the ALP activity is affected by many factors, it is possible that 
a 25 fold difference was measured in pH 7.4, 0.01 M Tris-HCl buffer. 
 
Figure 44. ALP specific activity of purified mutant and wild-type ALP from SM547 
pEK48/4-186 and SM547 pEK48/phoA, respectively. Bovine ALP was used as a control. 
ALP specific activity was normalised by protein amount determined by Dc protein assay. 
** p < 0.01 indicates statistically significant differences between the wild-type ALP with 
the bovine ALP. *** p < 0.001 indicates statistically significant differences between the 
mutant ALP with the other two groups. 
 
*** 
**  
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3.3.5 Effect of NaCl on ALP specific activity 
ALP specific activity can be affected by many factors, such as pH, temperature, salt and 
lyophilisation. The effect of the two most relevant factors in this study, salt 
concentration and lyophilisation, on ALP specific activity were determined in this 
Section and Section 3.3.6. Because NaCl was used in the elution buffer to exchange E. 
coli ALP from the column, the influence of NaCl concentration on ALP activity was 
important to explore. Bovine ALP was used as a model ALP in this measurement. Figure 
45A shows the bovine ALP activity in different concentrations of NaCl solution. The 
activity dropped sharply when the NaCl concentration increased from 0 to 0.025 M. A 
deceasing rate of ALP activity was observed in higher concentration of NaCl. An elution 
buffer containing 0.2 M NaCl was used in the ÄKTA explorer purification system, so that 
the eluted E. coli ALP was exposed to a maximum of 0.2 M NaCl. The NaCl 
concentration may further increase due to lyophilisation.  
 
Figure 45B compares the ALP activity of the freeze-dried mutant and wild-type ALP 
before and after dialysis. The activities of mutant ALPs were significantly increased 
after dialysis (p < 0.001). A small increase of ALP specific activity was also observed in 
the wild-type ALP although the increase was not significant. The result indicates that 
dialysis effectively recovers the ALP specific activity of E. coli ALP produced and purified 
from bacterial cells, especially for the mutant E. coli ALP. In order to avoid the reduction 
of activity, a dialysis was necessary to remove the NaCl in the solution. 
136 
 
 
 
Figure 45. Effect of NaCl on ALP specific activity. (A) 0.125 mg/ml bovine ALP in 0 M, 
0.025M, 0.05 M, 0.125 M, 0.25 M, 0.625 M, 1.25 M, and 2.5 M NaCl solution were 
prepared and the ALP specific activity was measured. (B) Freeze-dried mutant and 
wild-type ALP from SM547 pEK48/4-186 and SM547 pEK48/phoA before and after 
dialysis were compared. *** p < 0.001 indicates statistically significant differences 
between the mutant ALP after dialysis with the other groups. 
A 
B 
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3.3.6 Effect of lyophilisation on ALP specific activity 
Figure 46 compares the ALP specific activity of mutant and wild-type ALP before and 
after lyophilisation. Lyophilisation was used to concentrate the E. coli ALP from the 
elution buffer to increase the protein stability, and to maintain the protein for the long 
term [315]. However, protein activity may be decreased or lost during lyophilisation. 
Protein stabilisers such as sucrose, NaCl, and proline can be necessary when freeze-
drying the sample. NaCl, which stabilises proteins through the salting-in effect [316], 
was in the elution buffer and was chosen as the protein stabiliser. The wild-type ALP 
showed a drop in activity after lyophilisation. The mutant ALP, however, even in the 
presence of NaCl, had significantly decreased activity after lyophilisation (p < 0.001). 
The possible reason was the acute freezing and drying stresses of lyophilisation 
damaging the protein [317]. When the protein is rehydrated, denaturation and 
aggregation of mutations may affect their high activity [318]. In order to avoid the 
activity reduction, the protein was divided into aliquots and kept at -80°C. 
 
Figure 46. Effect of lyophilisation on desalted mutant and wild-type ALP from SM547 
pEK48/4-186 and SM547 pEK48/phoA before and after freeze-drying was compared. 
ALP specific activity was normalised by protein amount determined by Dc protein assay. 
*** p < 0.001 indicates statistically significant differences between the mutant ALP and 
*** 
138 
 
the other groups. 
 
3.3.7 Strategies to improve the expression of E. coli ALP  
In order to improve the E. coli ALP expression, two strategies were carried out: IPTG 
induction; and by using different host cells. The first approach is based on the structure 
of plasmid pEK48 that contains an IPTG inducible lac promoter derived from plasmid 
pUC119. Figure 47 shows the SDS-PAGE analysis of cell lysates after 3 hours IPTG 
induction. SM547 expressed multiple proteins, and most of them were under 35 kDa. 
Insignificant differences were found between the lanes (land 2 and 3; lane 4 and 5) 
with or without IPTG induction for both wild-type and mutant E .coli ALP. This result 
was in line with the fact that no induction of recombinant protein was described in 
previous studies of plasmid pEK48. This may due to the loose-controlling expression 
system and the weak promoter in the plasmid SM547. Although pUC119 contains 
essential function of protein expression, it was designed as a cloning vector for 
producing a high copy number of plasmids. Therefore the protein expression system 
in pEK48 that derived from pUC119 is not the best choice for the expression of protein 
at a high level.  
 
 
Figure 47. SDS-PAGE (8% w/v) gel electrophoresis analysis of cell lysates of SM547 
pEK48/4-186 and SM547 pEK48/phoA after 3 hours IPTG induction. 1 mM IPTG was 
added when the absorbance at 600 nm of the culture medium reached 0.8. Lane 1, 
ladder; lane 2 and 3, cell lysates of SM547 pEK48/phoA without and with IPTG 
induction, respectively; lane 4 and 5, cell lysates of SM547 pEK48/4-186 without and 
with IPTG induction, respectively. The gel was stained by silver stain kit. 
 
The second approach to improve the E. coli ALP expression was carried out by 
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transforming the plasmid pEK48/phoA and pEK48/4-186 into different host cells. There 
are different expression systems available to produce recombinant proteins as 
described in Section 1.5.2.1. However, the E. coli expression system is the best choice 
in this study because of the target E. coli ALP protein. In addition to SM547, E. coli 
DH5α and BL21 were chosen because they are the most commonly used strains in 
genetic engineering. Table 14 lists the main features between these strains. DH5α is 
known for the high production ability of plasmid DNA due to the deletion of recA and 
endA gene [319]. It also has the ability to expresses recombinant protein from the 
plasmid [320]. In addition, there is a loss of function mutant of phoA gene in DH5α so 
that the strain lost its ability to express ALP from its chromosome. This feature ensures 
that all E. coli ALP expressed from DH5α is the recombinant protein encoded by the 
plasmids. E. coli BL21 is a classic host strain for expression of recombinant proteins 
[321]. It lacks the protease which cleaves proteins so that high level of protein 
production can be achieved. Although a normal phoA gene encoding ALP protein is 
contained in the strain, recombinant E. coli ALP encoded from the plasmids should be 
in the majority.  
 
Strain E. coli genotype of phoA gene Main application 
SM547 Deletion  For recombinant protein production 
DH5α A loss of function mutation  For plasmid DNA production 
BL21 Normal For recombinant protein production 
Table 14. Main features of E. coli stains used in genetic engineering to produce 
recombinant proteins. 
 
After transforming the plasmids pEK48/phoA and pEK48/4-186 into competent cells 
DH5α and BL21, the successful recombinants were screened on the LB Amp BCIP 
selective plate. Blue colonies were found on plates with DH5α and BL21 containing 
plasmid pEK48/phoA and pEK48/4-186 (Figure 48). However, blue colonies appeared 
after 48 hours of culture on the selective plate grown with DH5α strains, while the 
BL21 strains needed less than 24 hours. Single colonies on these plate were picked and 
cultured to isolate the plasmids. Agarose gel electrophoresis indicated the correct 
plasmids were successfully transformed into the host cells.  
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Figure 48. Image of LB Amp BCIP selective plates grown with BL21 pEK48/4-186 after 
24 hours incubation at 37°C. All colonies grown on the selective plate indicating they 
contain the correct pEK48/4-186 plasmids. The blue colonies indicate they are 
expressing active E. coli ALP.  
 
The biomass concentration of bacterial culture was determined by measuring the cell 
wet weight. Cell pellets from the SM547, DH5α and BL21 hosts containing pEK48/4-
186 were collected from 500 ml LB media and weighted after 12 hours incubation at 
37°C. Among the three host cells, BL21 shown the highest biomass concentration 
(5.7778 g/l of cell wet weight), followed by SM547 (2.77710 g/l of cell wet weight). 
DH5α had only 0.6070 g/l of cell wet weight. The results indicate that two recombinant 
protein production strains are superior for achieving high density fermentation than 
DH5α. 
 
A further study was performed to compare the protein content of purified E. coli ALP 
produced from SM547 and BL21. Figure 49A shows BL21 produced a higher protein 
content than SM547 in the peak fractions after the ÄKTA explorer purification system. 
The difference of wild-type ALP between SM547 and BL21 strains was significant (p < 
0.005). For the mutant protein, although a higher concentration was found in the BL21 
group, the difference was insignificant. The ALP specific activity from these four 
fractions was determined (Figure 49B). Wild-type ALP produced from BL21 strains 
showed a significantly higher ALP specific activity than the SM547 strain (p < 0.05), the 
same trend as the protein content. However, mutant ALP expressed from SM547 
showed a significantly higher ALP specific activity than the BL21 strain (p < 0.001). The 
results indicate that although a higher protein amount was produced from BL21, the 
protein was not as active as from SM547. It may be that the mixture of wild-type ALP 
produced by the BL21 strain combined with the mutant recombinant protein reduced 
the ALP activity. 
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Figure 49. Quantification of total protein amount (A) and ALP specific activity (B) of 
purified mutant and wild-type ALP from SM547 and BL21. * p < 0.05, ** p < 0.005 
indicate a statistically significant difference of the wild-type ALP between SM547 and 
BL21 strains. *** p < 0.001 indicate a significant difference of the mutant ALP between 
SM547 and BL21 strains. 
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3.4 Conclusion 
The wild-type and mutated recombinant E. coli ALP with improved biological activity 
were successfully produced by bacterial E. coli cells, and purified using the ÄKTA 
explorer purification system. The mutant ALP produced in this study showed nearly 25 
times higher activity compared to the wild-type ALP, and 9 times higher than bovine 
ALP. The improved biological activity makes the mutant E. coli ALP a promising 
candidate for bone tissue engineering applications. The activity of E. coli ALP could be 
affected by NaCl in the elution buffer and lyophilisation treatment. In order to avoid 
the activity reduction, a dialysis was necessary after the ÄKTA explorer purification 
analysis. To improve the protein yield, the plasmids pEK48 were transformed into 
different host cells. The results indicated that BL21 strain produced the highest protein 
amount and highest ALP activity of wild-type E. coli ALP. For mutant ALP, BL21 
produced a higher protein amount, but SM547 expressed the highest ALP activity. 
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CHAPTER 4  
Engineering of recombinant His-ALP with 
improved functionality for controlled 
biomolecule immobilisation 
4.1  Introduction 
Mutated E. coli ALP with improved biological activity was produced and purified from 
the E. coli recombinant protein expression system in Chapter 3. Although this mutant 
ALP showed outstanding high activity compared to the wild-type ALP and bovine ALP, 
some features warranted further improvement. First, despite the attempts to increase 
the expression of E. coli ALP by IPTG induction or by different bacterial host strains, the 
protein yield was still low compared to literature reports [322, 323]. A powerful 
recombinant protein expression system with a strong promoter was therefore desired. 
Second, the purification step is the bottleneck in the production system. A Q-
Sepharose Fast Flow anion exchange chromatography column was used in the ÄKTA 
explorer purification system to purify E. coli ALP. The procedure was time consuming 
and laborious. In addition, due to the non-specific ionic binding of the anion exchange 
chromatography column, all negatively charged protein including E. coli ALP can be 
purified from the column. This may reduce the purity of E. coli ALP. Therefore, a simple 
and specific purification method is needed. Third, the recombinant E. coli ALP may 
have limited activity once combined with a scaffold for bone tissue engineering 
applications. The active sites of E. coli ALP may be hidden during random 
immobilisation, which may negate the outstanding property of high activity. In order 
to overcome these drawbacks, this chapter explored a new approach of engineering 
His-tag recombinant E. coli ALP with multi-functionality for bone tissue engineering 
applications. 
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4.1.1 Engineering His-tag recombinant alkaline phosphatase  
As described in Section 1.5.3, His-tag fusion proteins are widely used in recombinant 
proteins for the superior properties. First, they exhibit an outstanding protein 
purification ability [225]. By using a Ni-NTA metal-affinity column, which has a strong 
and specific binding to the His-tag recombinant protein, E. coli ALP can be purified 
directly from bacterial lysates and eluted by imidazole from the column under mild 
conditions (Figure 13). In addition, the fusion protein can be detected by anti-His-tag 
antibodies in ELISA, western blotting or other analytical methods [230]. Most 
importantly, the (His)6 tail allows an orientation controlled and orderly immobilisation 
to expose the active site of fusion proteins [231, 233]. For example, the same bioactive 
factor is immobilised on Ti implants to make active coatings by adsorption (Figure 50A) 
and by His-tag chelation (Figure 50B), respectively. Due to the random immobilisation 
upon adsorption, the active sites of the protein may be covered by each other. In 
addition, only a few proteins can be immobilised because of the complex conformation. 
However, if a His-tag is added on the protein, the orientation of the His-tag fusion 
protein is fixed once immobilised on the implant. The active site of the protein can be 
adjusted to achieve the maximal exposure. Additionally, due to the (His)6 tail, which 
acts like a linker between the implant and the proteins, more proteins can be loaded 
on the surface of implants to reach a higher loading rate and immobilisation efficiency. 
The activity of site-directed immobilised His-tag ALP was about 1.3-fold higher than 
random immobilisation [233]. 
 
 
Figure 50. The immobilisation of active factors on Ti implants by (A) adsorption and (B) 
chelation. The active factors are shown in green, the active sites are shown in red, and 
His-tag is shown in blue, and orange dots represent the nickel (Ni) ions on the Ti 
implant.  
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In order to improve the recombinant protein yield produced from bacterial cells, a new 
expression system was employed in this study: the pET expression system. The pET 
expression system is the most powerful system developed so far for the cloning and 
massive production of recombinant protein from E. coli bacterial cells [324]. It is based 
on a T7 promoter-driven RNA polymerase expression system developed by Studier in 
the 1980s [325, 326]. As described in Figures 10 and 11, the target gene that is inserted 
into the cloning/expression region of a pET vector can be highly expressed in the 
presence of T7 RNA polymerase [212, 324].  
 
There are more than 40 pET vectors available with different features. They vary in 
promoters, leader signal sequences, fusion tags, and antibiotic resistance markers, but 
all of them are derived from pBR322 plasmid [327]. Two promoters are provided in the 
pET system, a T7 promoter, and a T7 lac promoter. The latter contains an additional lac 
operator sequence, which can block transcription, and a lacI gene, which codes for the 
lac repressor protein, compared to the former. They provide a more tightly controlled 
transcription to suppress the basal expression in host strains [327]. In this study, a pET 
vector containing a T7 lac promoter is preferred. Based on whether they contain a 
leader signal sequence or not, the pET vectors can be divided into two parts: the 
transcription vectors, which lack the translation signal sequence such as pET21, pET23, 
and pET24; and the translation vectors, which contain the leader translation signal 
sequence. In this study, since the target phoA gene contains its own bacterial 
translation signals, a transcription vector is needed. Regards to fusion tags, a His-tag is 
desired because of its purification and immobilisation advantages. A pET24 vector was 
chosen based on these requirements. The pET24 vector contains a T7 lac promoter, a 
C-terminal His-tag, an N-terminal T7-tag, a kanamycin resistance cassette, a pBR322 
origin, and a colE1 origin (Figure 51) [327]. The T7-tag (11 amino acids) is a functional 
fusion tag for protein detection and purification. 
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Figure 51. Expression vector pET24 map and its cloning/expression region [327]. The 
blue arrow shows the cloning/expression region. It contains a T7 promoter, a lac 
operator, a ribosomal binding site (rbs), the multiple cloning sites, a T7-tag and a His-
tag. 
 
The T7 promoter-driven RNA polymerase expression system requires the presence of 
T7 RNA polymerase in the cell to start transcription. Therefore pET vectors need to be 
transformed into a λDE3 lysogen host strain, such as BL21(DE3), in which the host 
chromosome contains a T7 RNA polymerase gene. The expression of the T7 RNA 
polymerase gene is controlled by the bacterial lacUV5 promoter. This system allows a 
low level of transcription in the non-induced condition [327]. In this study, a general 
purpose expression host E. coli strain BL21(DE3) was used for recombinant protein 
expression. 
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Table 15 summarises the major challenges met in the production and purification of 
recombinant E. coli ALP from pEK48 plasmids in bacterial cells and their possible 
reasons. In order to solve these problems, the mutant and wild-type phoA genes were 
recloned into a pET24 expression vector, which contains a His-tag, to produce the 
engineered recombinant His-tag E. coli ALP in the pET expression system. 
 
Problem Possible reason Solution 
Low protein yield  Weak expression 
system 
pET expression system 
Difficult to purify Unspecific binding His-tag chelation binding 
Limitations in 
immobilisation  
Random 
immobilisation 
Orientation controlled 
immobilisation by His-tag 
Table 15. Main problems, possible reasons, and solutions in the production and 
purification of recombinant E. coli ALP in bacterial cells. 
 
4.1.2 Scope of the chapter 
This chapter demonstrates the development of a multi-functional recombinant His-tag 
ALP for bone tissue engineering. In addition to the high biological activity possessed 
by the mutant E. coli ALP, the His-tag ALP has the ability to control immobilisation on 
supporting materials such as a Ti implant. Therefore biomaterials incorporating the 
His-tag ALP benefit from enhanced biological activity. In this chapter, methods of 
recombinant His-tag ALP production and purification are described. 
 
4.1.3 Hypotheses 
The hypotheses tested was that recombinant E. coli His-tag ALP may improve the 
protein expression, simplify the purification, and has the ability to control 
immobilisation on supporting materials. In order to test these hypotheses, the 
following aims have been addressed in this Chapter: 
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(1) Construct the recombinant pET24/phoA and pET24/4-186 plasmids. 
(2) Confirm the expression of recombinant His-tag ALP. 
(3) Purify the recombinant His-tag ALP from bacterial culture media. 
(4) Optimise the expression of His-tag ALP.  
(5) Determine the biological activity of His-tag ALP. 
 
4.2  Materials and methods 
4.2.1 Materials 
Unless stated otherwise, all chemicals and bacterial cell culture reagents were 
purchased from Sigma-Aldrich (Gillingham, UK). The reagents mentioned in Section 
3.2.1 were omitted. Restriction enzymes were purchased from Invitrogen and New 
England BioLabs. PCR SuperMix High Fidelity was purchased from Invitrogen. Wizard 
PCR kit was purchased from Promega. Rapid DNA Ligation Kit was purchased from 
Fermentas. T4 DNA ligase was from New England Biolabs. RapidTransit 
Transformation kit was from Sigma-Aldrich. Anti-His antibodies were from QIAGEN. 
ECL Anti-Rabbit IgG Horseradish Peroxidase-linked whole antibody (from donkey) was 
from GC Healthcare.  
 
Bacterial BL21(DE3) (F-, dcm, ompT, hsdS(rB- mB-), gal, λ(DE3)) competent cells were 
from Agilent Technologies, CA, USA. All other strains and plasmids pEK48/phoA and 
pEK48/4-186 were kindly provided by Professor A. E. G. Cass. 
 
4.2.2 Design of recombinant pET24/phoA and pET24/4-186 
In order to construct the recombinant pET24/phoA and pET24/4-186 plasmids, the 
target phoA and 4-186 genes were inserted into the pET24 vector. Briefly, two 
restriction cleavage enzymes, NdeI and HindIII, were chose to cut the vector and 
inserted the target gene according to the restriction map of pET24. Because NdeI and 
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HindIII only have one cleavage site in the vector and no cleavage site in the target gene, 
they ensure a unique combination of the vector and the entire target gene. In addition, 
the NdeI and HindIII digestion of pET24 vector can delete the T7-tag which is not 
needed in this study. Then the target gene was amplified by PCR with the primers 
containing either of the NdeI and HindIII sequence so that the target genes produced 
from PCR contain the NdeI and HindIII on each end. Finally, the vector and target gene 
after double digestion with NdeI and HindIII can be ligated into a new recombinant 
plasmid with the use of DNA ligase. 
 
In this study, four different target genes were determined for both wild-type and 
mutant E. coli ALP gene (Table 16). The four target genes were different in whether or 
not they contained a signal sequence, and whether they had a C-terminal or N-
terminal His-tag. The pET24 vector provides a C-terminal His-tag, while the N-terminal 
His-tag was achieved through PCR. 
 
Number Target gene 
1 NdeI + signal sequence + mature sequence of ALP gene + HindIII 
2 NdeI + mature sequence of ALP gene + HindIII 
3 NdeI + His-tag + signal sequence + mature sequence of ALP gene + STOP 
codon +HindIII 
4 NdeI + His-tag + mature sequence of ALP gene + STOP codon +HindIII 
Table 16. Different types of target genes designed in this study. 
 
4.2.3 DNA amplification by PCR 
As described in Figure 15, PCR is a rapid way to in vitro amplify (duplicate) specific DNA 
sequences. It is an important technology for research and diagnostic analysis of DNA 
and RNA [328]. The cycling process contains three steps: (1) denaturation of double-
stranded DNA into single strands, (2) annealing of primers for new strand synthesis, 
and (3) extension of primers to form new strands [234, 235]. Several components are 
essential for the PCR including a defined DNA segment as a template; two single-
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stranded sequence of nucleotide primers, which are complementary to DNA template; 
excess deoxynucleoside triphosphates (dNTPs); DNA polymerase, and a mixture of 
buffers. The method was invented for diagnosis of sickle cell anemia in whole genomic 
DNA by Kary Mullis in 1985, who was awarded the Nobel Prize in 1993 [329]. At that 
time, the procedure was completed manually, and fresh DNA polymerase was added 
after each cycle [330]. Later an automatic DNA Thermal Cycler was invented after the 
discovery of the thermostable DNA polymerase, Thermus aquaticus (Taq) [331, 332]. 
 
In this study, a PCR SuperMix High Fidelity kit was used to amplify target DNA. This 
reagent contains Mg2+, dNTPs, and a mixture of recombinant Taq DNA polymerase and 
DNA polymerase from Pyrococus species GB-D, and offers a 6-fold improvement in 
fidelity over Taq DNA Polymerase [333]. 45 μl PCR SuperMix High Fidelity was 
incubated on ice with 1 μl 10 μM forward primer, 1 μl 10 μM reverse primer, and 0.5 
μl (approximately 12 ng) template DNA. The reaction was heated at 94°C for 30 
seconds, followed by 30 cycles of 94°C for 30 seconds, 56°C for 30 seconds, and 72°C 
for 2 min. The reaction products was stored at 4°C until the next step. A touch-down 
PCR program (Figure 52) was used to overcome amplification of non-specific products, 
and to increase the reaction’s specificity, sensitivity, and yield [334]. The ideal 
annealing temperature, which is an important parameter in PCR, was determine using 
a gradient decreasing temperature method during the cycling process for the 
annealing step [335].  
 
94°C    5 min 
94°C    30 sec 
66°C    1 min, -0.5°C per cycle         30 cycle 
72°C    2 min 
94°C    30 sec 
56°C    1 min                      30 cycle 
72°C    2 min 
72°C    10 min 
4°C     ∞ 
Figure 52. The touch-down PCR programme.  
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4.2.4 Restriction enzyme digestion 
The second step of the production process of recombinant proteins is to cleave the 
target gene and the vector (Section 1.5.1). This step need to be accomplished with the 
help of restriction enzymes. Restriction enzymes function by cutting double stranded 
DNA at specific target sequences to produce either sticky ends or blunt ends [193]. The 
choice of restriction enzymes were based on the specific features of the vector and 
the target gene. First, it was necessary to identify the restriction enzymes available on 
the vector by checking the restriction map. Those restriction enzymes that only have 
a single restriction site on the vector were chosen. Secondly, the gene sequences of 
these single-site restriction enzymes were verified, to ensure they are outside the 
target gene. Finally, two different restriction enzymes were chosen for both ends so 
that they do not self-ligated [336]. A sticky-end restriction enzyme is preferred due to 
the higher ligation rate. Ideally, the two enzymes function well in the same digestion 
conditions to permit a double digestion. 
 
Most of the restriction enzyme digestions in this study were carried out in a buffer 
containing 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, and 1 mM DTT with a 10 fold 
excess of enzyme and incubation for 2 hours at 37°C. 
 
4.2.5 Low melt agarose gel electrophoresis and DNA 
purification 
Low melt agarose gel electrophoresis was used to purify the DNA fragments after 
double digestion. The principle and procedure of low melt agarose gel electrophoresis 
is exactly the same as agarose gel electrophoresis described in Section 3.2.4. The main 
difference is this agarose has a low melting (65.5°C) and gelling temperatures (25°C) 
compared with standard agarose (80°C and 32°C, respectively) [337]. The low melting 
temperature is below the melting point of most nucleic acids so that DNA fragments 
can be recovered from the gel without denaturing.  
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In this study, 1% (w/v) low melt agarose gel was made with a TBE running buffer (see 
Appendices) containing SYBR Safe DNA gel stain. Samples were mixed with 6X sample 
loading buffer before loading on the gel. The agarose gel electrophoresis was 
performed in a gel box (Bio-Rad, USA) on ice at 100 V for 1.5 hours. The gels were 
visualized using a BioSpectrum 500 fluorescence reader from UVP (CA, USA). The 
target bands were cut and kept in buffer at 4°C. 
 
A Wizard SV Gel and PCR Clean-Up System was used to purify DNA fragments from the 
low melt agarose bands. The procedure is based on the ability of DNA to bind to silica 
membranes in the presence of chaotropic salts [338]. The target bands containing DNA 
fragments of interest were first vortexed and incubated with a membrane binding 
buffer at 65°C until the gel was completely dissolved. Then the gel mixture was 
transferred into a column containing the silica membrane, and incubated at ambient 
temperature for 1 min. Next, the column was centrifuged at 12000 rpm for 1 min at 
4°C to bind the target DNA fragment to the silica membrane of the column. The 
column was washed twice with washing buffers to improve the purity of the plasmid 
DNA. Finally, the DNA fragment was eluted in a clean Eppendorf in 25-50 μl nuclease-
free water, depending on the concentration. The concentration of DNA fragment was 
assessed on a NanoDrop 2000c (Thermo Scientific, USA). The DNA fragment purified 
from low melt agarose gel can be directly used for ligation. 
 
4.2.6 Ligation and transformation 
As described in Section 1.5.1, the target DNA fragment need to be inserted into the 
desired vector to construct a new recombinant DNA plasmid [339]. Both hydrogen 
bonds and covalent bonds of the target DNA and the vector need to be sealed to form 
a stable plasmid. The former can be achieved by the complementary sticky ends 
produced by the restriction enzymes. The latter need to be sealed by an enzyme DNA 
ligase during ligation.  
 
In this study, two ligation reagents were used: a rapid DNA ligation kit from Fermentas, 
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and the T4 DNA ligase from New England Biolabs. By using the rapid DNA ligation kit, 
DNA ligation can be accomplished in only 5 minutes at ambient temperature [340]. 
The vector and target DNA fragment after double digestion were completely mixed 
(insert/vector molar ratio is 3:1) with T4 DNA ligase and buffer, and incubated at 
ambient temperature for 5 min. Then the ligation mixture was ready for 
transformation. By using the second T4 DNA ligase, the vector and target DNA 
fragment after double digestion were still completely mixed with T4 DNA ligase and 
buffer, however, a 1:1 insert/vector molar ratio was required, and the incubation was 
carried out at 16°C overnight. 
 
Once the ligation was accomplished, the next step in cloning was to transform the 
newly formed plasmid into host cells for replication. The same transformation method 
was used as described in Section 3.2.7. pET24 recombinant plasmids containing wild-
type and mutant alkaline phosphatase genes were transformed into DH5α and 
BL21(DE3) competent cells. 
 
4.2.7 Verifying the recombinant plasmids 
The transformed cells were streaked on a selectable plate to screen trasformants. In 
this study, the LB Kan BCIP IPTG selective plate was used. Similar to the process of 
screening E. coli pEK48 recombinants, blue colonies developed on the selective plate 
to indicate the expression of the His-tag ALP from pET24 recombinants. Single blue 
colonies on the plates were picked and suspended in 4 ml of LB media containing 30 
μg/ml kanamycin. The cells were cultured in an incubator at 37°C, 200 rpm overnight. 
The plasmid DNA in BL21(DE3) cells was extracted using a QIAprep Spin Miniprep Kit 
described in Section 3.2.3. In order to verify the size of pET24 recombinant plasmids, 
the purified plasmids were analysed by restriction digestion and agarose gel 
electrophoresis.  
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4.2.8 Expression of the His-tag E. coli ALP in BL21(DE3)  
A vial of frozen bacterial cells was thawed and plated on LB media plates (see 
Appendices) containing 30 μg/ml kanamycin, 40 μg/ml BICP, and 0.5 mM IPTG. Single 
blue colonies on the plates carrying the wild-type or mutant His-tag alkaline 
phosphatase genes were picked and suspended in 4 ml of LB media containing 30 
μg/ml kanamycin. The cells were cultured in an incubator at 37°C, 200 rpm overnight. 
1 ml of overnight culture medium was sterilely transferred into 100 ml of LB broth 
containing 30 μg/ml kanamycin to incubate at 37°C with continuous shaking until the 
absorbance at 600 nm of the culture medium reached 0.5-1.0. The inducer IPTG was 
added to a final concentration of 0.2 mM to 1 mM, and incubated either at 30°C or 
37°C for another 0.5 hour or up to overnight. 
 
4.2.9 Purification of the His-tag E. coli ALP in BL21(DE3) 
The cells were harvested by centrifugation at 6500 rpm for 15 min. The cell pellet was 
washed twice with cold 0.01 M Tris-0.03 M NaCl washing buffer, resuspended in 0.033 
M Tris suspension buffer, and disrupted by sonication. Sonication was performed three 
times for 30 seconds with 1 min intervals for cooling on ice. The sonicated extract was 
either incubated at 65°C for 30 min and then centrifuged, or directly centrifuged at 
12000 rpm for 20 min at 4°C. Similar to E. coli ALP, His-tag E. coli ALP was purified on 
the ÄKTA explorer purification system with a HiTrap Ni Sepharose High Performance 
chromatography column. The supernatant containing His-tag E. coli ALP was filtered 
through a 0.45 μm filter before purification on a GC Healthcare ÄKTA explorer using 
HiTrap Ni Sepharose High Performance column (GC Healthcare). Proteins bound on the 
column were eluted with a linear gradient of 0-500 mM imidazole in TMZP buffer. Pure 
His-tag E. coli ALP fractions were collected by detecting the absorbance at 280 nm, 
identified by electrophoresis, and characterised by biochemical assays as described in 
Chapter 3. A flow rate of 1 ml/min was used and fractions were collected in Eppendorf 
tubes. 
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4.3 Results and discussion 
4.3.1 Construction of pET24/phoA and pET24/4-186 
The E. coli mutant and wild-type ALP were poorly expressed in the SM547 pEK48 
expression system. In order to achieve a high-level protein expression, the pET 
expression system was employed, which is one of the most powerful recombinant 
protein expression systems in E. coli. Figure 53 shows the construction process of 
pET24/phoA plasmid, which is an example for all the other plasmids containing 
different target genes. The 1.68 kb DNA fragment containing the entire phoA gene with 
the signal sequence was amplified by PCR from pEK48/phoA by using a forward primer 
(GGAATTCCATATGAGATTATCGTCACTGCAATG, containing an underlined NdeI site) and 
a reverse primer (CCCAAGCTTTTTCAGAGCGGCTTTC, containing an underlined HindIII 
site). The pET24 plasmid was purified from DH5α. Both the vector and the DNA 
fragments were digested with NdeI and HindIII, and ligated to form the pET24/phoA 
plasmid.  
 
A 
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Figure 53. Construction process of plasmid pET24/phoA and the cloning/expression 
region of the pET24 vector. (A) Plasmids pEK48 and pET24 DNA were double digested 
with NdeI and HindIII, mixed, and ligated to form a new recombinant plasmid 
pET24/phoA, which contains the entire phoA gene with the signal sequence (1.68 kb) 
shown in green. A kanamycin resistance marker is shown in light blue, a colE1 origin is 
shown in orange, a lacI gene is shown in red, and a pBR322 origin is shown in purple. 
The dark blue arrow represents the cloning/expression region of pET24. (B) The gene 
sequence of the cloning/expression region. It contains a T7 promoter, a lac operator, a 
ribosomal binding site (rbs), the multiple cloning sites, a T7-tag and a His-tag. The 
sequence shown in the red box between NdeI and HindIII restrictive cleavage sites was 
replaced by the phoA gene in the pEK48 plasmid. 
 
Figure 54 shows the agarose gel electrophoresis results of PCR products. The DNA 
fragment containing the phoA and 4-186 gene, which encodes the wild-type and 
mutant E. coli ALP, was amplified from pEK48/phoA and pEK48/4-186, respectively.  
Each type of E. coli ALP has two different genes with (1.68 kb) and without (1.34 kb) 
the signal sequence. All groups showed dark and thick signal bands at the desired 
position. The results indicate that the PCR amplification of target DNA fragments was 
successfully performed. The concentration of the DNA fragments after PCR was further 
determined on Nanodrop spectophotometer. The Nanodrop showed a yield of more 
than 200 ng/μl DNA in all groups. The results were in line with the agarose gel 
electrophoresis.   
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Figure 54. Agarose (1% w/v) gel electrophoresis of amplified target ALP genes after PCR 
from plasmids pEK48/4-186 and pEK48/phoA. Lane 1 is a 1 kb DNA ladder; lane 2 and 
3 are 2 μl and 4 μl wild-type phoA gene with the signal sequence (1.68 kb), respectively; 
lane 4 and 5 are 2 μl and 4 μl wild-type phoA gene without the signal sequence (1.34 
kb), respectively; lane 6 and 7 are 2 μl and 4 μl mutant 4-186 gene with the signal 
sequence (1.68b), respectively; and lane 8 and 9 are 2 μl and 4 μl mutant 4-186 gene 
without the signal sequence (1.34 kb), respectively. 
 
Figure 55 shows the agarose gel electrophoresis results of the pET24 vector. The 
bacterial stain DH5α containing plasmids pET24 was cultured in LB medium. The 
plasmids were isolated with a QIAprep Spin Miniprep Kit and verified by agarose gel 
electrophoresis. A single band of 5.3 kb was detected when the vector pET24 was 
digested with the restrictive enzymes NdeI or HindIII (Lane 3 and 4, respectively); only 
one sharp band (5.3 kb) was shown when the plasmids were double digested with NdeI 
and HindIII (Lane 5) because the other DNA fragment only have 70 bp, which is too 
small to show on the gel; a blurred band was shown when the undigested plasmids 
were loaded on the gel (Lane 2) due to their supercoiled structure. The results indicate 
the real size of the plasmid is consistent with the description, and demonstrate the 
digestion of the plasmids by restrictive enzymes is correct and efficient. 
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Figure 55. Agarose (1% w/v) gel electrophoresis of restriction enzymes digested 
plasmids pET24. Lane 1 is a 1 kb DNA ladder; lane 2, the undigested plasmid pET24; 
lane 3, the plasmid pET24 single digested with NdeI; lane 4, the plasmid pET24 single 
digested with HindIII; lane 5, the plasmid pET24 double digested with NdeI and HindIII. 
 
Figure 56 shows the low melt agarose gel electrophoresis results of the pET24 vector 
and target gene fragments after double digestion with NdeI and HindIII. A clear single 
band of 5.3 kb was shown when the vector pET24 was double digested with restrictive 
enzyme NdeI and HindIII (Lane 2); Lane 3-6 were the double digested PCR DNA 
fragments containing the phoA and 4-186 genes with and without the signal sequence. 
These double digested bands were cut and purified using a Wizard PCR kit, and 
prepared for ligation. 
 
 
Figure 56. Low melt agarose (1% w/v) gel electrophoresis of restriction enzymes double 
digested plasmids pET24 and target genes. Lane 1 is a 1 kb DNA ladder; lane 2, 10 μl 
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plasmid pET24 double digested with NdeI and HindIII; lane 3, wild-type phoA gene 
without the signal sequence double digested with NdeI and HindIII (1.34 kb); lane 4, 
wild-type phoA gene with the signal sequence double digested with NdeI and HindIII 
(1.68 kb); lane 5, mutant 4-186 gene without the signal sequence double digested with 
NdeI and HindIII (1.34 kb); lane 6, mutant 4-186 gene with the signal sequence double 
digested with NdeI and HindIII (1.68 kb). 
 
4.3.2 Confirmation of pET24/phoA and pET24/4-186 plasmids 
The ligation mixture containing the newly formed plasmids were transformed into the 
host cells for replication. The same transformation method was used as described in 
Section 3.2.7. pET24 recombinant plasmids containing wild-type and mutant alkaline 
phosphatase genes were transformed into DH5α and BL21(DE3) competent cells. 
 
As described in Section 1.5.2.2, during the molecular cloning, typically the target gene 
is first cloned into a cloning vector and then transferred to an expression vector [210] 
to ensure the accuracy of the cloned gene. A similar procedure is performed when 
transforming the recombinant plasmids into bacterial cells. The recombinant plasmids 
are transformed into bacterial host for cloning first to produce high copies of 
recombinant plasmids, then retransformed into a bacterial host for protein expression 
[215]. This strategy ensures the stability of the plasmids. In this study, DH5α was 
chosen as the cloning host. As described in Section 3.3.7, DH5α is a convenient host 
for cloning and maintaining recombinant plasmids due to the deletion of recA and 
endA gene [319], and high transformation efficiencies and good plasmid yields [324]. 
 
After transforming the plasmids pET24/phoA and pET24/4-186 into competent cells, 
the successful recombinants were screened on the LB Kan BCIP selective plate (Table 
17). More than 30 white colonies were grown on each plate, but no blue colonies were 
found on plates with DH5α containing plasmid pET24/phoA and pET24/4-186 after 48 
hours of culture. This may due to a very low level of background protein expression in 
the DH5α, which lacks the gene for T7 RNA polymerase in its chromosome to initiate 
protein expression.  
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Single white colonies on these plates were picked and cultured to isolate the plasmids. 
After restriction enzyme digestion, the plasmids in these colonies were verified by 
agarose gel electrophoresis. Figure 57 gives an example of some plasmids isolated 
from single colonies grown on the selective plates with DH5α containing recombinant 
plasmids pET24/wild-type phoA gene with and without the signal sequence. Two out 
of five successful recombinants were found in the pET24/wild-type phoA gene without 
the signal sequence group (Lane 3 and 5, 6.64 kb), while one out of five successful 
recombinants was found in the pET24/wild-type phoA gene without the signal 
sequence group (Lane 11, 6.98 kb). A signal band of 5.3 kb was found in Lane 2, 4, 6, 
8, 9, and 10.  
 
Strain vector/target gene Colony number 
DH5α pET24/ SS+ phoA 61 
DH5α pET24/ SS+ 4-186 67 
DH5α pET24/ phoA 35 
DH5α pET24/ 4-186 32 
DH5α pET24/His-tag + SS + phoA 59 
DH5α pET24/His-tag + SS + 4-186 53 
DH5α pET24/His-tag + phoA 38 
DH5α pET24/His-tag + 4-186 41 
DH5α pET24 70 
DH5α 3 
Table 17. Single colony numbers on the LB Kan BCIP selective plate with transformed 
cells after 48 hours of culture. SS represents signal sequence. 
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Figure 57. Agarose (1% w/v) gel electrophoresis of restriction-enzyme digested 
plasmids isolated from single colonies grown on the LB Kan BCIP selective plates. Lane 
1 is a 1 kb DNA ladder; lane 2-6, single digested with NdeI of 5 plasmids isolated from 
5 colonies on the plate with DH5α pET24/wild-type phoA gene without the signal 
sequence; lane 7-11, single digested with NdeI of 5 plasmids isolated from 5 colonies 
on the plate with DH5α pET24/wild-type phoA gene with the signal sequence.  
 
There are several possible reasons for this low recombinant rate. First, it could be 
insufficient digestion performed before ligation so that some of the pET24 plasmids 
were recombined without the insertion of the target ALP gene. 70 colonies were found 
on the pET24 plasmid control plate, where no colonies should grow if the digestion 
was complete. The blurred band shown on Lane 7 was further proofed that the 
digestion was not completely effective. Because only one band (5.3 kb) can be seen 
when the pET24 was double digested with NdeI and HindIII, with the other DNA 
fragment (70 bp) being too small to detect on the gel, the digestion results were 
difficult to determine by agarose gel electrophoresis. A possible solution was to use 
new enzymes that show more digestion ability and can perform well in the same 
digestion conditions during double digestion. The second possible reason to explain 
the low recombinant rate was due to the ligation enzyme and conditions. The ligation 
was carried out with the Rapid DNA Ligation Kit and finished after 5 min of incubation. 
Although the procedure strictly followed the protocol of the kit, the optimised 
conditions of ligation for pET24 vector and the target DNA fragments were not 
achieved. To solve this problem, a new T4 DNA ligase and buffer were purchased, and 
new ligation condition of overnight incubation at 16°C was carried out. Third, the 
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transformation efficiency of the competent cells was not high because some colonies 
without plasmids were found by the agarose gel analysis. DH5α competent cells used 
in this study were prepared by calcium chloride (CaCl2) treatment in the laboratory. In 
order to achieve a high transformation efficiency of the competent cells, BL21(DE3) 
competent cells were purchased. Finally, the kanamycin concentration (10 μg/ml) in 
the selective plate was not high enough to inhibit the growth of DH5α bacterial cells 
without the plasmid. In the following studies, 30 μg/ml kanamycin was used in the 
selective plates and LB Kan media. 
 
4.3.3 Verifying the recombinant E. coli His-tag ALP expression  
Successful recombinant plasmids containing the correct target ALP gene were isolated, 
and transformed again into the expression host BL21(DE3). The transformants were 
firstly screened by the LB Kan BCIP IPTG selective plate (Figure 58, Table 18). At the 
beginning, the LB Kan BCIP selective plates used for DH5α recombinants screening 
were used in this study. However, no blue colonies were found after 48 hours of culture 
even though the agarose gel electrophoresis analysis of the plasmids from white-
colonies showed a positive result. Considering the pET system is an IPTG inducible 
expression system, 0.5 mM IPTG was added into the agar plate to induce recombinant 
protein expression. Figure 58 shows the LB Kan BCIP IPTG plate with blue colonies of 
BL21(DE3) pET24/4-186 after culturing 24 hours in an incubator at 37°C. White 
colonies were found on the plate after 8 hours culture, after which they gradually 
turned blue. Within 24 hours of culture, the blue colour became darker with time. 
Similar to the process of screening E. coli pEK48 recombinants, blue colonies 
developed on the selective plate indicating the expression of His-tag ALP from pET24 
recombinants. 
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Figure 58. Image of LB Kan BCIP IPTG selective plates grew with BL21(DE3) pET24/4-
186 after 24 hours incubating at 37°C. All colonies grew on the selective plate indicate 
they contain the correct pET24/4-186 plasmids. The blue colonies indicating they are 
expressing active E. coli His-tag ALP. 
 
According to Table 18, fewer white colonies were found compared to Table 17. In 
addition, no colonies were grown in the control groups of BL21(DE3) pET24 and 
BL21(DE3). These indicate that the double digestion performed with the new enzymes 
was successful. The BL21(DE3) competent cells have higher transformation efficiency 
than DH5α. The higher kanamycin concentration of 30 μg/ml successfully inhibited the 
growth of non-plasmid bacterial cells. One important point was that all host cells with 
a non-signal sequence ALP gene in the plasmids were white-coloured colonies. That 
means that although the plasmids were successfully transformed in the protein 
expression hosts, no active ALP was expressed from the bacteria after 24 hours of 
culture. The result indicates that the signal sequence of phoA gene is essential for the 
expression of the protein. Therefore only the plasmids with the signal sequence were 
studied in the later research.  
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Strain vector/target gene Blue/white colony number 
BL21(DE3) pET24/ SS+ phoA 5/30+ 
BL21(DE3) pET24/ SS+ 4-186 3/30+ 
BL21(DE3) pET24/ phoA 0/20+ 
BL21(DE3) pET24/ 4-186 0/30+ 
BL21(DE3) pET24/His-tag + SS + phoA 2/20+ 
BL21(DE3) pET24/His-tag + SS + 4-186 2/20+ 
BL21(DE3) pET24/His-tag + phoA 0/20+ 
BL21(DE3) pET24/His-tag + 4-186 0/20+ 
BL21(DE3) pET24 0/0 
BL21(DE3) 0/0 
Table 18. Single colony numbers on the LB Kan BCIP IPTG selective plate with 
transformed cells after 48 hours of culture. SS represents signal sequence. 
 
Single blue colonies on these plate were picked and cultured to isolate the plasmids. 
After restriction enzyme digestion, the plasmids in these colonies were verified by 
agarose gel electrophoresis. Figure 59 gives an example of pET24/ SS+ phoA and 
pET24/ SS+ 4-186 plasmids isolated from single colonies grown on the selective plates 
with BL21(DE3). A clear single band of 6.98 kb was shown when the plasmids pET24/ 
SS+ phoA (Lane 2 and 4) and pET24/ SS+ 4-186 (Lane 6) were single digested with the 
restriction enzyme NdeI; two bands were shown when the plasmids pET24/ SS+ phoA 
(Lane 3 and 5) and pET24/ SS+ 4-186 (Lane 7) were double digested with the restriction 
enzymes NdeI and HindIII. The upper bands of 5.3 kb represent the pET24 vector gene, 
the lower bands of 1.68 kb were either the wild-type or the mutant ALP gene with the 
signal sequence. The agarose gel electrophoresis analysis indicates that all of blue 
colonies grown on the selective plates contain the correct recombinant plasmids. In 
order to further verify the accuracy of the recombinant plasmids, several rounds of 
DNA sequencing were performed by GATC Biotech Ltd. The wild-type and mutant ALP 
gene were exactly the same as shown in Section 3.3.1. The target gene was accurately 
inserted into the cloning/expression region in the pET24 vector as expected.  
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Figure 59. Agarose (1% w/v) gel electrophoresis of restriction enzyme-digested 
plasmids which were isolated from single colonies grown on the LB Kan BCIP IPTG 
selective plates. Lane 1 is a 1 kb DNA ladder; plasmid isolated from a blue colony 
containing the pET24/phoA gene with signal sequence either single digested with 
HindIII (lane 2), or double digested with NdeI and HindIII (lane 3); plasmid isolated from 
another blue colony containing the pET24/phoA gene with signal sequence either 
single digested with HindIII (lane 4), or double digested with NdeI and HindIII (lane 5); 
plasmid isolated from a blue colony containing the pET24/4-186 gene with signal 
sequence either single digested with HindIII (lane 6), or double digested with NdeI and 
HindIII (lane 7). 
 
Cell lysates of BL21(DE3) pET24/phoA and BL21(DE3) pET24/4-186 with and without 5 
hours IPTG induction in LB Kan media were analysed by SDS-PAGE and western blotting 
(Figure 60). On the SDS-PAGE gel (Lane 1-5), each sample shows many bands, which is 
similar as SM547 pEK48. The E. coli His-tag ALP showed a band at 53 kDa. The result 
indicates that E. coli His-tag ALP is not the main protein produced in BL21(DE3) even 
after 5 hours induction by 1 mM IPTG. The difference between the mutant (Lane 2 and 
3) and wild-type (Lane 4 and 5) His-tag ALP produced from E. coli BL21(DE3) expression 
system was insignificant. However, for both types of the His-tag ALP, protein bands 
were visibly darker after IPTG induction (Lane 2 and 4) compare to the non-IPTG groups 
(Lane 3 and 5). This means the protein expression amounts in the IPTG induction 
groups were higher than the non-IPTG groups. However, when the SDS gel transferred 
to a nitrocellulose membrane and reacted with anti-alkaline phosphatase antibody, 
only one strong and clear band of E. coli His-tag ALP was observed in all groups (Lane 
6-9). The western blotting result confirmed the expression of E. coli His-tag ALP from 
BL21(DE3). Unlike the SDS-PAGE result, similar bands were shown in the western 
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blotting among 4 groups. No difference was found between the IPGT induction groups 
and non-IPTG groups. This may because of the improper induction conditions. More 
induction studies were carried out to optimise protein expression. 
 
 
Figure 60. SDS-PAGE (8% w/v) gel electrophoresis (lane 1-5) and western blotting (lane 
6-9) of cell lysates of BL21(DE3) pET24/4-186 and BL21(DE3) pET24/phoA with and 
without 5 hours 1 mM IPTG induction in LB Kan media at 37°C. Samples were 
electrophoresed in a SDS gel, then transferred to a nitrocellulose membrane and 
detected with an anti-alkaline phosphatase antibody. Lane 1, ladder; lane 2, cell lysates 
of BL21(DE3) pET24/4-186 after 5 hours IPTG induction on gel; lane 3, cell lysates of 
BL21(DE3) pET24/4-186 on gel; lane4, cell lysates of BL21(DE3) pET24/phoA after 5 
hours IPTG induction on gel; lane5, cell lysates of BL21(DE3) pET24/phoA on gel; lane 
6, western blotting analysis of cell lysates of BL21(DE3) pET24/4-186 after 5 hours IPTG 
induction; lane 7, western blotting analysis of cell lysates of BL21(DE3) pET24/4-186; 
lane 8, western blotting analysis of cell lysates of BL21(DE3) pET24/phoA after 5 hours 
IPTG induction; lane 9, western blotting analysis of cell lysates of BL21(DE3) 
pET24/phoA. SDS-PAGE gel was stained with Coomassie blue. 
 
4.3.4 Optimising the expression of His-tag E. coli ALP 
Protein expression from bacterial cells can be affected by many factors including the 
strength of the promoter, the stability of the vector in E. coli host, the properties of 
the foreign gene such as whether or not it contains rare codons, the location of the 
recombinant protein within the host cells, and the property of the recombinant 
protein such as location and the stability [341, 342]. In order to produce the wild-type 
and mutant His-tag ALP from the pET expression system in a soluble and active form, 
induction starting time, IPTG concentration, inducing time, glucose, and incubation 
temperature were optimised in this study. According to the pET System Manual, the 
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recommended protein expression conditions are: for pET24 plasmid system, 1 mM 
IPTG is added to the culture media when the absorbance at 600 nm (OD600) of the 
culture medium reaches 0.6, followed by incubation at 37°C for another 3 hours before 
collecting the cell pellet [324]. Figure 61 shows SDS-PAGE gel electrophoresis result of 
the cell lysates of four different BL21(DE3) recombinants in this study with (Lane 9-15) 
and without (Lane 2-8) IPTG induction in LB Kan media under the recommended 
conditions. No difference was found among the groups with and without IPTG 
induction. Similar to Figure 60, many bands were shown on the gel, however, the His-
tag ALP was not the main protein expressed by the host bacterial cells. The results 
indicate that the induction of the recombinant protein from the pET expression system 
under the recommended conditions was not successful. This may because of the 3 
hours of induction time was too short for His-tag ALP expression, or the other 
induction conditions were not optimal.  
 
 
Figure 61. SDS-PAGE (8% w/v) gel electrophoresis of cell lysates of BL21(DE3) pET24/4-
186 and BL21(DE3) pET24/phoA with (Lane 9-15) and without (Lane 2-8) 3 hours 1 mM 
IPTG induction in LB Kan media at 37°C. Lane 1, ladder; lane 2, 3, 9, and 10, cell lysates 
of BL21(DE3) pET24/phoA with signal sequence; lane 4, 5, 11, and 12, cell lysates of 
BL21(DE3) pET24/4-186 with signal sequence; lane 6, 7, 13, and 14, cell lysates of 
BL21(DE3) pET24/ His-tag phoA with signal sequence; lane 8 and 15, cell lysates of 
BL21(DE3) pET24/ His-tag 4-186 with signal sequence. SDS-PAGE gel was stained with 
Coomassie blue. 
 
The bacterial cell growth curve was measured after both 30°C and 37°C incubation to 
determine the best induction starting time (Figure 62). The reason to lower the 
incubation temperature was to slow down the speed of protein expression so that the 
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protein can be folded correctly and produced in the soluble, active form. The best 
induction starting time should be in the exponential phase of growth [343, 344]. If the 
inducer is added too early in the culture medium, it may affect the growth of cells; but 
if too late, the protein expression cannot be induced anymore.  
 
 
Figure 62. The growth curve of BL21(DE3) bacterial cells containing pET24 recombinant 
plasmids incubated in LB Kan media at 30°C and 37°C. 
 
According to Figure 62, a higher temperature of 37°C promotes more cell growth 
compared to 30°C. When the BL21(DE3) cells were incubated at 37°C, the OD600 
increased quickly in the first 4 hours. The exponential phase started when OD600 
reached 1.1, and finished when the OD600 reached 2.8. After that, the cell growth 
became slower and entered the stationary phase. For the cells grown at 30°C, a lag 
phase of 2 hours was observed. The exponential phase began when the OD600 reached 
0.7, and finished when the OD600 reached 3.0, which was similar to the cells incubated 
at 37°C. The growth curve result indicates that the recommend induction starting time 
of OD600 0.6 is not suitable for the BL21(DE3) bacterial cells containing pET24 
recombinant plasmids. In the following studies, the IPTG was added when the 
absorbance at 600 nm of the culture medium reached 1.0. 
169 
 
A time course induction study was carried out to determine the best inducing time 
[345]. 0.05% glucose was added into the culture media to reduce the non-induction 
protein expression. Figure 63A shows the OD600 of BL21(DE3) pET24/His-tag 4-185 with 
the signal sequence incubated at 30°C in LB Kan medium after IPTG induction. Figure 
63B shows SDS-PAGE gel electrophoresis of the cell lysates of BL21(DE3) pET24/His-
tag 4-185 with the signal sequence after 0.5 hours to overnight induction by 1 mM 
IPTG.  
 
 
 
Figure 63. The time course induction study of BL21(DE3) pET24/His-tag 4-185 with the 
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signal sequence incubated at 30°C in LB Kan medium after 1 mM IPTG induction. (A) 
The absorbance at 600 nm of the culture medium changes with incubation time. The 
blue arrow indicates the induction starting time. (B) SDS-PAGE (8% w/v) of cell lysates 
of samples during the time course of induction. Lane 1, 0.5 hours after induction; lane 
2, 1.5 hours after induction; lane 3, 2.5 hours after induction; lane 4, 3.5 hours after 
induction; lane 5, 4.5 hours after induction; lane 6, overnight induction; lane 7, 4.5 
hours without induction; lane 8, overnight culture without induction; lane 9, ladder. 
The gel was stained by silver stain kit. 
 
The results of the time course induction study indicate that the BL21(DE3) cells with 
the pET24 recombinant plasmids show a similar growth curve with and without IPTG 
induction. After 4.5 hours of induction, the His-tag ALP started to accumulate when 
the cell entered into the stationary phase. A higher level of protein expression of the 
His-tag ALP was achieved after overnight incubation at 30°C in LB Kan medium 
compare to a shorter incubation time and non-incubation groups.  
 
4.3.5 ÄKTA explorer purification of E. coli His-tag ALP 
Similar to E. coli ALP, His-tag E. coli ALP was purified on the ÄKTA explorer purification 
system with a HiTrap Ni Sepharose High Performance chromatography column. 
However, fewer purification steps were needed because of the strong and specific 
binding between the His-tag and the column. Figure 64 shows one example of ÄKTA 
explorer purification analysis of E. coli His-tag ALP expressed from BL21(DE3) pET24/4-
186. Similar to Figure 41, temperature, pH, conductivity, and UV280 were shown on the 
figure. The OD280 detector shown that exclusive proteins were washed off from the 
column. However, only a small peak was detected in the linear gradient step, which 
should be the His-tag ALP. The corresponding fractions of pure His-tag E. coli ALP were 
collected and identified by electrophoresis and western blotting (Figure 65), and 
characterised by biochemical assays.  
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Figure 64. ÄKTA explorer purification analysis of E. coli His-tag ALP expressed from 
BL21(DE3) pET24/4-186. A peak was shown on the OD280 line (solid blue line) in the 
linear gradient step (shown in the red box).  
 
 
Figure 65. SDS-PAGE (8% w/v) gel electrophoresis (lane 2 and 3) and western blotting 
(lane 4 and 5) of purified E. coli His-tag ALP after ÄKTA explorer purification system. 
Samples were electrophoresed in an SDS gel, then transferred to a nitrocellulose 
membrane and reacted with anti-alkaline phosphatase antibody. Lane 1, ladder; lane 
2, E. coli His-tag ALP expressed from BL21(DE3) pET24/phoA; lane 3, E. coli His-tag ALP 
expressed from BL21(DE3) pET24/4-186; lane 4, western blotting analysis of E. coli His-
tag ALP expressed from BL21(DE3) pET24/phoA; lane 5, western blotting analysis of E. 
coli His-tag ALP expressed from BL21(DE3) pET24/4-186. SDS-PAGE gel was stained 
with Coomassie blue. 
 
Because the BL21(DE3) cell pellet after induction was disrupted by sonication, massive 
cell proteins were released in the cell lysate. These non-His-tag fusion proteins were 
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washed away from the column and showed high protein peaks. Only the target His-tag 
ALP was bound on the HiTrap Ni Sepharose High Performance column and eluted by 
imidazole in the elution step. The peak of the target His-tag protein was significantly 
lower compared to the non-His-tag fusion proteins produced in the cells. These results 
were in accordance with the SDS-PAGE electrophoresis analysis. The His-tag ALP 
concentration in the target peak fraction was too low to show on the gel (under 10 
μg/ml) so that several batches of peak fractions were combined and loaded on the 
SDS-PAGE gel in Figure 65. The E. coli His-tag ALP showed a weak band at 53 kDa. The 
result indicates the purification was successful. The western blotting result confirmed 
the expression of E. coli His-tag ALP from BL21(DE3). 
 
The ALP activity was measured during the purification process. Figure 66 compares the 
ALP specific activity of both wild-type and mutant His-tag ALP before and after 
purification. All groups show ALP specific activities in the supernatant of cell lysates 
before purification. There is no significant difference between the wild-type and 
mutant His-tag ALP before or after IPTG induction. The results indicate that the 
outstanding high ALP specific activity of the mutant ALP is lost after engineering. 
Brunel and Cathala found that histidine inhibits the activity of mammalian ALPs [346]. 
56% of enzyme activity of brain ALP was inhibited by 5 mM histidine in the presence 
of Mg2+ [347]. Therefore the reduction of the activity may relate to the His-tag added 
on the protein. In addition, after the purification through ÄKTA explorer purification 
system, no ALP specific activity was found in the His-tag ALP fractions, neither in the 
flow-through nor other fractions. This means the His-tag ALP was either stuck in the 
column or denatured during the purification process. Imidazole in the elution buffer 
was reported to strongly inhibit the activity of mammalian ALP isolated from brain, 
kidney, liver, bone, lung and spleen, and slightly inhibit the placental and intestinal 
ALPs [346, 347]. 36% and 50% of the enzyme activities of ALP purified from rat uterine 
deciduomata and brain were inhibited by 5 mM imidazole, respectively [347, 348]. The 
mechanism of the inhibition may relate to the chelation of Mg2+ in the system [347]. 
Mg2+ is believed to play essential role to maintain the activity of ALPs. A mutant E. coli 
ALP containing a substitution of aspartic acid into histidine at the 153 position, which 
is an indirect ligand of the Mg2+, was shown to be remarkably similar to mammalian 
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ALP properties such as the activity depending on the presence of Mg2+ [349]. Due to 
similarity of the structures of the E. coli and the mammalian ALPs in the active site 
region [168], the activity of E. coli His-tag ALP produced in this study may be inhibited 
in the same manner as the mammalian ALPs.  
 
Figure 66. ALP specific activity of mutant and wild-type His-tag ALP before and after 
purification by the ÄKTA explorer purification system, and after dialysis against TMZP 
buffer (see Appendices) for 12 hours. Wt represents wild-type His-tag ALP; M 
represents mutant His-tag ALP; I represents 1mM IPTG inducer. 
 
4.3.6 Troubleshooting of E. coli His-tag ALP 
Table 19 summaries all troubleshooting and some attempts to construct and produce 
E. coli His-tag ALPs. Most of the solutions were described in the chapter. The heat pre-
treatment of the supernatant at either 65°C or 80°C for 30 min before column 
purification was attempted to improve the protein recovery rate.  
 
 
 
Before purification After purification After dialysis 
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Table 19. Main problems, possible reasons, and solutions in the construction, 
production and purification of recombinant E. coli His-tag ALP in bacterial cells. 
 
Problem Reason Solution 
Unknown products 
after PCR 
Improper PCR 
conditions 
Using a touch-down program 
instead of standard PCR 
Low PCR recovery 
rate from agarose gel 
Incomplete dissolution 
of the gel 
Low melt agarose gel 
Low ligation rate  Incomplete 
digestion 
 Improper ligation 
conditions 
 New restriction enzymes  
 New ligation enzyme and 
conditions 
Low transformation 
rate 
Low efficiency of 
competent cells 
Purchasing competent cells 
instead of laboratory-made 
Unexpected colonies 
on the control plates 
Low antibiotic 
concentration  
Increasing Kan from 10 μg/ml to 
30 μg/ml 
No blue colonies on 
the selective plates 
No recombinant 
protein expression 
Adding 0.5 mM IPTG to induce 
protein expression 
Low protein induction 
level after IPTG 
treatment 
Improper induction 
conditions 
 Optimising the IPTG 
concentration from 0.2 mM 
to 1 mM 
 Incubation temperature at 
30°C or 37°C  
 Optimising the induction 
starting time from OD600 0.6 
to 1.0 
 Inducing time from 0.5 hour 
to overnight 
Low purification 
recovery 
Massive unwanted 
bacterial proteins in the 
cell lysates 
Heating the supernatant at 
either 65°C or 80°C for 30 min 
before column purification 
175 
 
This purification pre-treatment is based on the fact that ALPs are thermostable 
enzymes which can maintain their biological activity at 50 °C for 60 min and retain 
more than 90% of their original activity for 120 min [350]. Thermus caldophilus GK24 
ALP was purified from E. coli after the heat treatment of 80°C for 30 min [323]. A 
hyperthermophilic alkaline phosphatase was purified from Thermotoga neapolitana 
by incubating at 100°C [351].  
 
4.4 Conclusion 
The wild-type and mutated recombinant E. coli His-tag ALP were successfully 
constructed with genetic cloning methods, produced through bacterial E. coli cells, and 
purified using ÄKTA explorer purification system to improve the yield, purification 
efficiency, and immobilsation properties. The induction conditions were optimised to 
enhance the protein expression. However, the mutated recombinant E. coli His-tag ALP 
lost its outstanding activity after the incorporation of a His-tag on either the N-terminal 
or C-terminal. In addition, the activities of both the wild-type and mutated 
recombinant E. coli His-tag ALP were inhibited by the imidazole in the elution buffer. 
Although the inhibitions were weaker after dialysis, the activities of the mutated 
recombinant E. coli His-tag ALP were still significantly lower than the mutated E. coli 
ALP described in Chapter 3. Without the high activity, the His-tag ALP is not worth 
studying further to combine with scaffolds for bone tissue engineering applications. 
That is why the protein induction conditions have not been completely optimised to 
achieve a mass production. Future studies may consider the mechanism of the effect 
of His-tag on E. coli ALP since the majority of the research was focused on the 
mammalian ALPs. The mutant E. coli ALP with other fusion tags such as T7 tag may be 
designed to improve the production, purification, and immobilisation, as well as to 
maintain the outstanding activity. 
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CHAPTER 5  
Engineered ALP with improved functionality 
for bone tissue engineering applications  
5.1 Introduction 
ALPs play an important role in bone mineralisation and enhance bone formation by 
increasing the local concentration of inorganic phosphate, while decreasing the 
concentration of extracellular pyrophosphate. The mutated E. coli ALP with 
outstanding biological activity produced from the E. coli recombinant protein 
expression system in this study is potentially a superior candidate for bone tissue 
engineering. In order to use the ALPs, two bone tissue engineering strategies, one 
being a Ti implant with recombinant E. coli ALP coating, and the other being an ALP 
encapsulated PCL nanofibrous composite (ALP/PCL) scaffold, are described in this 
chapter. The motivation to develop ALP coated implants and ALP/PCL scaffolds is to 
accelerate mineral deposition and enhance implant fixation with the surrounding 
tissue by using the catalytic ability of ALPs (Figure 67). This chapter demonstrates the 
main concepts and design principles of the combination of ALPs with supporting 
biomaterials for bone tissue engineering applications. 
 
 
Figure 67. Concept of the development of bioactive metal implants (A) and polymer 
scaffolds (B) with ALPs for bone tissue engineering applications. Bioactive enzyme ALPs 
A B 
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(green with red active site) are either immobilised by covalent binding on implant 
surfaces (A) or co-electrospun with polymers (B). Immobilised ALPs collaborate with 
bone cells (purple) to produce mineral deposits (orange) on implant surfaces or 
electrospun fibres.  
 
5.1.1 Bone substituting implants with ALP covalent coatings 
As described in Section 1.3 and 2.1, Ti implants with bioactive molecule coatings 
facilitate the attachment of proteins and cells, maintain the native conformation and 
biology activity of proteins, and induce a specific cellular response to promote bone 
formation. In this study, ALPs were chosen as the bioactive molecule. Ti implants with 
ALPs coatings increase the local concentration of inorganic phosphate and accelerate 
mineral deposition to enhance implant fixation with the surrounding tissue.  
 
A variety of immobilisation methods have been explored for binding ALPs onto Ti 
implants, such as adsorption, covalent binding, cross linking and chelation (Section 
1.6.2). Cross linking immobilisation methods may cause significant changes to the 
active site and affect the biological activity of ALPs, which go against the purpose of 
using the superior activity of mutant E. coli ALP in bone tissue engineering. Similar to 
cross linking, chelation, which needs the His-tag ALP, was demonstrated to reduce the 
activity of the mutant. Therefore, covalent binding was chosen to immobilise ALPs 
onto Ti implants. Covalent binding provides high surface loading [352], low protein 
leakage [353], and most importantly, a site-specific binding to control the orientation 
of the ALPs to cells [354]. Although a loss of protein activity was detected after 
covalent biding, the loss was dependent on the protein types [352] and reagents used 
during covalent binding [355]. For example, the enzyme ALP shows higher activity and 
enzyme loading in organic solvents such as toluene and acetone than aqueous solvents 
during silanisation; coupling chemistries glutaraldehyde and arylamine yield the 
highest active loading by using the aqueous silanisation method [353]. Several 
coupling techniques are available for attaching biomolecules to biomaterial surfaces, 
such as the use of silanes to modify the surface of Ti implants, and the deposition of 
thiols as self-assembled monolayers onto stable metals such as gold [354, 356]. In this 
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study, the Ti implant surface was first treated by silanisation to add amino groups to 
titanium oxide, and then covalently bound with ALPs (Figure 68).  
 
 
 
Figure 68. Schematic representation of immobilised ALPs on Ti implants by silanisation. 
Ti implant (grey) surface is modified by 3-aminopropyltriethoxylsilane (APS, blue) to 
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add amino groups. A coupling agent glutaraldehyde (pink) is used to attach the 
terminal amino groups of ALPs (green). 
 
There are several advantages of covalently binding ALPs to Ti implants with a silane 
complex [357]. First, this immobilisation method strengthens the cell adhesion in vitro 
[358]. Second, the activities of enzymes immobilised by this method were well-
preserved, such as the enzymes trypsin [359] and ALPs [356, 360]. Third, the silane 
complex acts as a spacer between the biomolecules and the supporting materials. The 
spacer provides a flexible environment and enhance cell growth [354, 361]. ALPs 
immobilised by physical adsorption were used as a control to compare the 
immobilisation results. 
 
5.1.2 Electrospinning PCL fibres with encapsulated ALPs 
In addition to immobilisation of enzymes on biomaterial surfaces by adsorption and 
covalent binding, encapsulation of enzymes in the supporting nanofibre matrix has 
increasingly gained interest. Nanofibre matrices, which mimic the native structure of 
the extracellular matrix, range in diameter from 50 to 500 nm [362] and have great 
potential in bone tissue engineering. Nanoscaled structure plays important roles in cell 
behaviour. For example, osteoblast adhesion was enhanced by nanoscaled surfaces 
[363, 364]; in addition to osteoblast adhesion, cell proliferation, alkaline phosphatase 
activity, and ECM secretion were increased with deceasing diameter of nanofibres 
[365-367]. Various techniques have been developed to fabricate nanofibres including 
drawing, template synthesis, self-assembly, phase separation, and electrospinning 
(Table 20, [368, 369]). Among them the electrospinning technique is the most popular 
method because of its superior properties such as being simple, efficient, and its ability 
to encapsulate biomolecules by co-electrospinning.  
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 Advantage  Disadvantages  Fibre 
diameter 
Drawing Easy operation Discontinues process 2-100 nm 
Template 
synthesis 
Repeatable and 
controllable 
Need templates or 
moulds 
100 nm 
Self-assembly Good for smaller 
nanofibres 
Complex process,  
time-consuming 
7-100 nm 
Phase separation Easy operation, 
controllable  
Limited polymers,  
time-consuming 
50-500 nm 
Electrospinning Cost effective, easy 
operation 
Jet instability 3-1000 nm 
Table 20. Main features of techniques to fabricate nanofibres. 
 
This enzyme immobilisation method has several advantages [98, 99, 370]: 1) rather 
than the complex chemical modification process of covalent binding, electrospinning 
provides a simple and straightforward way to encapsulate enzymes; 2) the enzyme 
loading in the matrix can be further increased compared to covalent binding (up to 50% 
of the fibres) [371]; 3) because of the adjustable nanofibre-porosity structure, a huge 
surface area can be easily achieved to maximise the protein and cell binding sites; 
nanostructure also decreases the mass transfer limitation and retains the catalytic 
activity of the enzymes; 4) more than one kind of biomolecule can be encapsulated 
simultaneously in the same nanofibres; 5) different from the Ti implants, 
biodegradable polymers such as poly(lactic acid) (PLA), poly(ethylene oxide) (PEO), and 
poly(ε-caprolactone)(PCL) are used to fabricate the scaffold matrix, which is more 
desirable than the non-degradable metal implants in bone tissue engineering 
applications [369, 370, 372].  
 
In this study, PCL is chosen as the active matrix material to encapsulate the enzyme 
ALPs. As described in Section 1.3.3, PCL is a FDA-approved candidate and has great 
potential for bone tissue engineering applications due to its superior properties, such 
as its stablility, affordabilty, biocompatibility, and biodegradability [373, 374]. PCL 
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nanofibres encapsulated with proteins by electrospinning has gained increasing 
attention as a promising approach to fabricate bone tissue engineering scaffolds [98, 
99, 370]. High protein loading and high biological activity from the protein/PCL scaffold 
have been achieved. In this study, bovine ALP as a model ALP was co-electrospun with 
PCL to fabricate a bioactive ALP/PCL scaffold for bone tissue engineering. 
 
5.1.3 Scope of chapter 
The objective of this chapter is to incorporate the biomolecules that have been studied 
in this thesis with different biomaterials to determine their functionality and biological 
efficiency. In this chapter, two applications of engineered ALP for bone tissue 
engineering are explored, including a Ti implant with recombinant ALP coating and an 
ALP/PCL scaffold. 
 
5.1.4 Hypotheses 
The hypotheses tested was that ALP can incorporate with different supporting 
materials, such as Ti implants and PCL scaffolds, and improve the functionality and 
biological efficiency in bone tissue engineering applications. In order to test these 
hypotheses, the following questions have been addressed: 
(1) How to prepare ALP coatings on Ti implants? 
(2) What is the biological activity of Ti implants with ALP coating? 
(3) What is the effect of ALP coating on soaking experiments? 
(4) How to prepare ALP/PCL scaffolds? 
(5) What is the biological activity of ALP/PCL scaffolds? 
(6) What is the effect of ALP/PCL scaffolds on soaking experiments? 
(7) What is the effect of ALP/PCL scaffolds on MC3T3-E1 pre-osteoblasts? 
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5.2 Materials and methods 
5.2.1 ALP coated on Ti implants using silanisation method  
5.2.1.1 Materials  
Unless stated otherwise, all chemicals including 3-aminopropyltriethoxylsilane (APS), 
acetone, glutaraldehyde, and bovine intestinal ALP were purchased from Sigma-
Aldrich (Gillingham, UK). E. coli mutant and wild-type ALP were produced and purified 
from E. coli bacterial cells in this studies. Phosphate-buffered saline (PBS) and other 
soaking media were purchased from Gibco/Life Technologies, (Paisley, UK). A number 
of commercially available Ti alloy (grade 5, Ti 6AL/4V) discs (dimension 10 mm, height 
3 mm) were purchased from Ti-Tek Ltd (Birmingham, UK) 
5.2.1.2 Substrate preparation  
In order to obtain a consistent and reproducible titanium oxide layer, Ti discs were first 
soaked in a 5.0 M NaOH solution at 60°C for 24 hours, and then rinsed with abundant 
distilled water. This step ensures all contaminants were removed from the Ti surfaces. 
In addition to the alkali oxidation treatment, a heat treatment of incubation Ti discs at 
800°C for 6 hours was used to form an oxide layer on the Ti surface. Then the cleaned 
discs with uniform oxide layers were silanised by the following the procedure: 1) place 
the discs in acetone containing 10% (w/v) APS (pH 7.0) at ambient temperature for 4 
hours; 2) dry the discs at 37°C for 2 hours; 3) immerse the discs in 1% (w/v) 
glutaraldehyde in PBS (pH 7.0) at ambient temperature for 4 hours; 4) wash the discs 
with abundant PBS to remove glutaraldehyde. 
 
The used Ti discs were cleaned by the following procedure: 1) the discs were soaked 
in 2% HCl solution in the ultrasonic bath for 15 min, and rinsed twice with distilled 
water; 2) the discs were soaked in acetone in the ultrasonic bath for 15 min, and rinsed 
twice with distilled water; 3) the discs were soaked in isopropenol in the ultrasonic 
bath for 15 min, and rinsed twice with distilled water. Repeat step one once if 
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necessary. 
 
5.2.1.3 ALP addition 
Bovine intestinal ALP was used as a model enzyme to optimise the immobilisation 
conditions. Once the best immobilisation conditions were achieved, E. coli mutant and 
wild-type ALP were immobilised onto the Ti implants. The process of fabricating ALP 
coatings on Ti implants by silanisation is shown in Figure 69. Three bovine ALP 
solutions with different concentrations were prepared (10 μg/ml, 100 μg/ml, and 1000 
μg/ml). After preparation, the Ti discs were placed in ALP solutions at 4°C on a shaker 
(50 rpm) overnight. The samples were rinsed 3 times with PBS, and transferred to a 
new 24-well plate for the ALP activity assay. 
 
 
Figure 69. Treatment process of ALP coating on Ti implant by silanisation. 
 
5.2.1.4 ALP specific activity measurement of ALP silane coating 
The ALP activity assay depends on the hydrolysis of ρNPP by the enzyme ALP to 
generate ρ-nitrophenol and inorganic phosphate. ρ-nitrophenol is converted to a 
yellow product under alkaline conditions and exhibits a high absorbance at 400-420 
nm. The Ti discs with immobilsed ALPs in 24-well plates were immersed in ρNPP buffer 
solution and incubated at 37°C. The reaction was stopped by adding 1 M NaOH. The 
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reaction time was recoded. Light absorbance of these samples was measured at 405 
nm on a 96-well plate reader. A standard curve was constructed using ρ-nitrophenol 
as a standard. Experiments were performed independently in triplicate, and the ALP 
activity of each sample was normalised to sample surface area and expressed as mean 
± standard deviation. 
 
5.2.1.5 Soaking experiment of ALP silane coating 
The biological activity of the Ti implants with immobilised ALPs was determined in vitro 
by soaking experiments. In vitro soaking experiments in simulated body fluid (SBF) are 
commonly used as a standard procedure to predict the in vivo bone bioactivity of the 
bioactive implants [375]. The amount of calcium phosphate (CaP) deposition produced 
under in vitro conditions after soaking experiments indicates the potential bone 
formation ability in vivo. However, SBF does not contain any organic phosphates, which 
are the substrate of ALPs in the human blood plasma [53]. In order to better mimic the 
in vivo tissue conditions and take the advantage of the immobilised ALP coatings on Ti 
implants, a modified cell culture medium containing 10 mM organic phosphate β-
glycerophosphate (β-GP) was used in the soaking experiments [53]. 
 
The discs with immobilsed ALPs were placed in cell culture medium (α-Minimum 
Essential Medium (α-MEM) supplemented with 10% (v/v) FBS, 50 μg/ml gentamycin, 
50 μg/ml ascorbic acid, 100 nM dexamethasone, and 10 mM β-GP), and incubated at 
37°C. Non-coated Ti discs served as controls. The cell culture media were changed 
every 2-3 days. After 3, 7 and 14 days, the samples were removed from cell culture 
media, washed thoroughly first with PBS, then with distilled water, and dried at 40°C 
for 5 hours, and stored at -80°C until the deposited calcium was measured.  
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5.2.1.6 Deposited calcium measurement of ALP coating after soaking 
experiments 
The deposited calcium on the Ti implants after soaking experiments was measured by 
a calcium assay using the o-cresolphthalein complexone (OCPC) procedure. This 
procedure is based on the reaction between the Ca2+ and the OCPC in an alkaline 
solution to form an intense violet coloured complex and show a strong absorbance at 
577 nm [376-378]. The Ti implants with ALP coatings after soaking experiments were 
immersed in 0.5 N acetic acid overnight at ambient temperature on a shaker (50 rpm). 
The calcium deposition should dissolve in the acid solution, and react with working 
buffer containing OCPC at ambient temperature for 10 min. Light absorbance of these 
samples was measured at 577 nm on a 96-well plate reader. A standard curve was 
constructed using CaCl2 as a standard. Experiments were performed independently in 
triplicate, and the calcium concentration of each sample was normalised to sample 
surface area and expressed as mean ± standard deviation. 
 
5.2.2 ALP/PCL scaffold prepared by electrospinning 
5.2.2.1 Materials 
Unless stated otherwise, all chemicals including PCL (Mw 80000), acetone, 
dimethylformamide (DMF), and bovine intestinal ALP were purchased from Sigma-
Aldrich (Gillingham, UK). Chloroform (99%) and Tris buffer were purchased from VWR 
(Poole, UK). All cell culture reagents, phosphate-buffered saline (PBS) and other 
soaking media were purchased from Gibco/Life Technologies, UK. 
 
5.2.2.2 Electrospinning 
Electrospinning is a polymer-processing technology known for more than 70 years to 
create fibres [367]. The principle of electrospinning is to use high voltage (10–20 kV) 
electrical charge to form solid fibres from liquid polymers [379]. The liquid polymers 
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are obtained either by melting the solid form, or dissolving in a solvent. Usually a two-
dimensional non-woven film is produced from electrospinning, however, three-
dimensional non-woven fibrous meshes can be obtained by increasing the processing 
time [367]. 
 
The setup of electrospinning is shown in Figure 70 [380]. There are mainly three parts: 
a syringe containing the liquid polymer, a high voltage supplier, and a cylinder collector 
covered with a grounded aluminum sheet. The nozzle of the syringe is connected to 
the high voltage supplier, and a high electric field is formed between the nozzle and 
the collector. A 10 cm distance between the nozzle and the collector was used in this 
study. This collector can move horizontally while rotating so that a homogenous film 
of nanofibres can be formed on the aluminum sheet. 
 
 
Figure 70. Schematic diagram to produce polymer nanofibres by electrospinning [380]. 
 
5.2.2.3 Preparation of ALP/PCL scaffolds 
In this study, the ALP/PCL scaffolds were prepared by the following procedure (Figure 
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71). 12% (w/v) PCL was dissolved in solvent solution consisting of DMF and chloroform 
(v:v=2:3). At the same time, an ALP solution was prepared by dispersing different 
amount of ALP (10, 20, and 30% (w/w)) in 2 ml ethanol. The two solutions were mixed 
in a sonication bath for 15 min before poured into the syringe. To break up any 
aggregation, ALP was passed through the needle several times to make sure the ALP 
was well-dispersed. A flow rate of 2 ml/hour, and a voltage of 18 kV was used to 
fabricate ALP/PCL nanofibres. The electrospun ALP/PCL scaffolds were stored at 4°C 
before being cut into small pieces (diameter 10 mm) for further studies. 
 
 
Figure 71. The precedence of producing the electrospun ALP/PCL scaffolds. 
 
5.2.2.4 ALP specific activity measurement of ALP/PCL scaffolds 
A similar method to measure the ALP coating activity on Ti implants was used to 
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determine the ALP specific activity of ALP/PCL electrospun scaffolds. In brief, the small 
pieces of ALP/PCL scaffolds were immersed in ρNPP buffer solution in 24-well plates 
and incubated at 37°C, and the reaction was stopped by adding 1 M NaOH. The 
reaction time was recorded. Light absorbance of these samples was measured at 405 
nm on a 96-well plate reader. A standard curve was constructed using ρ-nitrophenol 
as a standard. Experiments were performed independently in triplicate, and the ALP 
activity of each sample was normalised to the weight of nanofibres and expressed as 
mean ± standard deviation. 
 
5.2.2.5 Soaking experiment of ALP/PCL scaffolds 
In order to determine the potential bone formation ability of the ALP/PCL scaffolds in 
vivo, in vitro soaking experiments were performed. A similar procedure was used as 
described in Section 5.2.1.5. In brief, the ALP/PCL nanofibres were placed in cell culture 
medium (α-Minimum Essential Medium (α-MEM) supplemented with 10% (v/v) FBS, 
50 μg/ml gentamycin, 50 μg/ml ascorbic acid, 100 nM dexamethasone, and 10 mM β-
GP), and incubated at 37°C. The cell culture media were changed every 2-3 days. After 
1, 3, 7, 14, and 28 days, the samples were removed from cell culture media, washed 
thoroughly first with PBS, then with distilled water, and stored at -80°C until the 
deposited calcium was measured.  
 
5.2.2.6 Calcium assay of ALP/PCL scaffolds after soaking experiments 
A similar calcium assay of the measurement of deposited calcium on ALP coatings of 
Ti implants after soaking experiments was used to determine the calcium deposition 
amount on ALP/PCL electrospun scaffolds. In brief, the ALP/PCL nanofibres after 
soaking experiments were immersed in 0.5 N acetic acid overnight at ambient 
temperature on a shaker (50 rpm). Then the samples were reacted with working buffer 
containing OCPC at ambient temperature for 10 min. Light absorbance of these 
samples was measured at 577 nm on a 96-well plate reader. A standard curve was 
constructed using CaCl2 as a standard. Experiments were performed independently in 
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triplicate, and the calcium concentration of each sample was normalised to sample 
surface area and expressed as mean ± standard deviation. 
 
5.2.2.7 In vitro cell culture study of ALP/PCL scaffolds 
In vitro cell culture studies were carried out to determine the effect of the ALP/PCL 
nanofibre scaffolds on MC3T3-E1 cells. MC3T3-E1 cells, a mouse osteoblast cell line, 
were seeded on ALP/PCL pieces in 24 well plates in the growth medium (α-Minimum 
Essential Medium (α-MEM) supplemented with 10% (v/v) FBS, 50 μg/ml gentamycin, 
50 μg/ml ascorbic acid, 100 nM dexamethasone, and 10 mM β-GP), in humidified 5% 
CO2 at 37°C. The cell culture media were changed every 2-3 days. After 1, 3, 7, 14, and 
28 days, the samples were removed from cell culture media, washed thoroughly first 
with PBS, then with distilled water, and stored at -80°C until the ALP activity assay, and 
SEM were performed.  
 
ALP activity assay for cells and SEM were performed according to the procedures 
described in Section 2.2.2. 
 
5.3 Results and discussion 
5.3.1 ALP coated on Ti implants using silanisation method 
5.3.1.1 Surface analyses of Ti implants  
Ti surfaces are spontaneously covered by a 3-10 nm stable oxide layer when the 
implants are exposed to oxygen [53]. This layer is responsible for the biocompatibility 
of Ti implants [68]. In addition, the oxide is necessary for coupling to silanes as shown 
in Figure 65 [381]. However, this native formed oxide layer is irregular in thickness and 
composition, and may contain contaminants [356, 382]. In order to form a 
reproducible and clean implant surfaces, oxidation pre-treatments of Ti were carried 
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out. Various oxidation methods are available, such as electrochemical treatment, acid 
treatment, alkali treatment, and heat treatment. In this study, alkali treatment and 
heat treatment were chosen.  
 
Figure 72 shows the SEM analysis of Ti implants surfaces with and without oxidation 
treatments. Untreated Ti disc with a native oxide layer show a relatively smooth 
surface (Figure 72A). Some contaminants can be found on the surface as well. After 
heat treatment (Figure 72B) and alkali treatment (Figure 72C), the surface roughness 
is significantly increased. High surface roughness is a desired property for implants in 
bone tissue engineering because more microtexture on the implant surface offers 
increasing surface binding sites for bioactive proteins and cells, therefore enhancing 
bone formation [383-385]. Although both oxidation methods produce microtexture on 
the implant surfaces, different morphologies were formed. When the alkali pre-
treated Ti implants were modified with silanes, the microtexture on the implants was 
further increased as shown in Figure 72D. 
 
  
  
Figure 72. Scanning electron micrographs of (A) untreated Ti disc received from the 
manufacturer, (B) Ti disc after heat treatment at 800°C for 6 hours, (C) Ti disc after 
alkali treatment in 5.0 M NaOH solution at 60°C for 24 hours, and (D) Ti disc silanised 
A B 
C D 
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by 10% (w/v) APS and 1% (w/v) glutaraldehyde as described in Section 5.2.1.2. Scale 
bars represent 1 μm. 
 
5.3.1.2 Optimising the Ti implants with ALPs coatings 
In order to optimise the Ti preparation and immobilisation methods, the ALP activity 
of the ALPs coatings on Ti implants by different treatments was determined. Bovine 
ALP was used in this study. In Figure 73A, all Ti discs were pre-treated with 5.0 M NaOH 
solution at 60°C for 24 hours before immersing in different concentrations of bovine 
ALPs (10 μg/ml, 100 μg/ml, and 1000 μg/ml). Bovine ALP immobilised on alkali treated 
Ti discs by silanisation showed significantly higher ALP activity compared to the 
physically adsorbed ALP coatings. The results indicate that immobilisation of the 
enzyme ALP on Ti surface by covalent binding is a preferred method to adsorption. ALP 
activity of the coating increased with the concentration of bovine ALP solutions in 
which the silanised Ti discs immersed. The ALP coating immobilised from the 1000 
μg/ml ALP solution showed the highest ALP activity compared to less concentrated 
solutions. All Ti discs pre-treated by incubating at 800°C for 6 hours before immersing 
in different concentrations of bovine ALPs showed a similar trend to alkali treatment 
(Figure 73B), in that silanised ALP coatings display significantly increased ALP activity 
compare to the adsorbed ALP coating. In addition, the ALP activity of the coating 
increased with the concentration of the bovine ALP solutions in which the silanised Ti 
discs were immersed. Higher ALP activity was shown from the ALP coating, indicating 
that more ALP was immobilised on the Ti implants. The results indicated that silanised 
Ti discs immersed in 1000 μg/ml ALP solution have the highest enzyme loading. 
Therefore, 1000 μg/ml ALP solution was prepared for enzyme immobilisation in the 
following studies.  
 
There was no significant differences of ALP activity of ALP coatings on Ti implants 
between the two oxidation methods. The alkali treatment was chosen as the oxidation 
method for the later experiments because it was easier to perform.  
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Figure 73. ALP activity of Ti implants with bovine ALP coatings was measured using 
ρNPP as a substrate. (A), the Ti discs were oxidised by alkali treatment; (B) the Ti discs 
were oxidised by heat treatment. * p < 0.05, ** p < 0.01, *** p < 0.001 indicate 
statistically significant differences. 
 
** 
*** 
* 
*** 
** 
* 
A 
B 
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E. coli mutant and wild-type ALP were immobilised on Ti implants by the optimised 
conditions. In Figure 74, ALP activity of ALP coatings on Ti implants with different types 
of ALPs were compared. E. coli mutant ALP coating showed significantly higher ALP 
activity compared to the bovine ALP coating (p < 0.01) and wild-type ALP (p < 0.001). 
Assuming that same amount of ALPs were immobilised on the Ti discs, the mutant ALP 
shows more than 17 times higher activity then the wild-type ALP, which is in line with 
the results shown in Figure 44. However, despite the significant difference in ALP 
activity that was found between the E. coli mutant and the bovine ALP coating, the 
difference is not as big as the activity difference between the mutant ALP and the 
bovine ALP. This may due to the different amount of enzyme being loaded, since the 
structure and conformation of the mutant ALP and the bovine ALP are different. 
 
Figure 74. ALP activity of Ti implants with E. coli mutant and wild-type ALP coatings 
was measured using ρNPP as a substrate. Bovine ALP was used as a control. The Ti 
discs were oxidised by alkali treatment, and immersed in 1000 μg/ml ALP solution. ** 
p < 0.01, *** p < 0.001 indicate statistically significant differences between the 
respective group and the mutant ALP group. 
*** 
** 
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5.3.1.3 Effect of silanisation coating on mineralisation after soaking 
experiments 
Surface morphology of the ALP coatings on Ti implants after soaking experiments was 
determined by SEM on days 3 and 14 (Figure 75). Ti implants with different ALP 
coatings show a similar morphology. Figure 72 only shows the bovine ALP coatings on 
day 3 (A), and E. coli wild-type ALP on day 14 (B). Organic matrix depositions covered 
the coating after 3 days soaking in cell culture media. A few mineral depositions were 
observed, which had a Ca/P ratio of between 1.6 and 1.8 as determined by EDS. On 
day 14, the implants were fully covered by a deposition layer. Abundant spheres were 
found in all groups, including the uncoated Ti implants on both day 3 and day 14. No 
mineral components were detected from the spheres, which may come from the cell 
culture media. In the future soaking experiments, the cell culture media were filtered 
through a 0.22 μm filter before adding it to the substrates. 
 
  
Figure 75. Scanning electron micrographs of (A) bovine ALP coating on Ti implants after 
a 3 day soaking experiment, (B) wild-type ALP coating on Ti implants after a 14 day 
soaking experiment. Scale bars represent 1 μm. 
 
The amount of deposited calcium on the surface of Ti implants with ALP coatings after 
soaking experiments was measured by a calcium assay (Figure 76). The calcium 
content from three ALP coatings was increased with soaking time. The control group 
without any coatings showed the lowest calcium content at every time point. No 
significant difference in the calcium content was observed between the bovine ALP 
coating and the E.coli mutant ALP coating at each time point. The E.coli wild-type ALP 
coating produced a significant decrease in calcium content on day 7 and day 14 of 
A B 
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soaking, compared to the bovine ALP coating and mutant ALP coating. However, 
compared to uncoated Ti implants, significant increases of calcium content were 
detected from the wild-type ALP coating. The results indicate that Ti implants with ALP 
coatings improve calcium deposition after 7 days soaking in cell culture media. The E. 
coli wild-type ALP coating on Ti implants with lower biological activity shows limited 
mineral producing ability compared to the E. coli mutant ALP coating and bovine ALP 
coating. Although the E. coli mutant ALP coating displays significantly high ALP activity 
than the bovine ALP coating as shown in Figure 74, no significant difference between 
the two groups was observed for mineral deposition ability. The possible reason is due 
to a limited source of organic phosphate and calcium ions in the cell culture media. 
 
 
Figure 76. Calcium deposited on the surface of Ti implants with ALP coatings after 
soaking in cell culture media was measured by a calcium assay. * p < 0.05, *** p < 
0.001 indicate statistically significant differences between the respective groups and 
the wild-type ALP coatings. 
 
*** 
*** 
*** * 
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5.3.2 ALP/PCL scaffold prepared by electrospinning 
5.3.2.1 Surface analyses of ALP/PCL scaffolds 
The properties of electrospun nanofibres such as the fibre diameter, porosity, pore size, 
and mechanical properties are adjustable by changing the percentage of PCL, the 
solvent, and the electrospinning parameters. In this study, 12% (w/v) PCL was dissolved 
in DMF/chloroform, and electrospun with and without bovine ALP under 18 kV voltage. 
 
Figure 77 shows the SEM images of PCL electrospun nanofibres with and without 
bovine ALP. High porosity networks with uniformed nanofibres were fabricated from 
12% PCL. The fibre diameter of pure PCL nanfibres ranged from 100 to 500 nm, and 
the pore size ranged from 500 nm up to several micrometers (Figure 77A and B). When 
the ALP was co-electrospun with PCL (Figure 77C and D), a similar porosity and pore 
size of the network was achieved as the pure PCL network. However, the ALP/PCL fibres 
were rougher and thicker compared to pure PCL. In addition, some nodules with a 
diameter of up to 10 µm were formed in the fibres. These nodules are believed to be 
encapsulated ALP aggregates. Although several strategies were carried out to reduce 
the ALP aggregates, such as dispersing the ALP lyophilised powder in ethanol before 
mixing with liquid polymers, sonication of the ALP/PCL solution, and passing the 
aggregates through a needle several times, some ALP aggregates still existed especially 
in the highly concentrated samples. Among them, the sonication treatment of the 
ALP/PCL solution was the most effective method to reduce aggregation.  
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Figure 77. Scanning electron micrographs of (A, B) pure PCL nanofibres, (C, D) 20% (w/v) 
ALP/PCL nanofibres. Uniform fibres were formed from pure PCL, rough fibres with 
some ALP nodules were formed from ALP/PCL mixture. Scale bars represent 10 μm in 
A, C, and D; scale bar in B represents 1 μm. 
 
5.3.2.2 Determining the ALP specific activity of ALP/PCL electrospun 
scaffolds 
Figure 78 shows the ALP specific activity of ALP/PCL scaffolds after electrospinning. 
Three different amounts of ALP (10, 20, and 30% (w/w)) were mixed and co-
electrospun with liquid PCL polymers. There was no significant difference of ALP 
activity between the pure PCL fibres and the 10% ALP/PCL fibres. ALP activity of the 
electrospun scaffold was significantly higher, following the increasing ALP amount in 
the fibres from 10 to 30% (p < 0.001). The results indicate that ALP/PCL scaffolds 
fabricated by electrospinning preserved the ALP activity. The more ALP encapsulated 
in the fibres, the higher the ALP activity detected from the scaffolds. However, due to 
the operating difficulties of dispersing a large amount of ALP powder in PCL liquid 
polymer, 30% (w/w) of ALP is a highest percentage can be achieved. 
A B 
C D 
ALP aggregates 
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Figure 78. ALP activity of ALP/PCL scaffolds was measured using ρNPP as a substrate. 
Pure PCL scaffold was used as a control. *** p < 0.001 indicates statistically significant 
differences between the respective group and the other groups. 
 
5.3.2.3 Effect of ALP/PCL scaffolds on mineralisation after soaking 
experiments 
Surface morphology of ALP/PCL scaffolds after soaking experiments was determined 
by SEM on day 3, 7, 14, and 28 (Figure 79). Figure 79 are pure PCL scaffolds after 
soaking in cell culture media after 3, 7, 14 and 28 days, respectively. A few mineral 
depositions on the surface of the PCL nanofibres were found starting at day 3. The 
number of mineral depositions was increased in line with the culture time. Similar to 
pure PCL scaffolds, mineral depositions on the surface of the ALP/PCL nanofibres can 
be found since day 3, and more depositions were observed with the increasing culture 
time. At each time point, more mineral depositions were found on ALP/PCL fibres than 
the PCL fibres. Especially on day 28, a layer of mineral deposition completely covered 
the 30% ALP/PCL scaffold, and no fibrous structure could be seen, while the fibrous 
PCL scaffold were still observed in other groups. 
*** 
*** 
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Figure 79. Scanning electron micrographs of pure PCL scaffolds and ALP/PCL scaffolds 
after soaking in cell culture media for 3, 7, 14 and 28 days, respectively. Scale bars 
represent 1 μm in Day 3, 7, and 14; scale bars in Day 28 represent 10 μm. 
 PCL Day3 
PCL Day7 
PCL Day14 
PCL Day28 
10% ALP/PCL Day3 
10% ALP/PCL Day7 
10% ALP/PCL Day14 
10% ALP/PCL Day28 
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Figure 79. (Continued) Scanning electron micrographs of pure PCL scaffolds and 
ALP/PCL scaffolds after soaking in cell culture media for 3, 7, 14 and 28 days, 
respectively. Scale bars represent 1 μm in Day 3, 7, and 14; scale bars in Day 28 
represent 10 μm.
20% ALP/PCL Day3 30% ALP/PCL Day3 
20% ALP/PCL Day7 
20% ALP/PCL Day14 
30% ALP/PCL Day7 
30% ALP/PCL Day14 
20% ALP/PCL Day28 20% ALP/PCL Day28 
201 
 
The SEM results indicate that PCL nanofibres support mineral deposition after soaking 
in cell culture media. The ALP/PCL scaffolds with higher ALP activity enhance the 
amount of mineral deposition and accelerate the mineralisation process. In order to 
identify the mineral deposition formed during the soaking experiment, EDS analysis 
was used (Figure 80). It revealed spherical structures on the nanofibres show a Ca/P 
ratio between 1.6 and 1.8 (Figure 80A, B, C), while no mineral signal was observed 
from the nanofibres alone (Figure 80D). The EDS signals were higher with a longer 
culture time (Figure 80A, B, C). The EDS result indicates that the spherical structures 
are mineral depositions.  
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Figure 80. EDS analysis of mineral depositions on ALP/PCL scaffolds after 3 days (A), 7 
days (B) and 28 days (C and D) soaking in cell culture media. A, B, and C analyse the 
spherical structures on the surface of the nanofibres, while D analysies the nanofibre. 
 
The amount of deposited calcium on the ALP/PCL scaffolds after soaking as measured 
by calcium assay (Figure 81). The calcium deposited on the scaffolds was higher with a 
longer soaking time in every groups. Before day 7 of the soaking experiment, there 
was little calcium deposition accumulated on the ALP/PCL scaffolds. After day 7, the 
calcium content increased significantly. In contrast to the ALP activity results shown in 
Figure 73, PCL scaffolds containing 10% and 20% ALP produced similar amounts of 
calcium deposition compared to pure PCL scaffolds at every time point. The results 
indicate that a similar mineral producing ability is provided by the PCL scaffold and PCL 
fibres electrospun with a lower amount of ALP. PCL scaffolds containing 30% ALP 
exhibit significantly higher calcium content compared to other groups on day 14 and 
28 (p < 0.001). Therefore PCL scaffolds containing 30% ALP were prepared for the 
following cell culture studies. 
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Figure 81. Calcium deposited on the ALP/PCL scaffolds after soaking in cell culture 
media was measured by calcium assay. *** p < 0.001 indicates statistically significant 
differences between the respective groups and other groups on the respective day. 
 
5.3.2.4 Determining the effect of the ALP/PCL scaffolds on MC3T3-E1 cells 
In order to determine the effect of the ALP/PCL scaffolds on cell behaviours, MC3T3-
E1 cells were seeded on the ALP/PCL scaffolds. A PCL scaffold was used as a control. 
Cell morphology and differentiation were verified with SEM, ALP activity and calcium 
content assay, respectively.  
 
Cell morphology of MC3T3-E1 cells cultured on ALP/PCL scaffolds was evaluated by 
SEM (Figure 82). No significant difference was observed before 7 days of cell culture 
between the ALP/PCL scaffold and the PCL scaffold. After day 7, extracellular matrix 
was gradually deposited on the nanofibres. Mineral signal was observed by EDS. On 
day 14, a layer of extracellular matrix and mineral depositions almost covered the 
ALP/PCL nanofibres (B). In contrast, less extracellular matrix and mineral deposition 
were observed on the PCL fibres (A). 
*** 
*** 
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Figure 82. Gross changes in cell morphology of MC3T3-E1 cells cultured on PCL scaffold 
(A) and ALP/PCL scaffold (B) for 14 days. Scale bars represent 1 μm. 
 
Cell differentiation of MC3T3-E1 cells cultured ALP/PCL scaffolds was determined by 
measuring the ALP activity (Figure 83), which indicates early osteogenic differentiation, 
and calcium content (Figure 84), which indicates the late differentiation of the cells. In 
Figure 83, the ALP activity of cells on ALP/PCL scaffolds was significantly increased 
compared to PCL groups at each time point (p < 0.001). A peak value of ALP activity 
was achieved after 14 days of culture for the ALP/PCL scaffold. The results indicate 30% 
ALP/PCL scaffold enhances cell differentiation compared to the PCL scaffold. However, 
the ALP activity of the cells was extraordinary high compared to other experiments. 
The possible reason is that the ALP/PCL scaffold contributes a part of the ALP activity. 
According to Figure 78, high ALP activity was displayed in the 30% ALP/PCL scaffold 
group. Due to the operating challenges of complete removing the thin electrospinning 
fibre film from the cells, ALP/PCL scaffolds were reacted with ρNPP as well as MC3T3-
E1 cells.  
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Figure 83. The ALP activity of EC3T3-E1 cell lysate grown on ALP/PCL scaffolds for 21 
days was measured using ρNPP as a substrate. *** p < 0.001 indicates statistically 
significant differences between the ALP/PCL scaffolds and the PCL scaffolds on the 
respective day. 
 
Figure 84 shows the calcium content deposited on the electospun nanofibres after 21 
days of cell culture. The deposited calcium amounts increased along with the culture 
time. Before day 7, no difference of calcium content was observed between the two 
scaffolds. The calcium deposited on the scaffolds was at a low level. After day 7, 
calcium depositions increased sharply in both groups. However, the ALP/PCL scaffolds 
accumulated more calcium depositions than the PCL scaffold (p < 0.01) at day 14 and 
day 21. This result was in agreement with the result of the soaking experiments. PCL 
nanofibres containing 30% of ALP showed the best ability to enhance mineralisation.  
*** 
*** 
*** 
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Figure 84. Calcium content of EC3T3-E1 cell lysate grown on ALP/PCL scaffolds for 21 
days was measured by a calcium assay. ** p < 0.01 indicates statistically significant 
differences between the respective groups and PCL scaffolds on the respective day. 
 
5.4 Conclusion 
Two applications of ALPs in bone tissue engineering, one being a Ti implant with 
recombinant E. coli ALP coating, and the other being an ALP/PCL scaffold, were 
successfully fabricated in this chapter. The surface roughness of the Ti implants was 
significantly increased after oxidation treatment. In addition, silanised ALP coatings 
displayed significantly increased ALP activity compared to the adsorbed ALP coating. 
Regards to recombinant E. coli ALPs, mutant ALP coatings showed a significantly higher 
ALP activity compared to bovine ALP coatings (p < 0.01) and wild-type ALP coatings (p 
< 0.001). After a soaking experiment in cell culture media containing organic 
phosphates, E. coli mutant ALP coatings on Ti implants with high biological activity 
show outstanding mineral producing ability compared to the wild-type ALP coatings. 
However, no significant difference in calcium deposition on the implants after soaking 
experiment was observed when comparing the E. coli mutant ALP coatings and bovine 
** 
** 
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ALP coatings. 
 
Electrospun ALP/PCL nanofibres showed significantly higher ALP activity than the pure 
PCL nanofibres. ALP activity of the ALP/PCL was significantly increased along with the 
increasing ALP amount in the fibres (p < 0.001). After soaking in cell culture media for 
28 days, a layer of mineral deposition completely covered the 30% ALP/PCL scaffold. 
Both EDS analysis and calcium assay after soaking indicated that the ALP/PCL scaffolds 
with a high ALP activity enhanced the mineral deposition ability and accelerated the 
mineralisation process. Similar results were obtained from the MC3T3-E1 cell culture 
experiments, where the ALP/PCL scaffold enhanced cell differentiation and 
mineralisation compared to the PCL scaffold. In conclusion, both ALP coated implants 
and ALP/PCL scaffolds show outstanding mineral-promoting ability, and can be 
considered promising candidates for bone tissue engineering applications. 
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CHAPTER 6  
Conclusions 
Bone tissue engineering has been considered as the alternative strategy to the current 
therapies for bone regeneration or substitution. Bioactive factors, being an important 
element in bone tissue engineering, have been thoroughly investigated over the 
decades to support bone formation. In particular, studies have been focused on well-
known bone growth factors and cellular matrix proteins, such as BMPs and collagen. 
In fact, biomolecules such as bioactive factor-derived peptides and mineralisation-
promoting proteins also have the ability to enhance bone formation and regeneration. 
This study concerns these biomolecules and reveals a novel strategy of engineering 
biomolecules with improved functionalities for bone tissue engineering applications. 
 
This thesis has explored the development of two biomolecules with improved 
functionality to accelerate and improve bone mineralisation, and therefore enhance 
bone formation. First, were short peptides derived from the bone growth factor BMP-
7, which are reported to enhance mineral deposition [136]. Second, was an engineered 
recombinant metalloenzyme E. coli ALP, which generates inorganic phosphate required 
for mineralisation [180]. Ti implants and PCL scaffolds have been used to incorporate 
these engineered biomolecules to verify the improvement of the functionality and 
biological efficiency for tissue engineering applications. In this chapter, the main 
results and findings are presented and concluded. 
 
Research in bone tissue engineering over the past decades has been focused on 
biomolecules to enhance bone formation and develop bone substitutes. In the 
Introduction chapter, a number of widely used biomolecules were reviewed, such as 
bone growth factors, cellular matrix proteins, bioactive factor-derived peptides, and 
other mineralisation-promoting proteins. In Chapter 2, the BMP-7-derived peptide 
KAISVLYFDDS, and the other two peptides with His-tag on both sides, 
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KAISVLYFDDSHHHHHH and HHHHHHKAISVLYFDDS, which strongly interacts with the 
nickel-Ti implant surface via metal-affinity coordination and allows a controlled 
immobilisation, were successful synthesised, purified, and characterised. Their 
biological activities were determined by the mouse myoblast cell line C2C12, and the 
mouse pre-osteoblast cell line MC3T3-E1. 
 
The other biomolecule of recombinant E. coli ALP was described in Chapter 3, 4 and 5. 
In Chapter 3, plasmids pEK48/phoA and pEK48/4-186, encoding the wild-type and 4-
186 mutant E. coli ALP were isolated and purified. Both the wild-type and mutant 
recombinant E. coli ALP with improved biological activity were successfully expressed 
from bacterial cells and verified by BCIP selective plates, SDS-PAGE and western 
blotting analysis. After purification from the ÄKTA explorer purification system, the 
mutant ALP showed a significantly higher activity compared to the wild-type ALP 
(nearly 25 times) and bovine ALP (more than 9 times) (p < 0.001). However, the wild-
type and mutant recombinant E. coli ALP have a low protein yield, difficulties in protein 
purification, and limited immobilization property. In order to further improve the 
recombinant E. coli ALP and solve the problems, the mutant and wild-type alkaline 
phosphatase genes were recloned into a pET24 expression vector which contains His-
tag to produce the engineered recombinant His-tag E. coli ALP in the pET expression 
system in Chapter 4. In chapter 5, two applications of bone tissue engineering with 
ALPs, one being a Ti implant with recombinant E. coli ALP coating, and the other being 
an ALP/PCL scaffold, were described to accelerate mineral deposition and enhance 
implant fixation with the surrounding tissue by using the catalytic ability of ALPs. 
 
The main findings draw in the study are listed below: 
(1) BMP-7-derived peptides support the proliferation of C2C12 cells, however, 10 
μg/ml BMP-7-derived peptides failed to converts the differentiation pathway of C2C12 
myoblast to osteoblast.  
 
This is the first report that BMP-7-derived peptides showed no burst of ALP activity 
when exposed to C2C12 cells. The possible reason is that the peptide KAISVLYFDDS is 
not derived from the related active site of the BMP. The regulation of C2C12 
211 
 
differentiation by BMPs may be related to the DNA binding and/or transcriptional 
activities of MyoD [275]. However, the peptide KAISVLYFDDS is derived from the Finger 
2 domain of BMP-7 that is responsible for ligand-receptor binding interaction. 
 
(2) BMP-7-derived peptides support the proliferation of MC3T3-E1 cells, but do not 
possess the same ability as BMP-2 to induce osteoblast differentiation.  
 
These results were different from the results in literatures. According to Chen and 
Webster, 100 μg/ml peptide KAISVLYFDDS in culture media increased alkaline 
phosphatase activity in human fetal osteoblasts after 14 days compared to negative 
controls and BMP-7 [136]. The possible reason is due to the different cell line. MC3T3-
E1 may fail to respond to the short peptides used in this study. Another possible reason 
is the concentration of peptides (100 μg/ml) was too low to induce cell differentiation 
in MC3T3-E1.  
 
(3) The E. coli mutant ALP showed a significantly higher activity compared to the wild-
type ALP (nearly 25 times) and bovine ALP (more than 9 times) (p < 0.001). The wild-
type ALP showed a significantly lower activity than bovine ALP (more than twice) (p < 
0.01).  
 
(4) The activity of E. coli ALP can be affected by NaCl and lyophilisation treatment.  
 
In order to avoid the activity reduction, a dialysis is necessary after ÄKTA explorer 
purification analysis. And the protein was directly frozen at -80°C instead of lyophilising.  
 
(5) BL21 strain produces the highest protein amount and highest ALP activity of wild-
type E. coli ALP. For mutant ALP, BL21 produces a higher protein amount, but SM547 
expresses the highest ALP activity.  
 
(6) A higher level of protein expression of the His-tag ALP was achieved after overnight 
incubation at 30°C in LB Kan medium compare to a shorter incubation time and non-
incubation groups. 
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(7) The mutated recombinant E. coli His-tag ALP lost its activity after incorporating a 
His-tag on either the N-terminal or C-terminal.  
 
According to the literature, histidine and imidazole in the elution buffer were reported 
to inhibit the activity of mammalian ALP [346-348]. The mechanism of the inhibition 
may relate to the chelation of Mg2+ in the system. Due to the similarity of the structures 
of the E. coli and the mammalian ALPs in the active site region [168], the activity of E. 
coli His-tag ALP produced in this study may be inhibited in the same manner as the 
mammalian ALPs.  
 
(8) The E. coli mutant ALP coating on Ti implants showed significantly higher ALP 
activities compared to bovine ALP coating (p < 0.01) and wild-type ALP (p < 0.001). 
 
(9) The E. coli mutant ALP coating on Ti implants with high biological activity showed 
outstanding mineral producing ability compared to the wild-type ALP coating after 
soaking in cell culture media containing organic phosphates.  
 
(10) PCL scaffolds containing 30% ALP exhibit significantly higher calcium contents 
compared to other groups on day 14 and 28 (p < 0.001), and the ALP/PCL scaffolds with 
higher ALP activity enhance the mineral deposition ability and accelerate the 
mineralisation process.  
 
(11) The ALP/PCL scaffold enhanced cell differentiation and mineralisation compared 
to the PCL scaffold.  
 
This study has therefore explored a novel strategy of engineering biomolecules with 
improved functionalities, increased the understanding of the mechanism of action of 
these engineered biomolecules, and demonstrated the potential applications of these 
engineered biomolecules in bone tissue engineering. At the same time, many 
challenges remain to be overcome in this study including the limited function of BMP-
7-derived short peptides, the difficulties in the E. coli ALP production, and the activity 
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loss of the E. coli His-tag ALP. These challenges expand the scope of the current 
research areas, and could be designed to follow up for the future research. 
 
The future research strategies could be designed are listed below: 
(1) Bioactive factor-derived peptides with biological function 
Despite previous studies had shown that BMP-7-derived short peptide KAISVLYFDDS 
enhanced mineral deposition, the results in this study demonstrate that it only shows 
limited function and is not promising candidate for bone tissue engineering 
applications. However, the findings in this research do not go against the benefits of 
using peptides, which include easier production, more precise control of the chemical 
components, and a higher using efficiency compared to whole proteins while 
preserving the entire or a certain part of the protein function. It would be an 
interesting approach for the future study that to verify the biological function of 
bioactive factor-derived peptides, especially from the bioactive regions. 
 
(2) High level of recombinant protein expression 
The mutant E. coli ALP possess outstanding biological activity, and could be considered 
promising candidate for bone tissue engineering applications. Although previous 
studies had shown the benefits of using the mutant E. coli ALP, few research had 
focused on bone tissue engineering applications. In this study, ALP coated implants 
and ALP/PCL scaffolds are two successful examples in bone tissue engineering 
applications, which show outstanding mineral-promoting ability. However, more bone 
tissue engineering strategies of the combination of ALPs with other supporting 
biomaterials are available and with a high possibility of success. One possible challenge 
of this approach would be the difficulties in protein production. The current expression 
system and purification method only satisfy a laboratory-scaled process. If the E. coli 
ALP-incorporated scaffolds are used in bone tissue engineering, a more efficiency 
protein production system, which produces large scales of E. coli ALP, is needed to 
meet the demands of manufacturing process.  
 
(3) Fusion tag ALP with improved functionalities 
One motivation behind the study of the E. coli His-tag ALP was to overcome the protein 
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production problem of E. coli ALP. However, the results demonstrate that the E. coli 
His-tag ALP lost its outstanding activity after incorporating a His-tag. Without the high 
activity, the His-tag ALP is not worth studying further to combine with scaffold for bone 
tissue engineering applications. However, adding fusion tags and engineering 
recombinant protein is still a feasible way to solve the problem. Future studies may 
use other expression systems and consider other fusion tags for purification. Regards 
to the feature of controlled immobilisation of the E. coli His-tag ALP, which was brought 
from His-tag, future study may achieve the controlled immobilisation by choosing 
specific functional groups through covalent binding. In addition, it is interesting for the 
future studies to consider the mechanism of the effect of His-tag on E. coli ALP since 
the majority of the research was focused on the mammalian ALPs.  
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Appendices 
1. Buffers and media used in the thesis 
 
1) Luria-Bertani (LB) Broth 100 ml 
Trypton enzymatic digest from casein 1 g 
Yeast extract 0.5 g 
NaCl 1 g 
Distilled water 90 ml 
 
Mix all components, adjust to pH 7.2, and then make up to 100 ml. Seal the bottle and 
autoclave at 121°C for 30 min. Store at 4°C.  
 
2) Luria-Bertani (LB) BCIP/IPTG Kan Plate 100 ml 
Trypton enzymatic digest from casein 1 g 
Yeast extract 0.5 g 
NaCl 1 g 
Agar 1.5 g 
BCIP 4 mg 
10 mg/ml kanamycin stock 0.3 ml 
100 mM IPTG stock 1 ml 
Distilled water 90 ml 
 
Mix all components, adjust to pH 7.2, and then make up to 100 ml. Seal the bottle and 
autoclave at 121°C for 30 min. When the solution is cooling down to 50°C, pour 15 ml 
solution to plate and place at room temperature until polymerised. Store at 4°C. 
 
3) Washing buffer 1000 ml 
Trizma base 1.2114 g 
NaCl 1.755 g 
Distilled water 900 ml 
 
Mix all components, adjust to pH 7.3, and then make up to 1000 ml. Store at room 
temperature. 
 
4) Suspension buffer 50 ml 
Trizma base 0.19988 g 
Distilled water 40 ml 
 
Mix all components, adjust to pH 7.3, and then make up to 50 ml. Store at room 
temperature. 
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5) Agarose gel 
Agarose powder 0.8 g 
SYBR Safe DNA gel stain 8 μl 
TBE running buffer 80 ml 
 
Mix all components, and heat the mixture to boiling in microwave. When the solution 
is cooling down to 50°C, pour all solution to gel mold and place at room temperature 
until polymerised. 
 
6) SDS gel 
A 4X Running gel buffer 500 ml 
Trizma base 90.83 g 
10% SDS 20 ml 
Distilled water 400 ml 
 
Mix all components, adjust to pH 8.8, and then make up to 500 ml. Store at room 
temperature. 
 
B 4X Stacking gel buffer 250 ml 
Trizma base 15.14 g 
10% SDS 10 ml 
Distilled water 200 ml 
 
Mix all components, adjust to pH 6.8, and then make up to 250 ml. Store at room 
temperature. 
 
C 10X Stacking gel buffer 1000 ml 
Trizma base 30.20 g 
SDS 10 g 
Glycine 144 g 
Distilled water 1000 ml 
 
Mix all components, and then make up to 1000 ml. Store at room temperature. 
 
7) Transformation buffer 
A Treatment buffer 1 500 ml 
RbCl 6 g 
MnCl24H2O 5 g 
1 M KOAc 15 ml 
CaCl22H2O 0.75 g 
Glycerol 75 ml 
Distilled water 400 ml 
 
Mix all components, adjust to pH 5.8, and then make up to 500 ml. Sterilised by 
filtration through 0.22 μm filter. Store at 4°C.  
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B Treatment buffer 2 500 ml 
RbCl 0.6 g 
CaCl22H2O 5.5 g 
Glycerol 75 ml 
0.5 M MOPS 10 ml 
Distilled water 400 ml 
 
Mix all components, adjust to pH 6.5, and then make up to 500 ml. Sterilised by 
filtration through 0.22 μm filter. Store at 4°C.  
 
C SOC medium 
Trypton enzymatic digest from casein 1 g 
Yeast extract 0.5 g 
NaCl 0.05 g 
MgCl2 0.0952 g 
KCl 0.0186 g 
1M Glucose 2 ml 
Distilled water 90 ml 
 
Mix all components, adjust to pH 7.2, and then make up to 100 ml. Seal the bottle and 
autoclave at 121°C for 30 min. Store at 4°C.  
 
8) TMZP buffer 1000 ml 
Trizma base 1.2114 g 
MgCl2 0.0952 g 
NaH2PO4 0.01379 g 
ZnSO47H2O 0.0028 g 
NaN3 0.2015 g 
Distilled water 900 ml 
 
Mix all components, adjust to pH 7.45, and then make up to 1000 ml. Store at room 
temperature. 
  
245 
 
2. Summary of permission for third party copyright works 
 Page 
Number 
Type of work: 
text, figure, 
map, etc. 
Source work Copyright 
holder & year 
Work out of 
copyright  
Permission to 
re-use 
Permission 
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permission 
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Orphan work  
Page 47 figure Acta Biomater, 
(2009), vol 5, 2773-
2782 
© 2009 
Radboud 
University 
Nijmegen 
Medical 
Center     
 
Page 50 table Biocatalysis and 
biotransformation, 
(2003), vol 21, 41-
47 
©2003 Wuhan 
institute of 
Virology, CAS  
    
 
Page 60 figure pET system manual © 2003 
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Page 64 figure The 
QIAexpressionist™ 
A handbook for 
high-level 
expression and 
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(2001) 
© 2001 
QIAGEN 
    
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© 2000 Brian 
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    
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copyright  
Permission to 
re-use 
Permission 
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permission 
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Orphan work  
Page 121 figure How do we 
sequence DNA?  
© The 
University of 
Michigan DNA 
Sequencing 
Core     
 
Page 186 figure What's 
electrospinning? 
© Yamagata 
University     
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3. A copy of the letter seeking permission to republish the 
copyrighted works 
 
Page 47 
10 Jan 2014 
Dear de Jonge, 
I have completed my PhD thesis at Imperial College London entitled ‘Engineered Biomolecules with 
Improved Functionalities for Bone Tissue Engineering’. 
I seek your permission to reprint, in my thesis an extract from In vitro responses to electrosprayed 
alkaline phosphatase/calcium phosphate composite coatings. The extract to be reproduced is the 
figure showing the function of ALP. 
I would like to include the extract in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then sign. 
Yours sincerely, 
Pinyuan Tian 
  
Permission granted for the use requested above: 
I confirm that I am the copyright holder of the extract above and hereby give permission to include 
it in the print and electronic version of your thesis. I understand that the electronic version of the 
thesis will be made available, via the internet, for non-commercial purposes under the terms of 
the user licence. 
Signed: 
Name: 
Organisation: 
Job title: 
 
Page 50 
10 Jan 2014 
Dear Xu, 
I have completed my PhD thesis at Imperial College London entitled ‘Engineered Biomolecules with 
Improved Functionalities for Bone Tissue Engineering’. 
I seek your permission to reprint, in my thesis an extract from Directed Evolution of E. coli Alkaline 
Phosphatase Towards Higher Catalytic Activity. The extract to be reproduced is the table showing 
the biological activity of E. coli ALP mutations. 
I would like to include the extract in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then sign. 
Yours sincerely, 
Pinyuan Tian 
  
Permission granted for the use requested above: 
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I confirm that I am the copyright holder of the extract above and hereby give permission to include 
it in the print and electronic version of your thesis. I understand that the electronic version of the 
thesis will be made available, via the internet, for non-commercial purposes under the terms of 
the user licence. 
Signed: 
Name: 
Organisation: 
Job title: 
 
Page 60 
10 Jan 2014 
Dear Novagen, 
I have completed my PhD thesis at Imperial College London entitled ‘Engineered Biomolecules with 
Improved Functionalities for Bone Tissue Engineering’. 
I seek your permission to reprint, in my thesis an extract from pET system manual. The extract to 
be reproduced is the figure showing the pET system. 
I would like to include the extract in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then sign. 
Yours sincerely, 
Pinyuan Tian 
  
Permission granted for the use requested above: 
I confirm that I am the copyright holder of the extract above and hereby give permission to include 
it in the print and electronic version of your thesis. I understand that the electronic version of the 
thesis will be made available, via the internet, for non-commercial purposes under the terms of 
the user licence. 
Signed: 
Name: 
Organisation: 
Job title: 
 
Page 64 
10 Jan 2014 
Dear QIAGEN, 
I have completed my PhD thesis at Imperial College London entitled ‘Engineered Biomolecules with 
Improved Functionalities for Bone Tissue Engineering’. 
I seek your permission to reprint, in my thesis an extract from The QIAexpressionist™ A handbook 
for high-level expression and purification of 6xHis-tagged proteins. The extract to be reproduced is 
the figure showing the purification method. 
I would like to include the extract in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then sign. 
Yours sincerely, 
Pinyuan Tian 
  
Permission granted for the use requested above: 
I confirm that I am the copyright holder of the extract above and hereby give permission to include 
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it in the print and electronic version of your thesis. I understand that the electronic version of the 
thesis will be made available, via the internet, for non-commercial purposes under the terms of 
the user licence. 
Signed: 
Name: 
Organisation: 
Job title: 
 
Page 83 
10 Jan 2014 
Dear Brian M., 
I have completed my PhD thesis at Imperial College London entitled ‘Engineered Biomolecules with 
Improved Functionalities for Bone Tissue Engineering’. 
I seek your permission to reprint, in my thesis an extract from High-performance liquid 
chromatography (HPLC). The extract to be reproduced is the figure showing the HPLC method. 
I would like to include the extract in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then sign. 
Yours sincerely, 
Pinyuan Tian 
  
Permission granted for the use requested above: 
I confirm that I am the copyright holder of the extract above and hereby give permission to include 
it in the print and electronic version of your thesis. I understand that the electronic version of the 
thesis will be made available, via the internet, for non-commercial purposes under the terms of 
the user licence. 
Signed: 
Name: 
Organisation: 
Job title: 
 
Page 121 
10 Jan 2014 
Dear DNA Sequencing Core of University of Michigan, 
I have completed my PhD thesis at Imperial College London entitled ‘Engineered Biomolecules with 
Improved Functionalities for Bone Tissue Engineering’. 
I seek your permission to reprint, in my thesis an extract from How do we sequence DNA? The 
extract to be reproduced is the figure showing the DNA sequencing method. 
I would like to include the extract in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then sign. 
Yours sincerely, 
Pinyuan Tian 
  
Permission granted for the use requested above: 
I confirm that I am the copyright holder of the extract above and hereby give permission to include 
it in the print and electronic version of your thesis. I understand that the electronic version of the 
thesis will be made available, via the internet, for non-commercial purposes under the terms of 
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the user licence. 
Signed: 
Name: 
Organisation: 
Job title: 
 
Page 186 
10 Jan 2014 
Dear Koyama Laboratory of Yamagata University, 
I have completed my PhD thesis at Imperial College London entitled ‘Engineered Biomolecules with 
Improved Functionalities for Bone Tissue Engineering’. 
I seek your permission to reprint, in my thesis an extract from What's electrospinning? The extract 
to be reproduced is the figure showing the electrospinning method. 
I would like to include the extract in the printed examination copy of my thesis and also the 
electronic version which will be added to Spiral, Imperial's online repository 
http://spiral.imperial.ac.uk/ and made available to the public under a Creative Commons 
Attribution-NonCommercial-NoDerivs licence. 
If you are happy to grant me all the permissions requested, please return a signed copy of this 
letter. If you wish to grant only some of the permissions requested, please list these and then sign. 
Yours sincerely, 
Pinyuan Tian 
  
Permission granted for the use requested above: 
I confirm that I am the copyright holder of the extract above and hereby give permission to include 
it in the print and electronic version of your thesis. I understand that the electronic version of the 
thesis will be made available, via the internet, for non-commercial purposes under the terms of 
the user licence. 
Signed: 
Name: 
Organisation: 
Job title: 
 
 
